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ABSTRACT 
This thesis describes study designs for the robust evaluation of complex patient safety 
interventions.  Fundamentally, the study designs available to measure the effectiveness of 
patient safety interventions fall into two categories – those that use contemporaneous 
controls, and those that do not.  A review of the recent literature (245 citations) revealed 
that most studies were single-centre (63%), and the majority of these did not use 
contemporaneous controls (84%); whilst in multi-centre studies (37%) the number of studies 
using contemporaneous controls (49%) equalled the number of studies that did not (51%).  
Studies that do not use contemporaneous controls dominate the literature, but they are 
inherently weak and subject to bias.   
Furthermore, this thesis discussed a case-study for the evaluation of a highly complex 
patient safety intervention – the Safer Patients Initiative (SPI), which sought to generically 
strengthen hospitals, whilst improving frontline activities.  The evaluation was a before and 
after study, with contemporaneous controls.  It used mixed-methods, so that the 
triangulation of one type of research finding could be reinforced when corroborated by the 
finding of another type.  Uniquely, it also, compared the rates of change across control and 
SPI hospitals – an approach referred to as the “difference-in-difference” method. 
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EXECUTIVE SUMMARY 
Background 
Many patient safety interventions are concerned with best to how organise health systems 
and deliver services.  They can be difficult to define and the effective element difficult to 
specify, and these are known as complex interventions.  This thesis is concerned with the 
evaluation of complex patient safety interventions, and attempts to answer the following 
research question: which study design provides a robust method of evaluation of complex 
patient safety interventions?  
Fundamentally, study designs available to measure the effectiveness of patient safety 
interventions fall into two categories – those that use contemporaneous controls, and those 
that do not.  This thesis firstly describes a review of the literature, which scopes out the 
patient safety evaluation literature, to determine which study designs are currently 
employed to determine effectiveness of interventions.  It then elaborates on a case-study of 
an evaluation of a highly complex patient safety intervention – the Safer Patient Initiative 
(SPI).   
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Literature review 
A review of the recent literature was conducted (2005 to present), and 245 citations met the 
search criteria.  Sixty-three percent of studies (154/245) were single-centre studies and 
evaluations that did not use contemporaneous controls dominated these types of studies 
(84% [129/154]).  Multi-centre studies were used less frequently 37% (91/245); however, the 
use of contemporaneous controls (49% [45/91]) was greater than in single-centre studies, 
and equalled those evaluations that did not use contemporaneous controls (51% [46/91]).  
Indicating that those studies that considered a multi-centre design, also considered a more 
robust evaluation.   
Studies that do not use contemporaneous controls dominate the literature, but they are 
inherently weak and are subject to bias.  Robust evaluations should include 
contemporaneous controls, as well as before and after measurements, as they account for 
any underlying secular trends.  Ideally evaluations should be augmented with mixed-
methods, as this enables research findings of one type to be reinforced when the are 
corroborated by the findings of another type.  These principles are applied to the case-study 
that constitutes the remainder of the thesis.   
Case-study - the Safer Patients Initiative 
The intervention was delivered in two phases -the first phase (SPI1) began in 2005, when the 
Health Foundation (an independent charity working to improve quality and safety) worked 
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with the Institute for Healthcare Improvement (IHI) to develop and launch the Safer Patients 
Initiative (SPI). They provided direct support to four NHS hospitals as they implemented an 
organisation-wide patient safety programme over 18 months.  The intervention sought to 
generically strengthen hospitals by engaging senior leaders to change the culture of the 
organisation whilst improving the reliability of specific front-line care processes within 
designated clinical areas   
The stated aim was to make a 50% reduction in the total number of adverse events at the 
four pilot hospitals. Each of the hospitals was carefully selected through a competitive 
bidding process. The Health Foundation gave £775,000 to each of the four hospitals to 
secure the services of IHI and to provide the capacity for change.  
To build on the experience and learning from SPI1, a second phase of the intervention, 
known as SPI2, was rolled out from March 2007 to September 2008 inclusive.  Following a 
competitive bidding process, 20 UK hospitals were selected to participate in this phase.  The 
SPI2 had an investment from the Health Foundation of approximately £270,000 per hospital.  
The SPI2 intervention was similar to SPI1, with somewhat modified goals.   
Methods 
The evaluation of SPI employed a before and after study designed with non-randomised 
contemporaneous controls.  It utilised mixed-methods – using both quantitative and 
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qualitative studies.  A series of linked sub-studies were organised around a conceptual 
model of the healthcare system:   
• management processes were studied by means of a series of qualitative 
interviews with strategic stakeholders; 
• intervening variables were assessed by using a quantitative staff survey, and a 
qualitative study using ethnographic methods on hospital wards; 
• clinical processes were studied by case-note review of acutely sick patients using 
explicit methods and holistic methods, an explicit case-note review of peri-
operative care, and by using indirect measures of hand hygiene; 
• outcomes were studied by case-note review of adverse events and mortality, 
outcomes within the intensive care unit, healthcare associated infection rates 
(HCAI), and quantitative patient surveys.    
The evaluation of SPI1 preceded the evaluation of SPI2 and not all sub-studies were 
conducted in both phases.  Primarily, how practitioners responded to acutely ill and 
deteriorating patients, were the only quantitative sub-studies conducted for both SPI1 and 
SPI2 evaluation, whilst the qualitative sub-studies were only carried out within the SPI1 
evaluation.   
For all quantitative comparisons, a “difference-in-difference” method was used, so that the 
intervention effect could be estimated as a rate of change above and beyond any 
background rate of change.   
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Results 
Overall, there was a marked and significant improvement in the response to acutely ill 
patients during the study, including the recording of vital signs. However, this was replicated 
at the control hospitals, and could not be attributed to the SPI. The evaluation found no 
reduction in errors or in adverse events in the patient group examined – patients with acute 
respiratory disease. Within the SPI2 evaluation, only one dimension of the staff survey 
changed significantly (in favour of control hospitals). 
Many aspects of evidence-based medical and peri-operative care were good at baseline, 
leaving little room for improvement.  There was marked improvement in use of hand-
washing materials, and a dramatic decrease in HCAI’s across all hospitals.  A significant 
additive effect of the SPI on the measures included in the evaluation was not detected.   
On the qualitative side, the interviews with senior stakeholders found that they were 
generally enthusiastic and knowledgeable about the SPI, and shared an understanding of 
the programme and its underlying theory of change. Ward staff on the other hand, tended 
to know little about SPI procedures, practices and principles, or viewed them as top-down 
rather than something that they had been involved in developing. There was little evidence 
of a shared sense of ownership and some evidence of a sense of elitism that had grown up 
around those who had taken part in the initiative. The SPI had little measurable impact on 
ward level staff, leading to the conclusion that its impact at ward level was, at best, modest. 
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Main findings 
Many aspects of care are already good or improving across the NHS, suggesting considerable 
gains in quality across the board. These improvements might be due to policy activities, 
including some with features similar to the SPI, and the emergence of professional 
consensus on some clinical processes.  
An additional effect of a large-scale organisational intervention (SPI) was not detected.  
There are a number of possibilities for this:  (i) any effects were too small to detect; (ii) the 
null additive effect was due to sub-optimal implementation; or that there may be longer-
term additive effects that take longer to surface.   
There was some evidence from the interviews that ward staff viewed the scale of the 
challenge as daunting, and that the resource implications and degree of cultural change 
required were underestimated. It may simply take a long time for programmes such as the 
SPI to achieve this effect. 
Hospitals did report positive effects from SPI participation, including heightened managerial 
awareness and/or commitment to safety, and organisational learning about how to 
implement safety improvement in future. Participating in the SPI may secure greater long-
term commitment to quality and safety, and improvements made in participating hospitals 
may either surface at a later date or prove more sustainable than the improvements seen in 
control hospitals. This hypothesis can only be tested through further data collection. 
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Conclusion 
In this thesis I have described a robust study design to evaluate complex patient safety 
interventions.  The evaluation has taken a mixed method approach, using both quantitative 
and qualitative methods.  All quantitative observations have been made with 
contemporaneous controls, and uniquely a “difference-in-difference” method was used.   
The approach has been vindicated – measures of fidelity, intervening variables, process and 
outcome, supported by qualitative methods – and has provided a wealth of information of 
the effectiveness of the intervention and theories as to why the intervention worked the 
way it did.   
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CHAPTER 1: INTRODUCTION 
How best to secure greater patient safety is one of the most challenging and pressing questions 
facing healthcare practitioners, managers and policy makers.  Increasing effort and resources 
have been focused on patient safety since the publication of two key reports at the turn of the 
century – the UK Chief Medical Officer’s Organisation with a Memory (2000) and the US 
Institute of Medicine (IOM) To Err is Human (2000).  This increased focus has gone hand in hand 
with an explosion of patient safety research literature (Lilford et al., 2006).   
Patient safety research builds on cognate disciplines such as psychology, sociology, 
organisational studies, ergonomics and education, and so the design of patient safety 
interventions to improve patient care requires knowledge distilled from these basic disciplines.  
Some of these interventions aim to replace unsafe treatments and technologies (such as 
medical devices or surgical) with safer alternatives, and the development and evaluation of this 
type of intervention are under the remit of the Health Technology Assessment (HTA).  However 
many patient safety interventions are concerned with how best to organise health systems, and 
deliver services so that they are safer.  Research of this type falls within health service, or 
Service Delivery and Organisational (SDO) research.  
Patient safety interventions that target the delivery and organisation of the service tend to 
comprise of a number of separate components, that can be complementary or work 
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independently.  They can also involve a number of behaviour changes; different 
levels/structures within an organisation; different elements being delivered at different times 
and intensity; and different methods of organising and delivering those elements.  These types 
of intervention, i.e. those that are difficult to define, and where the effective element of the 
intervention is difficult to specify, are known as “complex interventions” (Medical Research 
Council, 2000).   
In 2000, the Medical Research Council (MRC) published a framework for the evaluation of 
complex interventions, in which an analogy to a randomised control trial (RCT) of a 
pharmaceutical intervention was made (Campbell et al., 2000; Medical Research Council, 2000).  
Despite the framework being welcomed as an attempt to bring scientific rigour to the 
evaluation of complex interventions (Rosen et al., 2006), it also brought several criticisms that 
were raised at a subsequent meeting (Medical Research Council, 2008): 
• the guidance was derived from the evaluation of pharmaceutical and medical 
devices, and so was based on the assumption that the planning of a complex 
intervention is a linear process (Campbell et al., 2007); 
• the lack of evidence for the framework; 
• the lack of preliminary stages, such as early piloting and developmental work 
(Hardeman et al., 2005); 
• an assumption that conventional clinical trials provide a template for all the 
different approaches to evaluation; 
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• that processes were not as important/useful as outcome measurements (Oakley et 
al., 2006); 
• an assumption that interventions need to be standardised, and a lack of recognition 
that in some circumstances, the effectiveness of an intervention requires local 
tailoring (Hawe et al., 2004); 
In response to these criticisms, and from the subsequent learning that has arisen, new guidance 
was issued (Craig et al., 2008; Medical Research Council, 2008).  However, the updated 
recommendations do not claim to be comprehensive, and that achievable consensus on what is 
best practice has yet to be accomplished.  However, it recognises that the process of 
developing and evaluating complex interventions has several phases, which may or may not 
follow a linear sequence. 
The initial stage is the development of the intervention, which should have a sound theoretical 
basis.  At this stage the existing evidence for the intervention should be identified, preferably by 
a high quality systematic review.  Also, the intervention needs to be described in sufficient 
detail to allow it to be fully replicated.   
There should also be a feasibility and piloting stage to test whether the intervention can be 
delivered as intended, and to estimate the effect size, so that the sample size can be 
determined.  In the evaluation stage, the effectiveness of the intervention should be based on 
experimental design, but if the bias is small and the effect size is large or too rapid, then an 
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observational study may be more appropriate.  This is consistent with the “no one size fits all” 
approach advocated by Brown et al., (2008d).  Outcome measurements are still preferred, but 
the inclusion of process measurements would offer an explanation of observed effects.  Also, 
the inclusion of an economic evaluation to assess the cost-effectiveness of the intervention 
would make the findings useful to decision makers. 
Finally, the findings of an evaluation need to be disseminated and made available to key 
stakeholders.  There was also a recommendation of surveillance and monitoring of 
interventions, augmented with long-term follow up.   
The guidance also provided further clarity on what makes an intervention complex.  They 
concurred that there is no clear boundary between simple and complex interventions  in actual 
fact there are few interventions that can be described as truly simple, though there are some 
that are highly complex as they comprise of several multi-faceted components.  They offer 
some guidance as to the dimensions of complexity, and their implications for developing and 
evaluating them (Craig et al., 2008).  See Box 1.1 and Box 1.2.   
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Box 1.1: Dimensions of complexity (taken from Craig et al., 2008) 
• number of interacting components within the experimental and control interventions; 
• number and difficulty of behaviours required by those delivering or receiving the 
intervention; 
• number of groups or organisational levels targeted by the intervention; 
• number and variability of outcomes; 
• degree of flexibility or tailoring of the intervention permitted. 
Box 1.2: Implications for developing and evaluating complex studies (taken from Craig et al., 
2008) 
• a good theoretical understanding is needed of how the intervention causes change, so that 
weak links in the causal chain can be identified and strengthened; 
• lack of effect may reflect implementation failure (or teething problems) rather than 
genuine ineffectiveness  a thorough process evaluation is needed to identify 
implementation problems; 
• variability in individual level outcomes may reflect higher level  processes; sample sizes may 
need to be larger to take account of the extra variability and cluster randomised designs 
considered; 
• a single primary outcome may not make best use of the data  a range of measures will be 
needed and unintended consequences picked up where possible; 
• ensuring strict standardisation may be inappropriate – the intervention may work better if a 
specified degree of adaption to local settings is allowed for in the protocol.   
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This new guidance will provide a steer for this thesis, but as with the previous MRC guidance, 
there is debate on its relevance (Connelly, 2007; Hawe et al., 2004; Kernick, 2008; Mackenzie et 
al., 2010; Shiell et al., 2008).  Fundamentally, these arguments are on how knowledge is built 
up, and reflects the different ontological (what can be known) and epistemological (how can it 
be known, i.e. the theory of knowledge) that underpin the basic belief system, or world view 
that guides a person/investigation/discipline (Guba and Lincoln, 1994).  I take a pragmatic 
position using different ontological and epistemological philosophies depending on the 
research question that needs to be answered.  However, essentially I am positivist/realist, i.e. 
there are external objective facts but these can be interpreted through social conditioning.  This 
positivist/realist philosophy underpins this thesis and hence the use of the MRC guidance as 
point of reference for it.     
The research question for this thesis is: which study design provides a robust method of 
evaluation of complex patient safety interventions?  
To answer this, firstly a literature review was undertaken to assess study designs currently used 
in the evaluation of patient safety interventions (Chapter 2). 
I then progress to describe in detail a highly complex patient safety intervention (Chapter 3) – 
the Safer Patients Initiative (SPI), and the framework of the methods (both quantitative and 
qualitative) employed to evaluate it (Chapter 4).  The quantitative sub-studies are reported 
separately (Chapters 5 to 14), with a brief introduction, methods, results and discussion.  An 
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overall discussion of the findings is provided in the final chapter (Chapter 15), along with an 
exegesis of the findings and lessons for the evaluation of highly complex patient safety 
interventions, such as the SPI.   
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CHAPTER 2: LITERATURE REVIEW 
2.1 Introduction 
In Chapter 1, I briefly described the updated guidance for the evaluation of complex 
interventions (Craig et al., 2008; Medical Research Council, 2008).  By and large the authors 
endorsed the use of epidemiological methods in the evaluation of complex interventions, 
but what is not known is what study designs have been used to date to evaluate them, and, 
more specifically to this thesis, what study designs have been used to evaluate complex 
patient safety interventions.  This chapter will review the recent patient safety intervention 
literature to investigate this.   
2.1.1 Study design 
The gold standard for evaluating interventions is the randomised control trial (RCT) 
(Cochrane, 1979).  In this type of study the intervention is randomly allocated between 
control and intervention groups before the investigation begins.  However, randomisation is 
not always possible for either practical or ethical reasons (Black, 1996), and in these 
circumstances non-randomised designs have been used.   
This section outlines study designs that are commonly used to evaluate complex patient 
safety interventions (see Figure 2.1) (Brown et al., 2008b).  I shall start by describing study 
designs that measure endpoints “before and after” an intervention has been implemented 
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(section 2.1.2). These studies may involve many time points before, during and after the 
intervention phase, and depending on how the data is to be analysed then these designs 
may be referred to as time series analysis or Statistical Process Control (SPC) (see 2.1.2). 
I will then go onto describe study designs that make use of contemporaneous comparisons.  
These can be made after an intervention has been put in place (cross-sectional studies), or 
can be made both before and after the intervention phase (controlled before and after 
studies).  Designs with contemporaneous controls may be: a) non-experimental (natural 
experiments or “quasi-experimental” studies (Campbell and Stanley, 1963)) or b) they may 
involve experimental design in which intervention and controls are chosen at random, (i.e. 
RCT).   
Studies using these two design variables (the timing of data collection, and whether the 
allocation to control or intervention is randomised or not) are described in section 2.1.3.   
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Figure 2.1: Basic study designs.  Taken from Brown et al., (2008b) 
 
2.1.2 Before and after studies 
In some instances contemporaneous controls are not feasible, so neither RCTs nor natural 
experiments are possible.  This situation can arise when there is a national directive to 
implement a policy across a service, or when an intervention is being implemented in a 
single hospital.  In these instances, before and after studies are common, and are often the 
only practical method of evaluation.  However, they are a relatively weak method to 
distinguish cause and effect as secular trends, while other concurrent changes may make it 
difficult to attribute observed changes to the intervention being studied.  Before and after 
Control/intervention 
determined by convenience 
(natural experiment) or 
randomisation
Key
Aggregated assessments for individuals within a study group
Comparison of study points
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evaluations also tend to overestimate the effect size; Lipsey and Wilson (1993), reviewed 45 
meta-analyses of psychological, educational and behavioural interventions, noted that the 
observed effects from before and after studies were greater than those from controlled 
studies, a finding that was previously made in clinical research (Sacks et al., 1987).   
Factors influencing how much confidence can be placed on the results of before and after 
studies include: 
• the magnitude and rate of change; 
• the plausibility of the intervention; 
• compatibility with other contemporaneous and prior evidence (Brown et al., 
2008b).  
2.1.2.1 Time series and Statistical Process Control (SPC) 
Time series is a type of before and after study design, it attempts to detect if the effect of an 
intervention is significantly greater than any secular trend (Cook and Campbell, 1979).  A 
statistically significant interruption in a long series of observations has greater explanatory 
power than differences between a single before and after observation, as regression to the 
mean is less likely if serial observations show that the improvement was not preceded by a 
random “high”.   
Time-series are particularly useful when it is difficult to obtain contemporaneous controls, as 
in the dissemination of national guidelines or mass media campaigns (Eccles et al., 2003).  
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Data collected several times before and after the intervention allows underlying/seasonal 
(cyclical) effects to be estimated.  However, enough data points need to be collated prior to 
the intervention, to demonstrate that a stable estimate of the underlying secular trend has 
been obtained.  Also, the time period between successive data points should be chosen with 
care, as data points collected close in time are likely to be more similar to one another, than 
to data points collected further apart, i.e. close data points autocorrelate (Eccles et al., 
2003). 
SPC (see 3.6.3.2) is a method of monitoring a process through the use of control charts.  The 
advantage of using SPC is the ability to detect process changes and early trends.  Users 
making pragmatic improvements can move away from simple bar and line graphs, mainly 
descriptive analyses, to a method, that when used correctly, is statistically rigorous but 
requires less data than when testing for significance (Benneyan et al., 2003).  Although SPC is 
strictly a quality improvement method, it is included here as it is an approach that has been 
widely adopted in the patient safety field, and it possible that the findings of SPC will be 
reported for evaluation purposes.   
2.1.3 Studies with contemporaneous controls 
Comparative studies between hospitals exposed to the intervention and controls which are 
not, provide a much better basis for inferences about effectiveness, than a before and after 
study.  However, before explaining the different design elements of these comparative 
studies I will discuss the unit of comparison most commonly used – a cluster. 
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2.1.3.1 The unit of comparison 
Patient safety interventions are usually targeted at the service rather than the individual, 
and as interventions will affect a group of patients, cluster studies are often necessary 
(Donner, 1998; Edwards et al., 1999). 
Typically clusters consist of different organisations (hospitals, general practices, etc), but 
other types of cluster may be used.  For example, clusters can be comprised of patients 
treated by doctors exposed to different interventions (Landrigan et al., 2004).  A drawback of 
cluster studies is the loss of power that results from greater similarity across individuals 
within a cluster, than across individuals between clusters.   
As with other studies, sample size requirements in cluster studies depend on the size of 
effect sought, and the risks of false positive and false null study findings.  However, the 
sample size also depends on the extent to which endpoints tend to cluster within an 
organisation, which is measured by the intraclass correlation coefficient (ICC).  The ICC range 
is between 0 and 1, and will increase as the variance in endpoints between individuals within 
clusters falls.  If the ICC is 0, there is no correlation between individuals in a cluster, and the 
study is effectively a parallel design.  If the ICC is 1, the responses of individuals within a 
cluster are identical, and the effective sample size is the number of clusters (Killip et al., 
2004).   
ICC values are generally between 0.01 and 0.02 for healthcare organisations (Killip et al., 
2004).  A typical two-arm cross-sectional comparative study might include 20 clusters in each 
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arm with 40 individuals in each cluster.  Such a study would be sufficient to detect a 
statistically significant reduction in error rate from 10% to 5% assuming an ICC of 0.02 (alpha 
= 0.05; 80% power).  The total sample size of 1600 is almost twice the requirement of 868 if 
clustering is not taken into account.  Figure 2.2 shows the trade-off between the number of 
clusters and cluster size required to detect a difference in error rate from 10% to 5% with 
different ICC values.  Diminishing marginal returns to increasing cluster size on the power of 
study are well demonstrated (Campbell et al., 2004). 
Figure 2.2: Clustered sample size calculations for given ICC values (box).  The calculations 
are based on detecting a difference in error rate between control (0.1) and intervention 
(0.05), with alpha = 5% and power = 80%.  Taken from Brown et al., (2008b). 
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Ukoumunne et al., (1999) identify two types of cluster design: 
• cohort designs, in which repeated measures are taken from the same subjects in 
each cluster; 
• and repeated cross-sectional designs, in which the sample of subjects within 
each cluster changes when each measurement is taken. 
The latter design enables the repeated measurement of terminal end-points (those that only 
happen once) such as death, thus, the effect of a safety intervention on mortality or rates of 
infection can be measured in different organisations, and at different times. 
2.1.3.2 Design elements of studies using contemporaneous controls 
There are four types of controlled study designs (see Figure 2.1):  
• cross sectional (measurement of post intervention end points) with non-
randomised controls; 
• cross sectional with randomised controls; 
• “before and after” with non-randomised controls; 
• “before and after” with randomised controls.   
The advantages and disadvantages of these different types of study design are described in 
Table 2.1.  Of these study designs, the least reliable are non-randomised post-intervention 
comparisons, due to the inherent difference between intervention and controls.  Statistical 
adjustment for confounders can only be made for known and observed confounding 
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variables, but bias frequently originates in hidden variables (Lilford et al., 2004).  
Randomised studies with pre-intervention and post-intervention measures are arguably the 
most robust design, but non-randomised comparative studies with before and after 
measurements may be nearly as good, because measured rates of change can be taken into 
account (imperfectly) for baseline differences.  The method is imperfect, since clusters with 
a high (or low) baseline rates may be more (or less) responsive to the intervention.  In 
particular, clusters that actual have good practice may have little scope for improvement.  
Whether randomised or not, a controlled before and after design can control for secular 
change, since the intervention effect is estimated as a rate of change above and beyond any 
background rate of change, i.e. the difference-in-difference comparision.  With an 
appropriate statistical model both secular trends and intervention effects can be modelled 
(Saint et al., 2003).   
Sample size calculations for comparisons of rates of change in cluster studies do not need to 
take account of the ICC of the end points, but only of any ICC of the propensity to change, 
net of baseline differences.  Murray and Blitstein (2003) provide theoretical justification and 
practical evidence that these latter ICCs, based on pre-post differences, are smaller than ICCs 
that must be used in cross-sectional comparisons. 
However, there are caveats to using before and after controlled comparisons to minimise 
spurious claims about the effect of the intervention.  Firstly, intervention and control groups 
need to be comparable, and so need to be effectively matched; secondly, baseline 
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measurements need to be similar, as any differences between them may indicate that they 
experience secular trends differently (as mentioned above) (Eccles et al., 2003).   
Table 2.1: Controlled study design matrix 
 
Allocation 
Phasing Randomised Natural experiment 
Post 
Intervention 
Variance in end points due to baseline 
difference may bias the result 
Risk that comparisons will be 
confounded by difference at baseline  
Before and 
after 
Allows for specific comparison of change 
net of any baseline differences.  Enables 
comparison to be made between 
organisations that change most or least 
Controls for baseline difference possible  
2.1.4 The importance of context 
Epidemiological methods provide inferences on the effectiveness of an intervention, and 
should remain at the core of an evaluation.  However, it is recognised that a variety of 
methods are important in the evaluation of complex interventions.  These are particularly 
insightful for delving into the underlying processes and the social context within which an 
intervention is introduced.  These are an inherent part of change, and vital to understanding 
why an intervention does or does not work (Murtagh et al., 2007; Thomson et al., 2007), and 
can also explain why differences in capacity to benefit may exist.  For example, there may be 
a “ceiling” effect, whereby non-intervention organisations are already very good, and have 
less headroom for further improvement than intervention sites that demonstrated positive 
results.   
In order to make judgements regarding generalisability, it is necessary to have some 
knowledge of any systematic differences of those characteristics judged to be important 
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between study and non-study organisations.  In the event that such differences exist, the 
theory as to why and how an intervention may work, will help in predicting the impact of 
such differences.   
Finally, in addition to contextual differences, studies associated with greater (and significant) 
effects tend to be those where the intervention was implemented with greater fidelity.  It is 
therefore important that the fidelity with which an intervention was implemented (or the 
method by which it may have been adapted) are clearly described, as these will properly 
inform judgements about the generalisability of the findings. 
2.1.5 Literature review 
I will now describe a literature review to determine what study designs have been used to 
evaluate patient safety interventions.  As the new MRC guidance was issued in 2008 I will 
search the recent history of evaluations (2005 to present), and focus on those papers that 
report a study carried out in secondary care, as these directly relate to the subject of this 
thesis, an evaluation of a hospital intervention (Chapters 4 to 15).   
I will use a broad search strategy that includes quality of care improvement interventions, as 
well as patient safety interventions.  Since safety and quality are aspects on a continuum and 
there is no clear point at which safety becomes quality (Brown et al., 2008a).   
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2.2 Methods 
2.2.1 Identification of studies 
The following search strategy was used in OVID (MEDLINE and EMBASE) to locate primary 
studies of potential interest: 
(“patient safety” OR “quality improvement”) AND (“intervention$”) AND (“hospital$” OR 
acute) 
The strategy was limited to humans, English language and for articles published from 2005 
to present (13th February 2011).  The terms in the search string did not map to any Medical 
Subject Headings (MeSH) and were therefore used as keywords limited to the abstract.  A 
similar search strategy was used for the Web of Science database but with a restriction to 
articles.     
MEDLINE and EMBASE databases were de-duplicated within OVID, with a further de-
duplication step taken between OVID and Web of Science when all citations were imported 
into Reference Manager (version 12), a software tool for publishing and managing 
bibliographies.   
2.2.2 Exclusion criteria 
The abstracts that this search yielded were reviewed and discarded if they described: 
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•  a study targeting primary care; 
• a literature review; 
• a registry; 
• a purely qualitative study; 
• a descriptive study; 
• the implementation of national guidelines/policy with no additional intervention; 
• a clinical study;  
• an opinion paper. 
Full papers were retrieved of those abstracts that were of potential interest.   
2.2.3 Data extraction 
Relevant studies were initially categorised to single-site or multi-site evaluations.  Following 
on from this, studies were then divided into those that used before and after designs, versus 
those that used contemporaneous controls.  Among those using contemporaneous controls 
cross-sectional studies were distinguished from before and after controlled studies, and 
within both of these categories studies were further differentiated between randomised and 
non-randomised controls.   
  
2.3 Results 
2.3.1 Study flow 
The search strategy used in this literature review provided a yield of 938 citations.  From 
reviewing the abstracts 388 were identified as being potentially relevant.  Of these 3
available for detailed review, and a further 52 were reviewed by abstract only due to lack of 
availability and financial constraints.  After detailed review
excluded. In total, data was extracted from 245 citations (full papers and abstracts) for this 
literature review.  The literature search process is summarised by 
of citations included in this literature review can be found in Appendix A.
Figure 2.3: An overview of the literature search process
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2.3.2 Study designs used 
See Table 2.2 for a summary. 
2.3.2.1 Single-centre studies  
Of the 245 papers and abstracts included in the literature review, 63% (154/245) were 
evaluations conducted at a single-centre.  Of these single-centre evaluations, 84% (129/154) 
were without contemporaneous controls, with before and after studies making the largest 
proportion within this group (90% [116/129] before and after, vs. 4% [5/129] time-series, vs. 
6% [8/129] SPC).  
Contemporaneous controls were used in 16% (25/154) of single-centre studies.  Of these 
56% (14/25) used a cross-sectional design (43% [6/14] randomised, vs. 57% [8/14] non- 
randomised); and 44% (11/25) used an additional before and after design element (9% 
[1/11] randomised, vs. 91% [10/11] non-randomised). 
2.3.2.2 Multi-centre studies  
Thirty-seven percent (91/245) of the papers and abstracts included in the literature review 
utilised a multi-centre design.  Contemporaneous controls were used in 49% (45/91) of these 
studies, and this was virtually equal to the number of studies that did not use them (51% 
[46/91]).   
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Of those studies that did not include contemporaneous controls, before and after studies 
again predominated (83% [38/46] before and after, vs. 15% [7/46] time series, vs. 2% [1/46] 
SPC).   
Of the studies that used contemporaneous controls, cross-sectional studies were used less 
frequently (16% [7/45] cross-sectional, vs. 84% [38/45] before and after); and of those 
before and after studies using contemporaneous controls, 47% (18/38) used randomised 
controls versus 53% (20/38) that used non-randomised controls.   
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Table 2.2: Study designs used for the evaluation of complex patient safety interventions 
 
No contemporaneous controls Contemporaneous controls 
 Before & 
after 
Time Series SPC Before & after 
randomised controls 
Before & after 
non-randomised 
controls 
Cross sectional 
randomised 
controls 
Cross sectional 
non-randomised 
controls 
Total 
Single centre N 116 5 8 1 10 6 8 154 
% 75 3 5 1 6 4 5  
         
Multi-centre N 38 7 1 18 20 5 2 91 
% 42 8 1 20 22 5 2  
         
       TOTAL 245 
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2.4 Discussion 
2.4.1 Study designs used 
2.4.1.1 Single-centre studies 
The evaluation method that predominates within a single-centre design is before and after 
studies (84% vs. 16% using contemporaneous controls).  The dominance of this type of study 
design within single-centre studies is probably a reflection of the fact that it is the least 
resource intensive type of evaluation method to conduct.   
Although before and after studies are useful to measure change in a single organisation, or 
when polices are introduced simultaneously across a health sector, they are considered a 
weak design (Eccles et al., 2003).  This is as they do not provide information on cause and 
effect, have no estimate of any secular trends that may be occurring, and they tend to 
overestimate effect size (Lipsey and Wilson, 1993; Sacks et al., 1987).  We have discussed in 
section 2.1.2 factors that increase or decrease the confidence with which cause and effect 
conclusions can be made.   
When a before and after study is the only option available then an interrupted time-series 
design should be encouraged, as this affords some protection against secular trends.  
However, their use is underutilised, and across the whole sample (single-centre and multi-
centre studies) only 12 evaluations (Gallagher et al., 2009; Hixson et al., 2005; Jeffries et al., 
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2009; Krimsky et al., 2009; Levy et al., 2010; Miller et al., 2010; Pronovost et al., 2010; Riggio 
et al., 2009; Robb et al., 2010; Unahalekhaka et al., 2007; van Kasteren et al., 2005; Young et 
al., 2006) used this type of study design.  This is probably because they are methodologically 
more demanding and, again, there may be financial constraints limiting the collection of 
more data. 
Despite the growing use of quality improvement methods, only a small proportion of the 
literature was based on SPC analyses.  In the whole sample (single-centre and multi-centre 
studies) only nine papers (Beckett and Kipnis, 2009; Cohen et al., 2005; Ernst et al., 2010; 
Groome et al., 2009; Iyer et al., 2011; Kotagal et al., 2009; McPhail et al., 2010; Stevens et 
al., 2010; von and Aslaksen, 2005) cited this method for evaluation purposes.  This is 
probably a reflection of the fact that SPC is frequently reported as part of an intervention 
package.  For example, McCulloch et al., (2010) described the effect of a quality 
improvement method known as “lean” and SPC was used to improve processes and 
outcomes on a surgical wards.  However, in the report, chi-squared test was conducted to 
measure effectiveness.   
2.4.1.2 Multi-centre studies  
Within multi-centre evaluations, contemporaneous controls were used in studies as 
frequently as they were not (49% [45/91] vs. 51% [46/91]).  This may be a reflection that 
those evaluations that have considered putting in place an intervention in more than one 
site, have also considered a more robust evaluation.   
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Before and after studies with contemporaneous controls feature more frequently than 
cross-sectional studies (84% [38/45] vs. 16% [14/25]) in comparison to single-centre 
evaluations in which the split was more evenly distributed (44% vs. 56%).  This is again a 
reflection of a more considered design approach when using a more than one study centre.   
Across the whole literature review only a few studies (3% [10/245]) used the weakest study 
design, i.e. cross-sectional evaluations using non-randomised controls.  These are subject to 
bias and have poor generalisability, so it is encouraging to see that these are not frequently 
employed. 
Of those multi-centre studies that used before and after design, with no contemporaneous 
controls, it may be that the number of intervention sites was large and it was unfeasible to 
obtain controls.  For example, Wirtschafter et al., (2006) described a state-wide intervention 
promoting antenatal steroid use for foetal maturation in preterm babies.   
2.4.2 Limitations of the literature review 
This literature review lacks quality control as it was done by one individual.  It would have 
been useful if a sample was reviewed by another person so that a measure of agreement 
could be made.    
There were 11 papers in which the intervention being described could be argued as being a 
simple intervention. These included simple feedback mechanisms (Chern et al., 2005; Merle 
et al., 2009; Midlov et al., 2008; Quillen and Murphy, 2006); protocols and checklists (Paige 
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et al., 2009) and reminder systems (Agostini et al., 2007; Brackbill et al., 2010; Franklin et al., 
2006; Koplan et al., 2008; Vishwanath et al., 2009).  However, they could equally be defined 
as being complex, as they required behaviour changes and were implemented in complex 
systems.  This difficulty in defining interventions as being simple, complex, or even highly 
complex, is recognised as problematic, particularly for systematic reviewers, who have called 
for the development of a typology of the structural characteristics of complex interventions 
(Shepperd et al., 2009).   
2.4.3 Implications for evaluating complex patient safety interventions 
Despite guidance on how we should evaluate complex interventions being available for over 
ten years (Medical Research Council, 2000; Medical Research Council, 2008), before and 
after study designs still dominate the literature.  As stated previously, they are inherently 
often weak and are subject to bias.   
So, which study design should be used in the evaluation of complex patient safety 
interventions?  Firstly, contemporaneous controls should be used where possible.  Ideally 
these should be randomised controls, but this is often not feasible.  Before and after 
measurements are also important as they allow for any underlying secular trends to be 
identified, and in a cluster study, use of a difference-in-difference method enables smaller 
sample sizes to be used (see 2.1.3.2).   
The considerations outlined above should be central to any evaluation of complex 
intervention but they can be further augmented by the use of mixed-methods.  A mixed- 
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method evaluation involves measuring different end points and making both qualitative and 
quantitative observations.  There are four key advantages to using this approach 
(Sandelowski, 2000): 
• the ability to triangulate findings (the research findings of one type of 
observation are reinforced when they are corroborated by the findings of a 
different type).  Additional credence through triangulation adds to the strength 
and generalisability of findings.  Alternatively, where the results from different 
methods conflict, triangulation may prevent presumptive inferences that may 
have been made had results only been obtained from measurement of a single 
end point (Brown, 2004); 
• greater understanding, enabling better interpretation and elaboration of results.  
A mixed-method approach allows researchers to consider why an intervention 
has or has not been effective; 
• development of theory, thereby guiding generalisation and informing further 
studies; 
• linked qualitative studies may provide evidence of problems with the 
intervention at an early stage, which may lead to revisions of study protocols 
(Murtagh et al., 2007). 
Taking these considerations into account, I shall go on to describe a case-study for evaluating 
a complex patient safety intervention – the evaluation of the Safer Patients Initiative (SPI).  
However, before I do, a tenet of good practice is to fully describe an intervention to the 
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extent in which it can be fully replicated (Medical Research Council, 2008); something I shall 
do in the proceeding chapter.   
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CHAPTER 3: CASE-STUDY - THE SAFER 
PATIENTS INITIATIVE 
In the previous chapter, I detailed a literature review of the types of study design that are 
currently being used to evaluate patient safety interventions and I will go on to describe an 
evaluation of a highly complex patient safety intervention.  However, I firstly need to 
describe the intervention being evaluated – the SPI.  I will start by giving an overview of the 
provenance and the philosophy behind the SPI.  I will then go on to describe the selection 
process of the first phase (SPI1) intervention hospitals before providing a full description of 
the intervention itself.  Finally I will outline the second phase (SPI2) of the intervention and 
how it differed from SPI1.   
3.1 Introduction 
The SPI was funded by the Health Foundation (Health Foundation, 2010a), an independent 
charity working to improve quality and safety within the UK as well as abroad.  It does this 
through several work programmes including: demonstration projects (large-scale projects 
that test out new ideas for improving the quality of healthcare); a leadership scheme 
(investing in individuals from a wide range of organisational and professional backgrounds to 
help them deliver effective healthcare); and research and development (building knowledge 
of what works to improve quality and performance).  These programmes are supported by 
an endowment, which was worth £675 million in 2009 (Health Foundation, 2010b).  
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The Health Foundation worked with the Institute for Healthcare Improvement (IHI) (Institute 
for Healthcare Improvement, 2010a) in developing and delivering the SPI.  The IHI is a US-
based not-for-profit organisation dedicated to improving healthcare.  The SPI was 
developed under the premise that a good evidence-base existed on how to improve the 
safety of healthcare but an implementation gap existed.  The purpose of the SPI was to 
“transform organisations to deliver safer care” (Health Foundation, 2009) by developing a 
strong safety culture and fostering a leadership that placed safety as a strategic priority.  It 
had a number of features similar to the well publicised US “Saving 100,000 lives campaign” 
(Berwick et al., 2006; Bisognano et al., 2005); setting out to penetrate deeply into 
organisations, changing not only specific processes and standards, but also the attitudes, 
motives and behaviours of staff and how they understand the nature of their work.   
SPI1 was mentored by the IHI over an 18-month period starting in January 2005. Hospitals 
were expected to embed and spread learning following the IHI mentored component. 
Funding of £775k (€860k; $1.2 million) per hospital was provided by the Health Foundation; 
this was used to secure the services of the IHI and to provide the capacity for change in the 
individual hospitals.   
The aims of the SPI hospitals were to: 
• achieve a 50 percent reduction in adverse events (Health Foundation, 2006; 
Shirley, 2008);  
• develop an engaged leadership who made safety a strategic priority; 
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• develop individuals in safety practice methodology; 
• establish an appropriate measurement system, conduct ongoing assessments of 
organisational safety and act upon those assessments; 
• create a patient safety centric organisation; 
• disseminate knowledge and expertise (Institute for Healthcare Improvement and 
Health Foundation, 2005a).  
3.2 Selection of participating SPI1 hospitals 
The four SPI hospitals that participated in the first phase (SPI1) were selected following a 
competitive bidding process to demonstrate that they would be receptive to the 
intervention. A review panel, including members with an international perspective as well as 
safety, clinical, and organisational expertise, was convened by the Health Foundation to 
select the hospitals. The panel used a three-stage process. The first involved analysing all 
applications against explicitly agreed criteria, including:  
• leadership commitment; 
• capacity and capability; 
• openness, transparency and communication; 
• exemplar status. 
A shortlist of eight organisations was entered into the second stage, which involved hospital 
visits to explore:  
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• the information outlined in the hospitals’ applications; 
• the feasibility and sustainability of the initiative within the specific hospital’s 
context. 
The third stage was a selection panel meeting to consider the bids against these criteria: 
• capacity and capability; 
• leadership commitment; 
• patient Involvement; 
• openness and transparency; 
• willingness and capacity to be an exemplar for others; 
• sustainability and believability. 
An explicit assessment of current safety work was not a criterion for selection at any stage of 
the process. The four participating hospitals are described in Table 3.1.   
 42 
 
Table 3.1: Hospitals that participated in SPI1 
Hospital Rural/
Urban 
Bed No Teaching status A&E ICU Consultant 
(specialists) FTE 
Hospital A Urban 625  Associate teaching 
hospital  
Yes Yes 112 
Hospital B Rural 750  No Yes Yes 120 
Hospital C Urban 903  Principal teaching 
hospital 
Yes Yes 242 
Hospital D Rural 280  No Yes No 36 
These hospitals are all part of the NHS and have no private beds. Figures provided as of 
October 2004. A&E: Accident and Emergency Department; ICU: Intensive Care Unit; FTE: Full 
time equivalent. The hospitals have not been named as it was agreed that anonymity would 
be ensured as part of evaluation participation.     
 
3.3 The change package  
The approach taken to meet SPI aims was the IHI’s patient safety “change package”.  This 
was a three-tiered model (Figure 3.1) in which a leadership driven culture of safety, 
supported the strategies of prevention (processes that avoided harm and errors), detection 
(processes rapidly highlighting errors) and mitigation (processes that captured or softened 
the impact of errors) to improve clinical outcomes.   
To achieve this, SPI hospitals used case-note review to discover failings of care and then 
made evidence based improvements in these areas.  These improvements were described as 
change concepts:   
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“a general idea, with proven merit and a sound scientific of logical foundation, that can 
stimulate specific ideas for changes that can lead to improvement” (Institute for Healthcare 
Improvement and Health Foundation, 2005a) 
Change concepts included: standardisation, simplification, protocols/checklists, the use of 
forced functions, a reduction in the reliance of vigilance, and a reduction of handover points 
in the healthcare system.  It was intended that organisations would use Plan-Do-Study-Act 
cycles (PDSA) (see 3.6.3.1) to measure and improve practice over time.   
 
Figure 3.1: The Health Foundation’s SPI Patient Safety Change Package.  Taken from the 
kick off meeting (Institute for Healthcare Improvement and Health Foundation, 2005a) 
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The IHI made the strong claim
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Foundation, 2005a).  
3.4 A model of the healthcare system
A conceptual model in which the 
Donabedian (Donabedian, 1980)
outcome, and Reason (Reason, 2000)
of a system), and active errors (those lie with front
these concepts lies the generic idea of a service (frontline healthcare) embedded in a 
system.   
Figure 3.2: A model of the healthcare system 
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Next are the internal processes, which are within local control.  These processes can be 
defined as: generic management/organisational processes (e.g. human resource policy, staff 
training, supply chain management), specific management process (e.g. such as notices to 
remind staff to wash hands), and clinical (frontline) processes (e.g. adoption of particular 
evidence-based practices; the quality of clinical-patient communication).  This distinction 
concurs with Reason’s distinction between latent errors at an organisational (meso) level 
and active errors which involve direct human interaction (Reason, 2000) at the micro level.  
Interventions focused on management processes, such as human resource polices, e.g. staff 
appraisal and WalkRounds (see 3.6.1.1) will generally effect intervening variables, such as 
staff behaviours/attitudes, morale, culture and sickness absence.  Lastly there are outcomes, 
which can be clinical or patient reported such as satisfaction.  
A systems-wide approach in which this model is considered as a whole is useful in the 
development phase of a new intervention, and it is imperative that once developed new 
interventions are studied at all levels (Brown and Lilford, 2008).   
3.4.1 Framework for the SPI 
The SPI can be described as a highly complex intervention (Craig et al., 2008); it consists of 
many components that together comprise what the IHI calls the “change package” (see 3.3).  
It comprises of many components that target different structures and processes in a 
hospital.  These components can be linked to extended version of the causal chain described 
in section 3.4.  Conceptually the components of the intervention fall into two categories; 
those that generically strengthen the system to reduce adverse events whatever their cause; 
  
and those that have specific targets
the SPI are outlined in Table 
Figure 3.3: Embellished Donabedian’s causal chain (blue) linking 
process and outcomes 
 
 (Figure 3.3).  These categories and component parts of 
3.2.   
SPI (green) to 
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Table 3.2: Key elements of the SPI 
General aim: “to avoid unnecessary harm, pain or suffering as a result of error in medical interventions”   
 
AIM METHOD 
Generic improvement in the system to reduce adverse events 
whatever their cause 
 
Building a culture of safety and good leadership. 
 
Education so that organisations can identify problems and develop 
and evaluate methods to reduce risk.  
 
Fostering an understanding of the principles of safe practice. 
a. Collaborative residential learning sessions with IHI faculty (see 3.5.6); 
b. Web-based learning and hospital visits from IHI (see 3.5); 
c. Leadership projected in part by management WalkRounds (see 3.6.1.1); 
d. Know-how for Plan Do Study Act (PDSA) cycles (see 3.6.3.1); 
e. Electronic information sharing facility – for example to share results of 
PDSA cycles (see 3.5 and 3.6.1.3); 
f. Participation in safety culture surveys using the Sexton tool (see 3.6.1.2) 
Specific targets   
1. Identifying and responding to deteriorating patients.  To reduce: 
Need for “crash calls”; 
Avoidable mortality. 
 
a. Review of 50 deaths (see 3.5.1); 
b. Tools for monitoring patients’ condition and for triggering action.  These 
tools include a proforma to record vital signs and other salient 
information (the Early Warning Score System [EWSS]) (see 3.6.2.1); 
c. Promote the use of risk (severity) scores (see 3.6.2.1);  
d. Establishing a rapid response/outreach team (see 3.6.2.1)  
2. Reducing medication error. 
 
a. Medication safety assessment (involving staff in Failure Mode Effects 
Analysis [FMEA])  – educating staff to identify and remedy weak links in 
medication practice from prescribing to administration and monitoring 
(see 3.5.1 and 3.6.3.4); 
b. Tool to reduce adverse events to anti-coagulant therapy (see 3.6.2.3); 
c. Education to improve medicine reconciliation on admission (see 3.6.2.3). 
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3. Communication between staff to reduce adverse events/mortality. 
 
a. SBAR (Situation Background Assessment Recommendation) tool to ensure 
that information is communicated in a structured way (see 3.6.2.2); 
b. Safety briefings – briefings at shift changes to ensure staff are aware of 
relevant information for patients (see 3.6.2.2). 
4. Infection control including Methicillin-resistant Staphylococcus 
Aureus. 
a. Peri-operative antibiotics to reduce surgical site infection (see 3.6.2.5); 
b. Catheter insertion and maintenance drill to prevent central line infections 
in intensive care (see 3.6.2.6); 
c. Following the tenets of ventilator guidelines (bundles) to reduce 
ventilator acquired pneumonia, venous thromboembolism and stress 
ulcers in intensive care units (see 3.6.2.6); 
d. Improve hand hygiene, for example, by means of prominently displayed 
posters. (see 3.6.2.4) 
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I will now go on to describe the SPI in more detail, which was compiled using the following: 
• observations whilst attending “learning sessions” (see 3.5.6); 
• material presented at “learning sessions”; 
• materials found on the extranet for the SPI and the IHI website; 
• original or alternative sources when further clarification was required; 
• conversations and sharing of this description with the Health Foundation and the 
IHI. 
Section 3.5 describes how the SPI was delivered, structured, presented and supported.  
Section 3.6 details the contents of the SPI and what was presented at the learning sessions.   
3.5 The Safer Patients Initiative – format and structure 
Phase I of the SPI enabled each hospital to develop its own bespoke patient safety 
programme under the guidance of the IHI.  The structure of this collaborative model was as 
follows: 
• a self assessment of each organisation prior to the “kick-off” meeting (see 3.5.1); 
• a four day “kick-off” meeting (see 3.5.6); 
• followed by three, two day “learning sessions” (see 3.5.6); 
• support of IHI experts; 
• hospital visits by IHI experts; 
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• a virtual community, which included, conference calls, email, listserv and 
monthly progress reports using web-based systems. 
Learning sessions were comprised of plenary presentations (attended by all participants 
described in 3.5.5), small group discussions and team meetings.  They were held over two to 
four days and enabled participants to gather information on patient safety and on IHI 
”improvement” methodology.  The sessions were also an opportunity for participants to 
develop detailed improvement plans for their organisations, and share 
information/experiences with each other. 
The intervals between each meeting were described by the IHI as “action periods”.  These 
were times of intense activity occurring on hospital, in which learning was consolidated and 
organisations worked towards the goals that they had set (Institute for Healthcare 
Improvement and Health Foundation, 2005a).  
During these periods each hospital remained in contact with the IHI and other collaborative 
partners.  The communication took the form of conference calls, listserv and sharing of 
information on an extranet site.   
The conference calls were facilitated by the IHI with the purpose of problem solving, sharing 
experiences of improvements and a forum to generate new ideas.  The listserv was a mailing 
list to which all participants subscribed.  It allowed subscribers to post questions, share 
experiences and have discussions outside of scheduled calls and meetings.   
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The extranet was a website that could only be accessed with a valid username and 
password.  Materials from meetings, monthly reports and documents developed by 
hospitals were posted and shared here.  It also contained contact details of all team 
members and archived listserv messages.  At the beginning of each month hospitals were 
expected to submit progress reports and results.   
An outline of how the different aspects of the SPI fitted together and when they were 
delivered can been seen in Figure 3.4.  
Figure 3.4: The Phase SPI1 time-line (adapted from IHI learning materials) (Institute for 
Healthcare Improvement and Health Foundation, 2005a) 
 
Dec 04 Jan 04 June 05 Jan 05 June 06 Aug 06 Oct 05
4 day 
kick off
Learning sessions (LS)
2 day 
LS
2 day 
LS
2 day 
LS
2 months 
mentoring
Site selection
Key changes
Improvement
Measures
Support
•Expert clinical faculty
•Measures
•Listserv
•X2 site visits
•Conference calls
•Monthly on-line progress reports
Organisational 
self-assessment
 52 
 
3.5.1 Performing a safety self-assessment 
Prior to the kick-off meeting (see 3.5.6) each hospitals performed a base-line self-
assessment in the following areas (Institute for Healthcare Improvement and Health 
Foundation, 2004): 
• mortality diagnostic case-note review; 
• adverse event trigger tool case-note review; 
• medication safety self assessment survey; 
• healthcare acquired infection (HCAI) rates. 
The purpose of each of these exercises was to emphasise any underreporting of adverse 
events and to provide a baseline measurement.   
3.5.1.1 Mortality diagnostic case-note review 
This was a case-note review of fifty consecutive deaths using a structured proforma.  This 
proforma was developed by the Modernisation Agency and is an adaptation of an IHI 2x2 
matrix tool (Institute for Healthcare Improvement, 2003).  The objective of this exercise was 
to develop an understanding of the systems in healthcare and points at which failures occur. 
3.5.1.2 Adverse event trigger tool case-note review 
Using an adverse event trigger tool, each hospital was asked to review the case-notes of fifty 
randomly selected discharges with a minimum 24 hour length stay.  The allocated review 
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time was 20 minutes.  Again, the objective was to identify sub-standard care that could be 
remedied.   
3.5.1.3 Medication safety self assessment survey 
Each hospital was asked to perform a medication safety self assessment using an IHI tool.   
3.5.1.4 HCAI rates 
The hospitals were asked to collate any collected data from the previous 12 months on 
nosocomial infections in the following areas: ventilator acquired pneumonia; central line 
catheter bloodstream infections; surgical site infections; and methicillin-resistant 
staphylococcus aureus (MRSA).   
3.5.2 Identifying best practice 
Hospitals were encouraged to assemble and submit information on best practice that 
already existed within the organisation.  Possible areas included: 
• management of narcotics or anticoagulants; 
• reconciliation of medications during admission or discharge; 
• management of medicines during prescribing, dispensing and administration; 
• assessment and response to the deteriorating patient; 
• prevention or management of hospital acquired infection;  
• medical devices management. 
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Any areas of confusion in the preparatory assignment were collated by the IHI prior to the 
first session and were addressed at the meeting.   
3.5.3 Getting connected to resources 
An important component of the initiative was to put evidence into practice, and hospitals 
were asked prior to the kick-off meeting to identify a person that had access and knowledge 
of healthcare websites such as the National electronic Library for Health, the British Medical 
Journal and the National Patient Safety Agency.  Also all participants were required to 
subscribe to the IHI extranet prior to the meeting. 
3.5.4 Preparing a storyboard 
Storyboards were used as a method of sharing experiences and accomplishments.  Hospitals 
were expected to present a storyboard at each learning session.   
3.5.5 Participants  
Hospitals selected staff (“change agents”) to participate in the first meeting and to take a 
leading role in the SPI.  Hospitals were advised to appoint a leadership team and frontline 
pilot teams from the following clinical areas: medicines management; intensive care; general 
ward; and peri-operative care.   
The leadership team comprised of senior executives who could also serve as a “system 
leader” of frontline pilot teams (see below). 
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Each pilot team comprised of five to six members, of which four core members would attend 
learning sessions (Institute for Healthcare Improvement and Health Foundation, 2004).  The 
frontline pilot teams were responsible for developing, testing, and implementing specific 
interventions.  Each team comprised of a system leader, clinical/technical experts and day-
to-day leader.  More than one person could fill these roles and any individual could fill more 
than one role.   
The system leader needed to hold influence/authority within the organisation to implement 
change and achieve the aims of the frontline pilot teams.  It was important that they were 
influential in the areas that were affected by the change.  They were also expected to 
disseminate changes throughout the organisation (see 3.6.1.4).   
Clinical/technical experts were “opinion leaders” (individuals sought out for advice, who are 
not afraid to try changes) (Institute for Healthcare Improvement and Health Foundation, 
2004) that thoroughly understood the roles, functions, operations and processes in the pilot 
area.  They were described as “champions” interested in driving change but who still had 
good working relationships with colleagues and with day-to-day leader(s).  Clinical/technical 
experts could be a nurse, doctor, pharmacist or a key lead within the pilot area.   
The day-to-day leader had the task of directing, and motivating the frontline pilot team.  The 
leader needed to ensure that appropriate data were collected and changes evaluated.  The 
leader needed to understand the processes well enough to predict the effects of making 
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changes, and be able to work effectively with the system leader and the clinical/technical 
expert.   
At each hospital, an individual was also responsible for submitting monthly progress and 
data reports.  They needed to co-ordinate with the day-to-day leader of each frontline pilot 
team, and submit reports on behalf of the whole hospital. 
3.5.6 Kick-off meeting and learning sessions 2, 3 and 4 
The kick-off session was held in Bradford on 25th January 2005 (Institute for Healthcare 
Improvement and Health Foundation, 2005a) and lasted for four days.  At the kick-off 
meeting the SPI was described in its entirety.   
The meeting was launched with an orientation session in which the Health Foundation, the 
IHI and the hospitals were introduced to each other.  This was also an opportunity for the 
hospitals to present their self-assessment data.  
Subsequent learning sessions were 2 days long and took place in May 2005, November 2005, 
and June 2006 (Institute for Healthcare Improvement, 2005 (Institute for Healthcare 
Improvement and Health Foundation, 2005b; 2005c; 2006)  The materials presented were a 
consolidation of those presented in the kick-off session, with the addition of emerging 
problems, and discussion on how to overcome barriers.  In the final session, there was an 
emphasis on how to disseminate learning and achieve the aim of reducing adverse events by 
50% by November 2006.   
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Learning sessions were an opportunity for hospitals to meet, share, and to discuss progress 
and hurdles.  It was a chance for teams to have time away from their normal work duties, so 
that they could become focused and motivated on the tasks required of the initiative.  
Learning sessions were also an occasion to socialise with other hospitals and faculty (IHI, 
Health Foundation and guest speakers).   
The learning sessions followed the same basic format.  They started with a plenary session to 
report progress, present results, share achievements and discuss obstacles encountered.  
The plenary sessions were intermingled with breakout sessions on leadership, medicines 
management, critical care, peri-operative management, general ward and measurements.  
At the end of the first day teams were allocated time for hospital team meetings.  The 
format was repeated on the second day and the session was completed with agreement on 
tasks to accomplish in the next action period. 
3.6 The Safer Patients Initiative – the content 
As previously mentioned the components of the intervention can be divided into generic and 
specific categories (Table 3.2).  The generic components lend themselves to strengthening 
leadership within the organisation and are described in section 3.6.1, while those 
components that seek to improve front-line activities, are detailed in section 3.6.2.  Some 
activities, particularly measurement, are both generic and specific activities.  Thus, knowing 
how to do a PDSA cycles could generically strengthen the system, while the implementation 
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of these cycles to improve a particular area of practice is a specific front-line activity.  These 
activities with generic and specific components are described separately in section 3.6.3. 
3.6.1 Enhancing leadership and other generic components 
Leadership was placed as being central to the success of the initiative.  The leadership team 
(see 3.5.5) needed to make an initial assessment of patient safety issues at an executive level 
by reviewing board meetings.  Learning from this exercise the leadership team were 
expected to make safety a priority, set a “patient safety” organisational tone, and establish 
strategic safety goals.  To keep in touch with safety issues occurring at the front-line they 
were required to participate in WalkRounds (see 3.6.1.1) and to orchestrate a shift from a 
“blame culture” to a “patient safety” culture, which would be monitored by a safety climate 
tool (see 3.6.1.2).   
The leadership team needed to assure the success of the SPI by aligning the goals of the 
initiative with that of the hospital.  Changes needed to be sustained and become an integral 
part of the system of care.  This team were expected to become actively involved in projects 
by removing barriers, increase resource and by providing the necessary infrastructure.  They 
were expected to champion successful projects and develop robust dissemination strategies 
(see 3.6.1.4).   
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3.6.1.1 WalkRounds 
A WalkRound was a method for executives to learn about patient safety concerns of front-
line staff, and to reinforce patient safety culture (Frankel et al., 2005).  A weekly WalkRound 
was expected to take place at each hospital and convened at the convenience of front-line 
staff.  To keep conversations focused on patient safety executives were given a script of the 
type of questions that should be asked: 
• “how will the next patient be harmed in your area?” 
• “how does this environment fail you?” 
• “the last patient hurt of a failure in care – what happened?” 
During these sessions, a safety lead was expected to be present, to act on issues raised and a 
separate scribe to minute the conversation.  The collected information was analysed and 
reported to the executive team, so that priorities could be assigned and plans for action 
decided.  The outcomes (including no actions) needed to be reported back to the originator 
of the concerns so that interest was not lost by front-line staff. 
3.6.1.2 Culture 
Culture was defined as the values, behaviour and norms of a group.  It was stressed that 
when a culture was “good” then the objectives of an organisation are more likely to be met.  
Patient safety culture was measured by the Sexton safety climate tool (Sexton et al., 2006).  
This was a 19 question survey that measured the “culture of patient safety” from three 
perspectives: organisational; leadership and team. The hospitals were asked to distribute the 
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survey instrument to all staff that had significant patient exposure, i.e. those working in a 
clinical area for at least four weeks and at for at least 20 hours per week.  There was a 
recommendation that staff complete and return the survey to the co-ordinator within a 
week of receipt.  The surveys were then sent to the IHI for analysis.   
3.6.1.3 Leadership and measurement 
A key aspect underpinning the intervention was that of measurement and data.  All 
participants were expected to clearly understand the measurement philosophy but 
leadership were particularly required to do so.  There was belief that if leadership became 
involved in measurement they would become empowered to lead an organisation that 
delivered better care.  They were expected to put in place processes to accurately, and 
consistently collect data on a wide and balanced number of measures, principally those 
relating to organisational performance, which overtime could also be used to assess the 
sustainability of improvements and assist in improvement dissemination strategies.   
Hospitals needed to decide which key performance measures they wanted to use and were 
guided by the Institute of Medicine (IOM) six quality dimensions (Table 3.3).   
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Table 3.3: Measurements to track IOM dimensions (STEEP), taken from materials 
presented at kick-off session (Institute for Healthcare Improvement and Health 
Foundation, 2005a) 
IOM Dimension Measures 
Safe Adverse drug events (out and inpatient) 
Work days lost (inpatient) 
Timely Third next appointment available (outpatient) 
Effective Hospital specific mortality rate (inpatient)  
Functional outcomes: SF-6 (out and inpatient) 
Efficient Costs per capita (across region) 
Hospital specific standardised reimbursement 
Equitable *Note: The sixth IOM quality dimension is “equitable” care. 
This will be addressed by stratifying the above measures, 
when possible, into subpopulations. For example, many of 
these measures could be stratified by gender, age, or racial 
groupings using available data. 
Patient-centered Patient satisfaction (out and inpatient)  
Percent patients dying in hospital (across region) 
Once the measures were decided a target needed to be established (within a realistic time-
frame) and an implementation strategy developed to reach these targets.  Hospitals needed 
to make monthly measurements of the selected indicators 
The hospitals were encouraged to collaborate and share their results, in a league with other 
hospitals that were involved with other quality improvement programmes developed by the 
IHI [e.g. Pursuing Perfection (Berwick and Rothman, 2002) and IMPACT (Henderson et al., 
2003)].   
3.6.1.4 Dissemination 
The IHI had developed a framework for dissemination (Nolan et al., 2005; Rashad et al., 
2006) based on the literature and interviews with organisations both within and outside of 
healthcare.  Hospitals were expected to plan and initiate dissemination strategies of 
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successful projects as early as possible.  These strategies needed to have clear aims and be 
multipronged.  The strategies were requires to describe intended improvements, key 
performance indicators, communication methods, intended target population, time-frame of 
effort and an anticipation of training needs.   
Day-to-day leader needed to be involved in dissemination plans, as well as an executive.  
Projects which had a greater chance of being accepted were those that had achieved the 
desired outcome, that had an advantage and that were compatible with the adopter 
hospital.   
Hospitals were taught diffusion theory (Rogers, 2003), i.e. that in a population there are 
different categories of adopters, which are:  innovators, early adopters, early majority, late 
majority, and laggard.   
Innovators (2% of the adoption population) were the first individuals to adopt an innovation, 
and were willing to take risks - they were close to scientific sources and more likely to 
interact with other innovators (Rogers, 2003).  Early Adopters (14%) were the second fastest 
category of individuals to adopt an innovation. These individuals held influence and had the 
highest degree of opinion leadership amongst the other adopter categories; the support of 
these individuals was essential for successful dissemination.  The Early Majority (34%) would 
adopt an innovation after a varying degree of time but the time was significantly longer than 
with the innovators and early adopters. Late Majority (34%) individuals represented the 
average member of the population, and these individuals approached an innovation with a 
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high degree of skepticism.  Laggards (16%) were the last to adopt and typically had an 
aversion to change and tended to focus on “traditions” (Rogers, 2003). 
3.6.2 Improving specific front-line interventions 
Specific interventions were developed for four clinical areas: general medicine, peri-
operative care, critical care and medicines management.  Those that targeted the general 
ward included better monitoring of patients using early warning score systems (see 3.6.2.1), 
structured methods of communicating this deterioration to doctors and outreach services 
(see 3.6.2.2), and the use of safety briefings at shift changes (see 3.6.2.2).  Interventions 
developed to reduce medication error included the targeting of high risk drugs, principally 
anticoagulants and the development of tools to ensure that on admission (or any handover 
point) drugs were continued (or discontinued) appropriately, i.e. medicines reconciliation 
(see 3.6.2.3).  Interventions to be used in critical and peri-operative care primarily targeted 
the prevention of hospital acquired infections (see 3.6.2.5 and 3.6.2.6).   
3.6.2.1  Identifying and responding to deteriorating patients 
At risk patients within a hospital could reside on general wards, and are not necessarily 
supported by the skills, knowledge and attitudes of those delivering services in critical care 
(Institute for Healthcare Improvement and Health Foundation, 2005a).  Outcomes for these 
patients including increase length of stay and mortality, which are potentially avoidable 
through diligent monitoring of vital signs and appropriate response when deterioration 
occurs (Institute for Healthcare Improvement and Health Foundation, 2005a).  Therefore, 
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according to the IHI, an effective programme was one able to identify these patients early, 
and provide appropriate care, in the correct location and in a timely manner by either early 
admission to a critical care unit or continued care on the ward reinforced where necessary 
by ICU outreach services (Institute for Healthcare Improvement and Health Foundation, 
2005a).  
A tool developed to detect the early deterioration of patients is the Early Warning Score 
System (EWSS) (McGaughey et al., 2007) and its use was advocated by the IHI.  It is a simple 
algorithm based on the following bedside observations: 
• staff member worried about the patient; 
• acute change in heart rate to <40 or >130 bpm; 
• acute change in systolic blood pressure to <90 mmHg; 
• acute change in respiratory rate to <8 or >30 breaths per minute; 
• acute change in pulse oximetry saturation to <90% despite oxygen; 
• acute change in conscious state; 
• acute change in urine output to <50 mL in 4 hours. 
These observations were recorded onto a colour banded patient chart (to provide a visual 
cue) and assigned a score.  If the total score exceeded a threshold level it initiated an 
outreach team.   
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The outreach approach defines critically ill patients by need or level of care required, and 
not by geographical boundaries of where the patient is located.  The team prevents 
admissions to the ICU, facilitates more timely ICU discharges and enables critical care skills, 
knowledge and expertise to be shared.   
3.6.2.2 Effective communication of patient safety concerns 
Communication failure has been estimated to be a major factor in 60-70% of serious patient 
safety incidents (Greenberg et al., 2007; Patterson et al., 2004) and hence an improvement 
in communication was an SPI focus.  There were two methods employed by the IHI to 
enhance patient safety communication:  the first was set at team level and utilised safety 
briefings; whilst the second involved a structured mechanism for imparting patient 
information between individuals.   
3.6.2.2.1 Safety briefings 
The use of safety briefings originates from the aviation industry and they enabled front-line 
staff, without fear of reprisal, to share information about potential safety problems and 
concerns on a daily basis (Institute for Healthcare Improvement, 2010b).  It was 
recommended that they were five minutes long, and that they took place at the start and 
end of each shift.  The briefing at the start of the shift posed open questions on safety 
awareness, whilst the session at the end of the shift asked specific questions of safety 
incidences that may have occurred during that shift.  All responses were recorded and it was 
expected that those requiring further action would be acted upon.   
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Initially safety briefings were conducted with nurses and then over time expanded to include 
all of the multi-disciplinary team.  Moreover, it was intended that the drive for these 
briefings was from front-line staff themselves with little or no impetus from management. 
3.6.2.2.2 Situation Background Assessment Recommendation (SBAR) 
In other high risk industries, such as aviation, rail and the military, standardised 
communication is used so that information is shared consistently and imparted accurately.  
SBAR (see Figure 3.5) is a tool that was developed by the US Navy for standardising 
important and urgent communication in nuclear submarines, and has been adopted by the 
IHI as a model that health providers should use in clinical communication.  The advantages 
are that hierarchies are overcome; junior staff are less likely to miss out important 
information and the recipient knows in which order information will be given (Lingard et al., 
2005; Marshall et al., 2009). 
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Figure 3.5: SBAR tool (taken from (Marshall et al., 2009) 
S 
Situation 
State purpose: “The reason I am calling is ...............” 
If urgent – say so e.g.  “Thus is urgent because the 
patient is unstable with a BP of 
90”. 
B 
Background 
Tell the current problem 
Relevant: 
History/examination/test results 
Management 
If urgent: 
Relevant vital signs 
Current management 
A 
Assessment 
State what you think is going on 
e.g. “So the patient is febrile and I 
can’t find a source of infection”. 
Urgent, e.g. “the patient seems to 
be deteriorating, I think they may 
be bleeding” 
R 
Request 
State request 
 
e.g. “I’d like your opinion on the 
most appropriate test” 
e.g. “I need help urgently, are you 
able to come?” 
 
3.6.2.3 Reducing medication error 
3.6.2.3.1 Medicines reconciliation 
An area identified as having a particularly high opportunity for medication errors were 
“handover points” within the healthcare system.  Errors include: wrong dose, wrong route, 
incorrect frequency being administered, and medicines being omitted.  To minimise them a 
review or “reconciliation” of medications should be done at these interchanges.   
Reconciliation was described as a three step process: verification – collection of medication 
history; clarification – ensuring that the medications and doses are appropriate; and 
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documentation – changes to prescriptions or reason for differences.  During the review the 
following pieces of information were required to be recorded: 
• current drugs prescribed by the general practitioner (GP); 
• time of last dose; 
• source of information (patient/family, patient’s pharmacy, previous medical 
records, packages of patients medication, GP); 
• medications ordered on admission; 
• if possible document patient adherence; 
• any other drugs, e.g. over the counter, herbal remedies, including dose, route 
and frequency. 
Hospitals needed to identify who is best suited to complete the reconciliation.  However, the 
IHI suggest that pharmacists undertake the most effective drug history.   
The reconciliation form should be used every time that a prescription is changed, and 
whenever a patient changes service setting or level of care.  Participants needed to identify 
the handover points that needed to be reconciled, but the most important were admission 
and discharge.   
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3.6.2.3.2 Anticoagulants 
The prescribing and management of anticoagulant drug therapy is complicated and was 
considered an area of special concern for the SPI hospitals.  Problems identified after the 
medication audit (see 3.5.1) by hospitals were: 
• poor documentation of: 
o the indication for prescribing of anticoagulants; 
o the target International Normalised Ratio (INR); 
o the duration of treatment; 
• lack of evidence of GP referral information; 
• lack of evidence of patient counselling; 
• unconsidered co-prescribing of other interacting drugs; 
• lack of guidance for junior doctors on dosing schedule. 
Hospitals were expected to perform a Failure Mode Effects Analysis (see 3.6.3.4) to improve 
core processes associated with prescribing, monitoring and discharging patients on 
anticoagulation therapy.   
 
 
 70 
 
3.6.2.4 Infection control and hand hygiene 
SPI hospitals were taught the basics of infection control and recommendations to prevent 
them: 
• clean hands (wash hands with soap and water or waterless alcohol products); 
• remove lines and drains as soon as possible; 
• identify patients with potentially important communicable diseases and 
epidemiologically important infections and establish procedures to prevent 
transmission; 
• isolate patients with multi-drug resistant or epidemiologically important 
organisms; 
• vaccinate and/or treat patients and healthcare workers for important 
communicable diseases; 
• have a robust and viable local infection control programme (Institute for 
Healthcare Improvement and Health Foundation, 2005a). 
They were informed that patients particularly vulnerable to healthcare associated infections 
were those with: 
• severe underlying disease;  
• confinement to a bed; 
• poor clinical prognosis; 
• prolonged hospital stay; 
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• prior antibiotic therapy; 
• severe burn and open wounds/drains.   
3.6.2.5 Peri-operative 
Within the surgical setting the intervention focused on preventing surgical site infections 
(Ryckman et al., 2009).  The following actions were recommended (Institute for Healthcare 
Improvement, 2007): 
• appropriate prophylactic antibiotic; 
• control of glucose intra-operatively and 24 hours post-operatively in diabetic 
patients; 
• use of clipping instead of shaving; 
• normothermia (maintenance of normal core body temperature). 
In addition prophylactic antibiotics were recommended as part of this bundle.   
3.6.2.6 Critical Care Systems 
The IHI described an “ideal” ICU model in which there are three groups of people were in 
play; the leadership team, the care team and patients.  Leadership should be focused on 
infrastructure and provide realistic, but aspirational goals in quality, safety and productivity.  
The care team are in charge of the delivery of a reliable process, developed on the 
foundations of best practice.  They were required to work collaboratively by including all 
staff, patients and family.  In the centre of these two groups was the patient.   
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To achieve this model hospitals needed to employ multidisciplinary rounds to review patient 
status, schedule tests, co-ordinate care, clarify patient objectives and plan the care for that 
patient for that day.  These rounds would enable protocol/guidelines to be delivered 
consistently across disciplines, highlighting any need for refinement and further education of 
staff.   
Other key changes and measures within the ICU were: 
• daily goals; 
• ventilator bundles (Bonello et al., 2008; Resar et al., 2005); 
• central line bundles (Bonello et al., 2008; Galpern et al., 2008; Pronovost et al., 
2006a). 
A bundle was defined as being: 
“a grouping of failure mode processes (bundle elements) with approximate time and space 
characteristics that when done collectively can have an enhanced effect on outcome” 
(Institute for Healthcare Improvement and Health Foundation, 2005a). 
The bundle consisted of a minimal number of elements that could be measured in a binary 
manner, (i.e. present, not present).  Each element was based on “non-refutable” evidence, 
and be completed at a similar time and within the same environment.  Although initially the 
emphasis of the bundle was that of process improvement they were ultimately expected to 
improve outcomes.   
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The purpose of the “ventilator bundle” was to reduce the rate of ventilator acquired 
pneumonia in the ICU.  There were four elements to the bundle: 
• raising the head of the bed; 
• an assessment on the appropriateness of further sedation; 
• administration of peptic ulcer disease (PUD) prophylaxis; 
• administration of deep venous thrombosis (DVT) prophylaxis. 
The “central line bundle” was designed to help decrease the incidence of catheter-related 
bloodstream infections.  The key components were: 
• a daily review of the necessity of the line; 
• strict compliance to hand washing; 
• maximal barrier precautions upon insertion, i.e. the individual carrying out the 
procedure should wear a cap, mask, sterile gown and gloves.  The cap should 
cover all hair and the mask should cover the nose and mouth tightly.  The patient 
should be covered from head to toe with a sterile drape with a small opening for 
the site of insertion; 
• the site of insertion should be made sterile by scrubbing with chlorhexidine (2 
percent in 70 percent isopropyl alcohol) skin antiseptic.  The skin should be 
allowed to dry before insertion; 
• optimal catheter site selection, with subclavian vein as the preferred site for non-
tunnelled catheters.   
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3.6.3 Tools and skills developed 
A key concept of the SPI was that of measurement.  It was believed that the process of 
collecting information, whilst making small structured changes, would empower and 
transform hospitals, leaders, and front-line staff into delivering better quality and safer care.  
The structured methodology employed was the PDSA cycle and this is described in more 
detail in section 3.6.3.1. 
Hospital staff were instructed in the analyses of performance data by means of Statistical 
Process Control and is described in section 3.6.3.2. 
Finally hospitals were taught techniques to improve processes.  These were: a) Failure Mode 
Effects Analysis (see 3.6.3.4), a systematic method of revealing weaknesses in a process and; 
b) Reliability Design (see 3.6.3.3), a means of developing robust and more stable processes 
through process mapping.   
3.6.3.1 Plan-Do-Study-Act (PDSA) cycles  
PDSA is an iterative four-step problem-solving methodology used in business process 
improvement (Speroff and O'Connor, 2004; Varkey et al., 2007).  The first stage is to “Plan” a 
specific improvement.  At this stage organisations must know what they were trying to 
accomplish.  This should state clear aims and quantifiable goals.  At the “Do” stage the 
improvement plan is implemented.  The “Study” step requires there to be appropriate 
measurement systems in place (see 3.6.3.2) to determine if there had been a change, and if 
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this has resulted in an improvement.  The final “Act” stage was a period of reflection to 
determine what further changes were needed in light of what had been learnt i.e change 
concepts (see 3.3).  A suggested method of developing change concepts was by “divergent, 
and convergent thinking” used during “nominal group technique” – a structured method of 
brainstorming.   
These stages were described by the IHI as the “Model for Improvement”.  Hospitals were 
advised to use repeated uses of the PDSA cycle and use a “1-3-5-all” strategy.  Firstly they 
needed to have a successful prototype phase in which a small number staff executed a 
change, and determined if the change created improvement.  Once it worked well in one 
setting, it was tested in three, when it worked well in three settings it was tested in five.  
Once it was worked well in five the change moved into an implementation phase.    
The implementation phase worked in a similar fashion:  
• 1-3-5-all nurses on a ward 
• 1-3-5-all surgeons in a theatre or service 
• 1-3-5-all pharmacists 
• 1 day – 3 days – 5 days – all days 
• 1 shift – 3 shift s – 5 shifts – all shifts 
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Hospitals were told that this strategy would see an idea move from a thought, to an actual 
change that could result in improvement, which could then be disseminated to other areas 
(see 3.6.1.4).   
One of the key aspects of PDSA was making appropriate measurements.  The data collected 
during this process was described as being for quality improvement (effectiveness) rather 
than that for accountability (efficiency) or research (experimental) (Brook et al., 1996).  The 
differences between these types of data can be found in the Table 3.4 (Solberg et al., 1997):  
Table 3.4: The three faces of performance management  
Aspect Improvement Accountability Research 
Aim Improvement of care Comparison, choice, 
reassurance, spur for 
change 
New knowledge 
Methods 
Test observability Test observable No test, evaluate 
current performance 
Test blinded or 
controlled 
Bias Accept consistent 
bias 
Measure and adjust 
to reduce bias 
Design to eliminate 
bias 
Sample size ‘Just enough’ data, 
small sequential 
change 
Obtain 100% of 
available relevant 
data 
‘Just in case’ data 
Flexibility of 
hypothesis 
Hypothesis flexible, 
changes as learning 
takes place 
No hypothesis Fixed hypothesis 
Testing strategy Sequential tests No tests One large test 
Determining if a 
change is an 
improvement (see 
below) 
Run charts or 
Shewhart control 
charts 
No change focus Hypothesis, 
statistical tests (t-
test, F-test chi 
squared), p-values 
Confidentiality of the 
data 
Data only used by 
those involved with 
improvement 
Data available for 
public consumption 
and review 
Research subjects 
identities protected 
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Three types of measurement were described:   
• outcome measure that inform a system or process and describe the level of 
performance; 
• process measures – changes to the system; 
• balancing measures, which are signalling measures and usually look at a system 
from a different direction/dimension, e.g. financial data/intervening variables. 
3.6.3.2 Statistical Process Control (SPC) 
SPC is a method of monitoring a process through the use of control charts.  The advantage of 
using SPC is the ability to detect process changes and trends early.  Users making pragmatic 
improvements can move away from simple bar and line graphs, which are mainly 
descriptive, to a method, which when used correctly is statistically rigorous but requires less 
data than when testing for significance (Benneyan et al., 2003).  
This method was developed by Shewhart (who also developed PDSA cycles) in the 1920’s, 
whilst working at Bell Telephone Laboratories (Shewhart, 1939). Deming, a student of 
Shewhart, developed a theory of management based on these statistical methods and 
introduced them to industry in the 1930’s (Deming, 1986).  These methods were widely 
adopted by the Japanese industry in the 1950’s and provides the foundations of “Six Sigma”, 
a current business management strategy developed by Motorola (Tennant, 2001).  
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Shewhart discovered through experimentation that physical processes do not behave the 
same way as nature, i.e. it does not necessarily follow a normal distribution curve.  He 
concluded that processes display two types of variation (Benneyan et al., 2003):  
• common cause variation: this is random, unassignable variation that is inherent 
in the design of a process and is associated with a stable process.  This is the 
variation that is expected to occur according to the underlying statistical 
distribution if parameters remain constant; 
• special cause variation, is uncontrolled/unnatural variation, not inherent in the 
design of a process. 
Central to SPC is the plotting of control charts.  These are similar to run charts, i.e. a simple 
line graph of 15-20 data points are plotted against time.  However, control charts have the 
additional features of a centre line which represents the median, and upper and lower 
process control limits (usually set at ±3 sigma).  These additional features enable users to 
distinguish between common and special cause variation.   
There are several kinds of control charts and the type used will be determined by the type of 
data collected, i.e. continuous (measurement) data or discrete (or count or attribute) data.  
For continuous data in which there is only one observation per sub group an XmR is 
appropriate.  In instances where discrete data has been collected p-charts, u-charts, and c-
charts are more appropriate.  Details on how to construct these charts and how to interpret 
them, using worked examples are described by Mohammed et al., (2008a).  
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There are a number of rules to determine if special cause variation has occurred.  Some are 
contentious but three are widely accepted as signifying a trend (Mohammed et al., 2008a):  
• a run of eight points or more on one side of the centre line; 
• two out of three consecutive points greater than 2 sigma on the same side of the 
centre line; 
• a run of eight or more points following an upwards or downward trend. 
The use of control charts reveals which type of variation is occurring but not the cause of the 
variation, which requires further investigation.  For example, special cause variation can be 
deliberate and be part of an improvement strategy or it could be due to something 
unforeseen, such as a staff shortage.  On the other hand common cause variation is not 
inherently good; a process maybe stable but can still be delivering poor care.  Once the 
cause of variation has been determined practitioners needed to determine which course of 
action is required.   
3.6.3.3 Reliable design 
Reliable design stems from reliability and human factors science.  It has been used in 
manufacturing and aviation as a way of designing systems that consistently produce a 
desired outcome (Nolan et al., 2004).  Within healthcare, systems are chaotic, inconsistent 
and have been developed by trial and error.  These systems were described as having a 
performance of 10-1 and hospitals were expected to shift their processes to a performance 
level of 10-2.   
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To improve the reliability of a process they were expected to convene a small team 
(knowledgeable of the process) who would map the procedure in order to identify 
common/important failures.  The team were expected to segment parts of the process in 
which failures occurred, redesign and test that part whilst keeping other segments 
unchanged.  They were expected to do this until the performance reached 10-2.  In the initial 
stages change should be expected and users of the process could opt-in to the change.  
However, as the process became more robust and finalised, users had to provide valid 
reasons for opting out. 
In making process more stable hospitals were expected to use the IHI’s three-step model: 
• prevention of a failure by standardising processes; 
• indentifying and mitigating failures by designing a redundancy function to trap 
and minimise harm; 
• redesigning the process based on the critical failures identified by process 
mapping. 
3.6.3.4 Failure Mode and Effects Analysis (FMEA) 
FMEA is a systematic method of evaluating a process and identifying opportunities for the 
failure and its likely impact (Institute for Healthcare Improvement, 2010c; Williams and 
Talley, 1994).  Each failure received a numerical score between 1 and 10 for the following: 
• likelihood the failure would occur (1 = very unlikely, 10 = very likely)? 
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• likelihood the failure would be detected (1 = likely, 10 = very unlikely)? 
• amount of harm or damage the failure would cause (1 = no harm, 10= harmful)? 
The mathematical product of these scores is known as the Risk Priority Number (RPN) and 
the sum of these gives the RPN for the process.  The RPN for the process can be used as a 
measure of comparison with other processes within the same organisation. 
It was recommended that hospitals should first tackle the 10 failures with the highest RPN; 
use these to plan improvement efforts and to track and monitor over time a reduction of 
RPN of a process.   
In practical terms, hospitals were to recruit a multidisciplinary team involved in the process 
of interest.  The team produced a detailed map of the process, listed all the failure modes, 
failure causes, failure effects and calculated the RPN. 
If the failure was likely to occur the team needed to assess the cause and determine if it 
could be eliminated; if the failure was likely to be undetected they needed to consider 
adding processes upstream to identify the failure; and if the failure was likely to cause 
severe harm they should introduce early warning signs and extra information at the points of 
care for such events. 
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3.7 The SPI2 intervention phase 
To build on the experience and learning from SPI1, a second phase of the intervention, 
known as SPI2, was rolled out from March 2007 to September 2008 inclusive. SPI2 included 
a further 20 UK hospitals (ten in England and ten in the other countries of the UK) that were 
selected following a recruitment process similar to that used for SPI1.  
The intervention remained much the same as that which was put in place during SPI1. Again 
the initiative was mentored by the IHI and was designed to strengthen the organisations 
generically while putting in place specific front-line activities, such as the introduction of 
early warning score systems to improve the management of the acutely sick patient, the use 
of ventilator bundles to reduce ventilator-acquired pneumonia in intensive care, and the 
introduction of a surgical “bundle” of evidence-based standards to reduce surgical 
complications. There were five main differences between SPI1 and SPI2 in the overall 
management of the programme based on experiences gleaned from SPI1 hospitals: 
• the hospitals were required to work with a partner organisation (a “buddy 
system”) and encouraged to hold regular meetings between the lead 
implementation teams (10-12 people) from each hospital. By using this system it 
was envisaged that hospitals would support each other, share the burden and 
provide mental support in quickly achieving the goals of the intervention.  
• there was a longer period between dissemination of the preparatory materials 
(December 2006) and the first “kick-off” session where the various teams came 
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together with IHI to share experiences (March 2007). This gave hospitals more 
time for planning and developing the intervention and to obtain a baseline 
measurement in the safety climate survey.  
• the financial package was smaller than in the case of SPI1; a mean of £270k 
(€390k; $430k) per hospital rather than £775k (€860k; $1.2 million). 
• there were four learning sessions as with SPI1 but an additional reliability and 
capability workshop was provided.  
• SPI2 sought a 15% reduction in mortality rates; this was not an explicit SPI1 aim. 
Specific aspects of the intervention also changed: 
• the reduction of adverse event target was revised from 50% to 30% as it was felt 
that this was a more achievable yet “aspirational” target; 
• removal of the routine use of beta blockers in the surgical “bundle” as this 
clinical standard was contentious in the UK; 
3.7.1 Selection of participating SPI2 hospitals 
As with the selection of the SPI1 hospitals, SPI2 hospitals were selected through a 
competitive bidding process. A similar format to the phase one selection was followed with 
initial applications reviewed by an international panel with expertise in patient safety, 
organisational change and improvement methodology. With applications being assessed 
against the following criteria: 
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• leadership commitment; 
• capacity and capability; 
• openness, transparency and communication; 
• collaboration. 
The short-listed hospitals were subject to an on-site assessment and the final 20 hospitals 
were chosen by a final selection board.  
3.8 Summary 
The SPI comprised of two intervention phases.  The first phase (SPI1) started in January 
2005 in 4 intervention hospitals, one in each of the four nations.  The second phase (SPI2) 
consisted of 20 intervention hospitals across the UK and began in March 2007.  This is 
summarised in Figure 3.6. The evaluation took place in all the SPI1 hospitals and 9 English 
SPI2 hospitals.  The rationale for this and an explanation of how control hospitals were 
selected for the evaluation is described in the following chapter in section 4.3.   
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Figure 3.6: A summary of the hospitals participating in the SPI1 and SPI2 phases of the 
intervention 
 
The SPI intervention itself was focussed on improving the reliability of specific front-line 
care processes within designated clinical areas (general wards, critical care, peri-operative 
care and medicines management). Specific interventions targeted particular problems 
identified by the IHI, including medication error and identifying and responding to patient 
deterioration. Generically, the programme aimed to secure commitments to safety, culture 
and behaviour across hospitals and to improve performance in relation to patient safety. 
Generic interventions – those not specific to any particular clinical problem, but capable of 
being used to pursue the goal of improving patient safety overall – included training on how 
to conduct a structured process to identify problems and then to develop and evaluate 
customised solutions using the “Plan Do Study Act” (PDSA) technique which is based on 
quality improvement methodology with a long provenance going back to Deming (Deming, 
1986).  
SPI1 hospitals (intervention phase Jan ‘05 – Sept ‘06) 
England Wales Scotland N Ireland
SPI2 hospitals (intervention phase Mar ‘07 – Sept ‘08) 
England
England
England
England
England
England
England
England
England
England
England
Wales
Wales
Wales
Scotland
Scotland
N Ireland
N Ireland
N Ireland
N Ireland
Key: 
Hospitals included in the 
evaluation:
SPI2 hospitals worked in 
pairs:   
SPI1 hospitals: 
SPI2 hospitals:
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To evaluate this highly complex intervention, a mixed-method approach has been taken and 
this is described in Chapters 4 to 15. 
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CHAPTER 4: OVERVIEW OF THE 
EVALUATION 
This chapter will provide an outline of the methods used in the evaluation of the SPI, which 
uses a before and after study design with contemporaneous controls.  The evaluation 
comprises of several sub-studies and uses both quantitative and qualitative methods, and 
relate to the causal chain described in section 3.4.  The proceeding chapters will report on 
each individual sub study following an Introduction, Methods, Results, Discussion format.  
The final chapter “triangulates” the results (the reinforcement of one finding with a different 
type, see 2.4.3) and discusses the SPI evaluation overall.  I will end the thesis with answering 
the questions of which study design provides a robust method of evaluation of complex 
patient safety interventions.  However, firstly I will give an outline of what can be measured 
and how we measure it (see 4.1).   
4.1 End points and measurements 
To determine whether or not a patient safety intervention has been effective, 
measurements of key objects, events or abstract constructs need to be undertaken as part 
of an evaluation.  These objects, events or constructs are referred to as end points and are 
discussed below. 
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4.1.1 Patient outcomes 
This section will focus on clinical outcomes (e.g. morbidity, mortality, quality of life and 
patient satisfaction).   
Two issues arise when patient outcomes are used as endpoints: 
• the signal, (i.e. improvement caused by the intervention) to noise (stochastic 
variance in outcome) ratio (i.e. issues of precision); 
• defining outcomes (both the numerator and denominator) consistently and 
minimising case-mix bias. 
4.1.1.1 Signal to noise ratio 
A common problem for evaluators is that the patient outcomes that may plausibly be 
affected by an intervention are also influenced by many other factors, making it an imprecise 
end point.  This is illustrated in Figure 4.1 with errors forming just one component of the 
model.  The figure also demonstrates that an evaluation of a patient safety intervention 
using patient outcomes is at a higher risk of a beta (or type II) statistical error – the error of 
accepting the null hypothesis when it is not true.   
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Figure 4.1: Intellectual framework to classify links between care and poor outcome 
 
A way in which to improve the signal to noise ratio is by selecting as the numerator only the 
cases of poor outcome (harm) that were caused by poor care – that is, those resulting from 
error.  This requires identification of poor outcome and then examination of the process of 
care to identify instances of poor care.  Such methods do have limitations, as firstly 
judgments on preventability of poor outcomes is difficult; secondly there maybe 
disagreement between different reviewers as demonstrated in the Harvard Medical Practice 
Study (Brennan et al., 1991), and finally such judgements are affected by hindsight bias (see 
4.1.3), where reviewers are skewed by awareness of the outcome (Caplan et al., 1991; 
Hayward and Hofer, 2001). 
4.1.1.2 Minimising bias 
Patient outcomes may be difficult to measure in a consistent way.  For example Bruce and 
colleagues (2001) undertook a systematic review that identified over 40 definitions of two 
surgical adverse events (wound infection and anastomotic leak).  They documented 
considerable variations in the definitions across organisations.  In the context of research, it 
is important to ensure that the same observers make measurements across organisations 
Unalterable features 
of disease
Treatment properly 
given
Error (of commission 
or omission)
Poor outcome
Poor outcome
Poor outcome
Adverse event
Latent factors
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wherever possible to ensure that the results will not be biased due to differences across 
observers, even when they are applying the same definitions.  This principle has been 
applied to this evaluation (see Chapters 6, 7 and 8).   
A comparison of outcomes between organisations may also be affected by difference in 
case-mix.  Patients who are sicker and/or older have more co-morbidities and are at 
increased risk of both worse outcomes and experiencing more errors due to the requirement 
for more interventions.  This situation leads to case-mix bias in comparative studies even 
after statistical adjustment for known co-founders (Lilford et al., 2004; Lilford et al., 2003).  
Bias can be minimised by randomisation and by conducting controlled before and after 
comparisons, as described in section 2.1.3.   
4.1.2 Surrogate end points 
This section focuses on measurements occurring at the process level of the causal chain (see 
4.1.3).  Oakley et al., (2006) have argued that including a process evaluation alongside a 
more traditional outcomes-based approach would improve the science of evaluations of 
complex interventions.  There are three types of surrogate end points considered here: the 
fidelity with which an intervention is implemented, the effect of the intervention on 
intervening variables such as morale and the effect of the intervention on clinical error rates. 
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4.1.2.1 Fidelity 
Fidelity measures whether the intervention was implemented as intended or describes how 
it might have been adapted.  Where the benefit of the intervention is not in doubt, 
measuring compliance with directive to deploy the intervention is sufficient. In the more 
usual situation where the benefits of a service level intervention are contested, 
demonstrating high fidelity at least shows that the distal benefits (in terms of patient 
outcomes) are plausible and vice versa.  Evaluations can make use of this asymmetry in two 
contexts: 
• where direct measurements of safety (clinical errors and/or outcome) can be 
made with high precision (and accuracy).  In this case the fidelity measure may 
help explain a null result; 
• where direct measurements of safety cannot be made with sufficient precision.  
In this case, showing that the intervention was implemented as planned provides 
reassurance that the desired effects on safety are plausible   
4.1.2.2 Intervening variables 
Intervening variables are described in section 3.4 and tend to be the target for more diffuse 
interventions aimed at strengthening an organisation generically (Shortell et al., 2000; 
Wagner et al., 2001).  For example, improved human resources (HR) polices (such as staff 
appraisal) are expected to impact on errors by means of effects on staff motivation, and 
morale and reduced sickness.  If the intervening variable can be measured they can be used 
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as surrogate end points in evaluations of complex interventions.  It may thus be informative 
to measure the effects of such HR polices on these intervening variables.  However, as with 
fidelity measurement, changes in surrogate measures do not prove that the “down-stream” 
clinical effects will be realised. 
4.1.2.3 Clinical process measurement: error 
4.1.2.3.1 What is an error? 
Clinical error, which causes or may cause an adverse outcome is both logically and 
chronologically the closest surrogate to patient outcomes (Figure 3.2).  Clinical error can be 
broadly defined as: 
• the failure to apply the correct standard of care (an error of omission); 
• the failure to carry out a planned action as intended (an error of omission); or 
• the application of an incorrect plan (an error of commission) (Reason, 2000). 
Sometimes the error and the outcome are the one and the same, for example, wrong site 
surgery.  In other instances the error and the poor outcome occur with the same frequency 
such that the problems of rarity resurface.  In most cases, however, the error is considerably 
more common than the corresponding adverse event, because many errors, even if carried 
through to the patient, will not be harmful (Dean et al., 2002; Taxis and Barber, 2003).  
Where errors are markedly more common than contingent adverse events their relative 
frequency affords greater precision in measurement. 
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There are three methods employed to measure error: reporting systems; trigger tools and 
error rates, which are outlined below.   
4.1.2.3.2 Reporting systems 
Reporting systems may be compulsory or voluntary (Boxwala et al., 2004).  Denominators 
are not of the whole population (Pronovost et al., 2006b; Vincent, 2007), and tend to be 
fitted later such as a unit of time or a population of patients.  Problems with this 
methodology include: 
• differences between study units in the number and type of patients mean that 
there is a high likelihood of bias in an any comparative study based on reporting 
and retro-fitting a denominator risks a data driven (self-fulfilling) hypothesis; 
• incomplete reporting which is highly selective (Begaud et al., 2002; Cullen et al., 
1995; National Audit Office, 2005); 
• any change in reporting may reflect propensity to report rather than a true 
change in the underlying problem.  Moreover, a tenet of safe practice is a culture 
of open reporting. 
Despite these problems with reporting systems reported events are still of value.  National-
level data from reporting systems are useful for identifying priorities for patient safety 
interventions or detecting previously unsuspected hazards such as side effects of drugs or 
device malfunction (Giles et al., 2005; World Health Organization, 2005).  However, as a 
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method for comparing institutions or evaluating interventions, they carry a significant risk of 
bias.   
4.1.2.3.3 Trigger tools 
Trigger tools are used to identify sentinel events, such as abnormal laboratory values, the 
prescription of antidotes or reports of patient harm, which indicate that a preventable 
adverse event may have occurred (Barber et al., 2006; Resar et al., 2006).  Positive triggers 
are subjected to further investigation to determine whether an error had occurred.  Since a 
detailed case-note review is only required when there is a positive trigger, the method is less 
resource intensive than a detailed manual review of all case notes in the sample.   
There are three main problems associated with the use of trigger tools: 
• their lack of sensitivity, (i.e. the number of adverse events detected by the tool).  
For example, the first study of the use of trigger tools in the UK (Barber et al., 
2006) found that the tool identified less than 1% of prescribing errors (identified 
through the trigger tool, spontaneous reporting, pharmacist review and 
retrospective case-note review).  The proportion of errors identified was higher 
for serious errors but never exceeded 50% (Barber et al., 2006); 
• their low specificity, (i.e. the proportion of triggers that are preventable) and 
thus positive predictive value (PPV).  If the trigger is not specific the PPV will be 
low and scarce resources will be devoted to investigating false negative.  
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Estimates of PPV vary considerably but do not exceed 38% (Brown et al., 2008c); 
and  
• the risk of bias inherent in their use, as there is a risk that the tools will identify 
different events with different sensitivities, depending on local factors such as 
the type and completeness of information held. 
However, trigger tools are likely to yield less biased results when used over time within an 
organisation so long as there is no material change in the type of data collected.  As a basis 
for comparison across institutions or interventions they are liable to be biased. 
4.1.2.3.4 Error rates 
Errors affecting clinical process require measurement of both numerator and denominators 
if they are to be used for comparative purposes.  Errors are often denominated at the level 
of the patient (i.e. errors per patient).  However, this may yield biased results, particularly in 
non-randomised and unmasked studies.  This is because case-mix across time or place may 
yield different opportunities for error.  A method to reduce this type of bias is to denominate 
errors on the opportunity for error, rather than the number of patients (Lilford et al., 2003).  
However, this method does not completely negate the bias as: 
• it may be easier to detect opportunities for error in one place than in another, 
for example due to differences in note keeping; and 
• equally performing clinicians may find some errors more difficult to avoid than 
others and this confounds comparisons when the opportunities for error differ 
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from place to place.  For example, if patients with more comorbidities “cluster” 
under the care of particular clinicians, it may be seen that these clinicians make 
more error, even after case-mix adjustment (Greenfield et al., 2002).   
Despite these caveats, denominating error on the opportunity for error provides at least 
some protection against case-mix bias.  The opportunity for error method also provides a 
method to deal with contingent errors, where the opportunity for error arises only if certain 
pre-existing conditions are fulfilled. 
4.1.2.3.4.1 Formal methods for detection of error rates 
There are four main methods for the direct measurement of error: 
• case-note review – retrospective construction of a cohort; 
• prospective data collection by clinical staff; 
• prospective data collection by independent observers; 
• prospective data collection by a participant observer, either simulated (Merien et 
al., 2010) or real patients. 
The important distinction between all these methods and reporting systems is that the data 
are recorded from all cases in a predefined cohort.  Evidence suggests that the four different 
methods above will not result in identification of the same set of errors.  For example, 
Michel et al., (2004) show that prospective data collection by clinical staff produced a higher 
error rate than retrospective evaluation of case-notes in the context of accident and 
emergency care. 
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The relative strengths and weaknesses of these (and other methods) of data collection have 
been reviewed by Thomas and Petersen (2003), Murff et al., (2003) and the UK’s National 
Patient Safety Agency (2005).  Thomas and Petersen (2003) suggest that the relative utility of 
different methods depends on the type of error or incident being investigated.   
4.1.2.3.4.2 Holistic versus explicit review 
Data on error can be collected using holistic (implicit) and/or explicit methods.  The holistic 
(see Chapter 8) method involves experts making their own judgements about the quality of 
care provided and can be either structured or unstructured.  In a structured holistic review, 
experts are presented with a series of preparatory questions designed to elicit a complete 
review of the important facets of care, whilst in an unstructured holistic review experts are 
given little guidance and typically follows the format used by expert witnesses in litigation 
cases.   
Explicit review (see 6.2.5) involves the objective application of predetermined standards, 
which are developed using expert groups and/or national care protocols.  Explicit reviews 
can be focussed (using a limited set of supported and feasible measures) or global (using a 
broader set of quality measures for a large number of conditions).  The quality of care in USA 
has been studied using a global approach, applying 439 indicators for 30 conditions 
(McGlynn et al., 2003).  These global indicators have been adapted for use in the UK (Kirk et 
al., 2003), using a limited set of 200 indicators across 23 conditions.  However, criteria or 
indicators should only be applied in an explicit review if they are considered relevant to the 
patient in question (Kahn et al., 1990).   
 98 
 
Both holistic and explicit methods of data collection have advantages and disadvantages, 
which are described in Table 4.1.  Data extraction can be enhanced by combing review 
methods (Hutchinson et al., 2010), and so both holistic and explicit methods have been 
employed in this evaluation (see Chapter 6 and Chapter 7). 
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Table 4.1: Comparison of holistic and explicit methods of data extraction in case-note review 
Holistic Explicit 
Advantages  
Easy to develop and administer Explicit (evidence based) criteria 
High face validity, since experts define “good” and bad care Reproducible 
Self-updating through use of experts Easy to explain low score in terms of criteria – which may narrow score of 
improvement efforts 
Reflects the full scope of clinical decisions that apply to a particular patient Can be conducted by researchers rather than clinicians, once the criteria 
have been agreed, reducing costs 
Involves physicians and other expert clinicians in the quality of care process  
  
Disadvantages  
Requires (expensive) clinical experts Require training of reviewers 
More arbitrary than evidence based Need to be updated constantly 
Developed principally for inpatient care Limited scope in terms of content and context (relevant publications) 
Poor reproducibility of judgements Possible bias if different numbers of criteria apply to patients between 
comparative organisations, particularly if some criteria are harder to meet 
than others 
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4.1.2.3.4.3 Validity 
Any method of data collection needs to demonstrate construct validity: the results need to 
be an accurate reflection of the underlying concept intended for the data.  A surrogate end 
point has construct validity if it has shown empirically to correlate with outcome or if it this 
is judged to be self-evident (Lilford et al., 2004).   
Moreover, many actions (or failures to act) may be more ambiguous and hence their 
construct validity is less clear cut.  For example, it is commonly believed in patient safety 
circles that minor prescription errors are a good surrogate for major prescription errors.  This 
assumption is based on Heinrich’s seminal work of 1931, where he outlined a ratio in which 
there were 29 minor injuries and 300 no-injury accidents for every major incident (Heinrich, 
1931).  However the empirical basis for this conclusion is poorly described and a review of 
studies on prescribing error found insufficient evidence to support a single ratio that could 
be used to validate the use of minor errors as a surrogate for major errors (Barber et al., 
2006; Dean et al., 2002).   
4.1.2.3.4.4 Reliability 
Any measure of patient safety needs to be reliable (repeatable).  Inter-observer reliability 
implies that more than one observer/reviewer would come to the same conclusion when 
evaluating a single care process.  The traditional methods of assessing the extent of inter-
rater reliability between two or more independent reviewers is the Cohen kappa κ (Cohen, 
1960), although the sensitivity of κ to the prevalence of error (Lilford et al., 2007) has 
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resulted in other methods, such as tetrachoric or polychoric correlations being advocated 
where possible (Hutchinson, 1993).  It should be noted that the κ statistic is used for 
dichotomous judgements and the intra-class correlation coefficient (ICC) is used for rating 
scales, as used for the quality of care ratings in section 7.3.3.  Since duplicating observations 
is expensive it is important to optimise the sample size for the measurement of reliability 
using formulae to calculate the precision of measurements if inter-observer agreement 
(Altman, 1991). 
A recent review by Lilford et al., (2007) considered factors that may affect the κ obtained 
and reported that the following factors raised the mean κ: a) the use of explicit, rather than 
holistic; b) assessing outcomes rather than causality and processes.  It was also noted that κ 
was positively correlated with the prevalence of error. 
4.1.3 Masking 
As with all other evaluations, masking patients, caregiver and observers as well as those 
undertaking the statistical analysis is important in minimising information bias (Schulz and 
Grimes, 2002).  Masking is particularly important when the end-point being measured is 
subjective rather than objective (Morrison and Lilford, 2000).  Where assessments are being 
made about the quality of care reviewers tend to give worse rating if an adverse outcome 
occurred – hindsight bias (Caplan et al., 1991). This can bias the estimated size of the 
problem and lead to exaggerated estimates of cost effectiveness.  Evaluating all cases of care 
and looking for all errors, rather than first selecting adverse events and then looking into to 
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see whether an error occurred, can reduce such a bias – an approach taken in this 
evaluation.   
Hindsight bias does not prejudice assessment of relative safety improvements in a 
comparative study if it is applied equally across comparison groups.  Here, bias is a risk if the 
observer is aware of the group (intervention or control) to which an individual or cluster has 
been assigned.  Observers should therefore be blinded to the allocation of the data, be it 
intervention, control, or before or after.  This principle as has been applied in this evaluation, 
see 6.2.4). 
Biases associated with the measurement of patient outcomes are discussed separately in 
section 4.1.1.2. 
4.2 Framework for the evaluation 
In section 4.1 I described what can be measured to determine if a patient safety complex 
intervention has been effective.  However, it is important to understand the fidelity to which 
an intervention was implemented and to understand why it worked the way it did (see 
2.1.4).  In these circumstances a mixed-method evaluation, using both quantitative and 
qualitative studies is useful.    
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The evaluation of the SPI used mixed-methods and was based on a systems-wide approach 
that is described in section 3.4.  In this approach the system is conceptualised as the setting 
in which care is delivered and five levels can be distinguished:  
• structure (e.g. size of hospital and types of services provided). This has been 
described in Table 3.1 and Table 4.3; 
• management processes (e.g. leadership style, management WalkRounds); 
• intervening (mediating) variables (e.g. culture, morale, absence due to sickness) 
that connect management to clinical process; 
• clinical processes (error rates/compliance with tenets of evidence based care); 
• outcome (adverse events, mortality, patient satisfaction). 
The data collection and analyses was organised around this conceptual model, using a series 
of linked sub-studies (Figure 4.2):  
• management processes were studied by means of a series of qualitative 
interviews with strategic stakeholders (Appendix B); 
• intervening variables were assessed by using quantitative staff survey (Chapter 5) 
and a qualitative study using ethnographic methods on hospital wards (Appendix 
C); 
• clinical processes were studied by: case-note review of acutely sick patients using 
explicit methods (Chapter 6) and holistic methods (Chapter 7); an explicit case 
  
note review of peri
hand hygiene (Chapter 9);
• outcomes were studied by: case
mortality (Chapter 11
associated infection rates (HCAI) (
(Chapter 14).    
 
Figure 4.2: Causal chain linking 
points across the chain to provide information on context, fidelity, and effectiveness of 
SPI 
-operative care (Chapter 8); and by using indirect measures of 
 
-note review of adverse events (
);, outcomes within the ICU (Chapter 12
Chapter 13) and quantitative patient surveys 
SPI to outcomes. The evaluation sub-studies
104 
Chapter 10) and 
), healthcare 
 were made at 
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The evaluation of SPI1 preceded the evaluation of SPI2 and not all methods were employed 
in all hospitals: 
The qualitative studies (Appendix B and C) were conducted in the four SPI1 intervention 
hospitals only, as the funder of the evaluation believed that “data saturation” would be 
reached, i.e. no further data collection would elicit new information.   
The only studies conducted in both the SPI1 and SPI2 evaluations were the staff surveys 
(Chapter 5), case-note review of acutely sick patients (Chapters 6, 7, 10 and 11) and patient 
surveys (Chapter 14).  This was because at the time of commissioning the SPI1 evaluation, a 
decision needed to be made on what could be measured within the funding envelope.  The 
staff survey and patient surveys utilised data already collected within the NHS, whilst the 
decision to collect case-notes of the acutely sick patient was based on the opportunity to 
measure several facets of the intervention, mainly the use of EWSS (see 3.6.2.1) and 
medicines management (see 3.6.2.3) within one episode of care.  In addition one of the SPI1 
hospitals did not have an ICU, which was a target of the SPI.  These measures were 
extended to the SPI2 evaluation so that the data collected in the SPI2 evaluation could act as 
control data for the evaluation of SPI1, the details of which can be found in section 4.3. 
For the evaluation of SPI2 the funders requested that the quantitative data collection be 
expanded to evaluate additional aspects of the intervention not measured within the SPI1 
evaluation, such that, case-note review of peri-operative care (Chapter 8), indirect measures 
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of hand hygiene (Chapter 9), outcomes with the ICU (Chapter 12) and HCAI rates (Chapter 
13) were conducted in the SPI2 evaluation only.   
All the quantitative sub-studies were before and after studies in intervention and concurrent 
control hospitals. Use of both before and after observations across control and hospitals 
enabled rates of change to be compared across control and SPI hospitals – an approach 
referred to as the “difference-in-difference” method (see 2.1.3.2). The sub-studies are 
summarised in Table 4.2. 
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Table 4.2: Summary of sub-studies comprising the evaluation of the SPI 
Sub-study Purpose Location Data collection Analysis 
Interviews with strategic 
stakeholders 
Study impact at a senior 
management level. Arguably a 
necessary if not sufficient 
condition for effectiveness 
SPI1 hospitals 
and strategic 
commissioners  
Semi-structured 
interviews 
Constant comparative method 
Staff survey Measure effects of SPI on staff 
morale, culture and opinion 
Control, SPI1 
and SPI2 
hospitals 
Validated structured 
questionnaire 
1) Comparison of control versus SPI hospitals: 
a. At baseline 
b. Over time, i.e. difference-in-difference 
2) Comparisons within control and SPI cohorts 
Ethnography study at 
ward level 
Discover the impact of SPI1 on 
‘hearts and minds’ of those 
actually delivering care 
Medical wards 
treating 
patients with 
acute 
respiratory 
disease in SPI1 
hospitals 
Ethnographic study 
consisting of three 
rounds of visits, 
including 
observations, 
interviews and focus 
groups 
Constant comparative method 
Quality of care:  
acute medical care 
(clinical process)  
Measure effects of SPI on the 
quality of care being delivered 
using independent case-note 
reviews in acute medical care 
(both explicit and holistic). 
Control, SPI1 
and SPI2 
hospitals 
Before and after  
intervention phase of 
SPI1 and SPI2 
1) Comparison of control versus SPI hospitals: 
a. At baseline 
b. Over time, i.e. difference-in-difference 
(Epochs 1 vs. 2 for the SPI1 evaluation) 
(Epochs 1+2 vs. Epoch 3 for the SPI2 
evaluation )* 
c. Measurement of reliability and 
learning/fatigue effects 
 
Quality of care: peri-
operative care 
(clinical process) 
Measure effects of SPI on the 
quality of care using independent 
case-note reviews in peri-operative 
care (explicit). 
Control and 
SPI2 hospitals 
Before and after  
intervention phase of 
SPI2 
1) Comparison of control versus SPI2 hospitals: 
a. At baseline 
b. Over time, i.e. difference-in-difference 
(Epoch 2 vs. Epoch 3)* 
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Indirect measures 
(clinical process) 
Measure used hand hygiene 
consumables. 
Control and 
SPI2 hospitals 
Trend data collected 
as part of the 
National Observation 
Study of 
Effectiveness of the 
national 
“cleanyourhands” 
Campaign study 
1) Comparison of control versus SPI hospitals: 
a. At baseline 
b. Over time, i.e. difference-in-difference 
Outcomes Measure effects of SPI on: 
a. Adverse events among acute 
medical care case-notes 
reviewed 
b. Mortality among acute medical 
care case-notes reviewed 
c. ICU outcomes [SPI2 only] 
d. HCAI  rates [SPI2 only] 
e. Patient satisfaction 
Control, SPI1 
and SPI2 
hospitals 
Before and after 
study using: 
a) and b) Case-notes 
c) d) and e) Routine 
data 
f) Validated 
structured survey 
1) Comparison of SPI versus control hospitals: 
a. At baseline 
b. Over time, i.e. difference-in-difference 
2) Comparisons within SPI and control cohorts 
3) Measurement of reliability and 
learning/fatigue effects 
 
*Sub-studies involving case-note review that overlapped with SPI1 have two pre-intervention phases (Epochs 1+2), while sub-studies specific to SPI2 have only 
one pre-intervention phase (Epoch 2). In all cases Epoch 3 is the post-intervention phase. 
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4.3 Controls and intervention hospitals 
The SPI hospitals were selected by the Health Foundation (see 3.2 and 3.7.1).  For the SPI1 
evaluation all four intervention hospitals were evaluated. In the SPI2 phase of the 
intervention 20 hospitals across the UK were selected to participate, however, the evaluation 
focused on the ten English SPI2 hospitals only so that routinely collected data in England 
(staff survey, hospital mortality, ICU outcomes, HCAI rates and patient survey) could be 
accessed.  
Although the SPI2 hospitals worked in pairs each hospital formed a unit of analysis for the 
statistical power calculation and for the evaluation.  Participation in the evaluation was not 
compulsory and one of the ten SPI2 hospitals declined to partake as they felt they did not 
have the capacity to assist in the evaluation, leaving nine available for the study.   
The selection of the control hospitals for the SPI1 evaluation capitalised on the evaluation of 
SPI2. The SPI2 intervention was scheduled to start after the completion of the SPI1 
intervention phase. For this reason it was possible to use both control and intervention 
hospitals from the SPI2 evaluation as controls for SPI1. This was achieved by choosing two 
separate pre-intervention epochs for SPI2. Thus, nine of the control hospitals for SPI1 were 
destined to be SPI2 intervention hospitals and nine were SPI2 matched control hospitals (for 
the SPI1 evaluation these are described as the “18 controls”).  
 
 110 
 
SPI2 controls were selected using the following criteria (it should be noted that some of the 
matching was done at trust level and some at hospital level): 
• only non-specialist acute trusts in England were considered; 
• control and SPI2 trusts should have a similar directorate structure (as described 
in the NHS national staff survey); 
• the trusts should have the same foundation or non-foundation status (to gain 
foundation status a trust must satisfy the government that it has the 
management capacity to warrant greater operational autonomy); 
• the trust should be similarly located in either urban or rural settings; 
• once these criteria were satisfied, the hospital within a trust with the most 
similar size (usually within 1000 staff) to the SPI2 hospital was selected as the 
control hospital; 
• if a trust had more than one hospital, quantitative data collection was focused on 
the largest hospital with an ICU, as the ICU was targeted for improvement in the 
SPI. 
Characteristics of SPI2 hospitals and the matched controls can be found in Table 4.3.   
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Table 4.3: Hospital characteristics of SPI2 hospitals and matched control hospitals 
 
SPI2 hospitals Matched control hospitals 
Pair n
o Bed 
numbers 
(current) 
Urban/ 
rural† 
Teaching status ‡ Bed 
numbers 
(current) 
Urban/ 
rural 
Teaching status 
1 411 Rural Affiliated 475 Rural Nil 
2 455 Urban Nil 511  Urban Nil 
3 620 Urban/ 
rural 
Nil 618 Urban Teaching hospital 
4 634 Urban Nil 723 Urban/ 
rural 
Nil 
5 688 Urban Teaching hospital 447 Urban/ 
rural 
Affiliated 
6 804 Urban Teaching hospital 789 Urban Affiliated 
7 668 Urban Teaching hospital 988 Urban Affiliated 
8 523 Urban Teaching hospital 532 Urban/ 
rural 
Nil 
*9 566 Urban Affiliated 1,036 Urban Affiliated 
* The discrepancy in size has arisen as matching was based number of staff at trust level, which was 
the best available data at the time of matching.  The bed numbers in this table are those at hospital 
level and have only recently become available.  
† Based on visual inspection of population density map 
‡ Based on hospital website 
The hospitals have not been named as it was agreed that anonymity would be ensured as part of 
evaluation participation. 
 
The method by which SPI2 hospitals could serve as controls for SPI1 is explained by Figure 
4.3.   
Although four SPI1, nine SPI2 and nine control hospitals agreed to participate in the 
evaluation further consent for each sub-study was required. In some instances this was not 
granted. In addition some of the study hospitals did not participate in the national routine 
data collection exercises that were external to the evaluation but were accessed for 
analyses.  Whilst yet others failed to supply case-notes for specific analysis. It is for these 
 112 
 
reasons that discrepancies exist in the number of hospitals agreeing to participate in the 
evaluation and the number included in each sub-study.  
Figure 4.3: Schematic diagram demonstrating staggering of the data collection enabling 
the use of pre-SPI2 intervention data as control data for the evaluation of SPI1.  
 
 
Epoch 1
S
P
I
1
In
te
rv
e
n
tio
n
 P
h
a
se
Epoch 2
S
P
I
2
In
te
rv
e
n
tio
n
 P
h
a
se
Epoch 3 
Follow-up
SPI2
4 SPI1 Intervention
Hospitals
9 SPI2 Intervention
Hospitals
9 SPI2 Matched Control 
Hospitals
Timeline
Oct ‘03 – Mar ‘04 Jan ‘05 – Sept ‘06 Oct ‘06 – Mar ’07 Mar ‘07 – Sept ’08 Oct ‘08 – Mar ‘09
Note:
a) Those time periods in which a cross appears pertain to the control data for the SPI1 evaluation 
b) No SPI1 data was collected during the SPI2 follow-up phase;
c) The “epochs” relate to the times when patients whose notes were reviewed were treated.  The reviews of the 
notes themselves followed the epochs but they were overlapped so that any learning/fatigue effects on part of the 
reviewers could be controlled for.
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CHAPTER 5: STAFF SURVEYS 
5.1 Introduction 
Strategic support for any programme may not reflect views at the “sharp end” of practice. 
Thus, intervening variables such as staff morale, attitudes and various factors relevant to 
‘culture’ that might be affected by the SPI were assessed by staff survey.  The aim of this 
sub-study was to measure the effects of SPI on intervening variables.     
5.2 Methods 
This sub-study was conducted in both the SPI1 and SPI2 evaluations.  The methods for this 
sub-study are summarised in Figure 5.1. 
All hospitals in England participate in the National Staff Survey, a yearly survey run by the 
Care Quality Commission (CQC) (formerly the Healthcare Commission).  For the evaluation of 
SPI1 arrangements were made to conduct the same survey, using the same survey methods 
and questionnaire in the three non-English hospitals. It was not possible for the surveys to 
take place at exactly the same time in all hospitals. The first round of the survey was 
undertaken in the English hospital in Autumn 2004 and in the non-English hospitals in Spring 
2005 (note that this was three months after the intervention had started). The second round 
of the survey was conducted in Autumn 2006 for the English hospital and Spring of 2007 for 
the non-English hospitals, but this time it was not possible to include one of the SPI1 
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hospitals because it was undergoing a merger and a period of major reorganisation. Data 
were therefore available for three of the four SPI1 hospitals in the second round. 
Figure 5.1: An outline of the staff survey sub-study 
 
Questionnaires were sent to all staff in the four SPI1 hospitals. In the 18 control hospitals, a 
simple random sample of 850 staff was used instead, as this is the standard methodology 
employed by the Care Quality Commission. A sample size of 850 is such that an average 60% 
response rate (around 500 responses per hospital) would yield 95% confidence intervals of 
no greater than 10% for all scores within a single organisation.  
In the SPI2 evaluation all nine control hospitals and nine intervention hospitals were 
included in both the 2006 and 2008 National Staff Surveys, conducted between October and 
What?
Staff 
surveys
to measure 
intervening 
variables such as 
culture and staff 
morale
Where?
4 SPI1
intervention & 18 
control* hospitals
9 SPI2
intervention & 9 
control hospitals
Who?
All staff in SPI1 non-
English hospitals
Random sample of 850 
staff in all other hospitals
When (SPI1 evaluation)?
Data collection (“before”): 2004/2005
SPI1 intervention: Jan ‘05 - Sept ‘06
Data collection (“after”): 2006/2007
When (SPI2 evaluation)?
Data collection (“before”): 2006
SPI2 intervention: Mar ‘07 – Sep ‘08
Data collection (“after”): 2008
*The controls for the SPI1 evaluation comprise of the pre-intervention data collected for the SPI2
evaluation. For a full explanation see section 3.2.
 115 
 
December in each of these years, and so data from these surveys were used to test for 
effects of the intervention.  Again questionnaires were sent to a simple random sample of 
850 staff in each hospital. The detail of the survey methods is not repeated here but is 
available from the staff survey advice centre website (www.nhsstaffsurveys.com).  
5.2.1 Statistical methods 
Approximately 28 survey scores are regularly reported by the CQC. Thirteen of these (Box 
5.1) were identified at the start of the evaluation as being of likely relevance to the SPI 
programme, either because they reflect safety issues directly, or because they relate to 
working practices known from research to be linked to safety and health outcomes. Details 
of these questions and how they are calculated can be found in Appendix D. 
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Box 5.1: Staff survey variables deemed relevant to the SPI 
1. Well structured appraisals (Guzzo et al., 1985; West et al., 2006) 
2. Working in well-structured teams (Borrill et al., 2000) 
3. Witnessing potentially harmful errors or near misses in previous month 
4. Suffering work related injury 
5. Suffering work related stress 
6. Experiencing physical violence from patients/relatives 
7. Intention to leave 
8. Job satisfaction 
9. Quality of work life balance 
10. Support from supervisors 
11. Organisational climate (Michie and West, 2004) 
12. Fairness and effectiveness of incident reporting procedures* 
13. Availability of hand washing materials* 
* These scores were not included in the 2004 and 2006 staff survey and consequently were 
unavailable for the SPI1 evaluation.  However, these were included in proceeding surveys and hence 
included in the SPI2 evaluation. 
 
Differences between the control and SPI hospitals in terms of changes between the two 
survey periods were tested using a generalised linear mixed model with SPI/control and 
survey period as fixed factors (with interaction), and hospital as a random factor. In order to 
control for known differences between groups of staff, the following background factors 
were included as covariates in the models: age, sex, ethnic background (white or other), 
occupational group (nursing/midwifery, medical/dental, allied health professional/scientific 
& technical, admin/clerical, general management, maintenance/ancillary, or other), length 
of service, and management status (line manager or not). A formal statistical correlation for 
multiple observations was not applied but statistical significance is claimed for p-values less 
than 0.01, and 99% confidence intervals are used throughout. 
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5.3 Results 
5.3.1 Results of the SPI1 evaluation 
For the first staff survey, the mean response rate was 45% (7826 of 17,507 returned) in the 
four SPI1 hospitals; for the second it was just 35% (4191/11,922) across the three hospitals 
that participated (see Table 5.1).  In the eighteen control hospitals, the response rate for the 
first survey varied from 38% to 71%, with an average of 57%, and for the second survey 
varied from 26% to 62% with an average of 52%.   
There was no significant difference in response rates between control and SPI1 hospitals at 
baseline.  Table 5.1 shows the values of the 11 survey scores in each of the four SPI1 
hospitals for the two surveys, along with details of response rates. Table 5.2 shows the 
changes in both control and SPI1 hospitals on each of the 11 scores identified, along with 
the differences between the groups in these changes and associated 99% confidence 
intervals. 
Comparison with control hospitals is important because national changes in the NHS over 
this period resulted in generally more negative scores at the second survey than at the first 
(Healthcare Commission, 2007a).  At baseline, the percentage of staff reporting “well-
structured appraisals within the previous 12 months” was significantly lower in SPI1 hospitals 
than control hospitals. “Job satisfaction” and “support from supervisors” were also 
significantly lower in SPI1 hospitals than control hospitals (p<0.01). None of the other 
baseline differences was statistically significant. 
 118 
 
Only one of the eleven scores shows a statistically significant difference (p<0.01) in changes 
between the control hospitals and SPI1 hospitals between the two surveys. “Organisational 
climate”, which refers to extent of positive feeling within the organisation relating to 
communication, staff involvement, innovation and patient care (Michie and West, 2004), 
was similar between the control and SPI1 hospitals at baseline (3.11 versus 3.08 on a scale 
where 1 is very negative and 5 is very positive). This score decreased by 0.22 in the control 
hospitals but only by 0.15 in the SPI1 hospitals (p<0.001). The effect size for this difference 
in change between the control and SPI1 hospitals after covariates are taken into account 
was modest, at 0.08 points on a 5 point scale where there was a range at baseline of 0.5 
points between hospitals.  
5.3.2 Results of the SPI2 evaluation  
In the nine SPI2 hospitals, the overall response rate for the first, “before”, survey was 53% 
(3957 of 7402 valid questionnaires returned). This remained the same (53%) for the second, 
“after”, survey (3940/7448). In the nine control hospitals, the response rates were 50% 
(3634/7301) and 49% (3616/7424) respectively.  Table 5.3 shows the changes in both control 
and SPI2 hospitals on each of the 13 scores identified, along with the differences between 
the groups in these changes (with associated 99% confidence intervals). 
Comparison with control hospitals showed that national changes in the NHS over this period 
resulted in generally more positive scores at the second survey than at the first (Healthcare 
Commission, 2007a).  
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Again, only “organisational climate” (out of 13 scores) shows a statistically significant 
(p<0.01) change over time between the control hospitals and SPI2 hospitals. On this 
occasion it was significantly lower in the control hospitals than the SPI2 hospitals at baseline 
(2.79 versus 2.91 on a scale where 1 is very negative and 5 is very positive). Thus, although 
the increase in this score in control hospitals was higher than in SPI2 hospitals (0.08 
compared with 0.01), the score was still higher in the SPI2 hospitals at the second survey. 
The effect size for this difference in change between the control and SPI2 hospitals after 
covariates are taken into account was modest, at 0.07 points on a 5 point scale where there 
was a range at baseline of 0.55 points between hospitals.  
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Table 5.1: Staff survey scores in SPI1 hospitals at the two periods* 
 Hospital 1 Hospital 2 Hospital 3 Hospital 4** 
 N Survey 1 
[2004/2005] 
score 
(SE) 
N Survey 2 
[2006/2005]
score 
(SE) 
N Survey 1 
[2004/2005]
score 
(SE) 
N Survey 2 
[2006/2007]
score 
(SE) 
N Survey 1 
[2004/2005]
score 
(SE) 
N Survey 2 
[2006/2007]
score 
(SE) 
N Survey 1 
[2004/2005]
score 
(SE) 
% staff having well 
structured 
appraisals within 
previous 12 
months (Guzzo et 
al., 1985; West et 
al., 2006) 
1094 41  
(1) 
1079 33 
(1) 
2458 39 
(1) 
1045 28 
(1) 
2101 27 
(1) 
1869 23 
(1) 
458 28 
(2) 
% staff working in 
well structured 
teams (Borrill et 
al., 2000) 
1091 37 
(1) 
1073 38  
(1) 
2450 41 
(1) 
1043 37 
(1) 
2090 34 
(1) 
1845 33 
(1) 
457 42 
(2) 
% staff witnessing 
potentially harmful 
errors or near 
misses in previous 
month 
1119 54  
(1) 
1122 45  
(1) 
2517 44 
(1) 
1074 47 
(2) 
2138 50 
(1) 
1937 42 
(1) 
468 46 
(2) 
% staff suffering 
work related injury 
in previous 12 
months 
1129 22 (1) 1082 19 
(1) 
2514 20 
(1) 
1045 20 
(1) 
2139 22 
(1) 
1896 17 
(1) 
464 19 
(2) 
% staff suffering 
work related stress 
in previous 12 
months 
1147 36 (1) 1104 32 
(1) 
2541 32 
(1) 
1072 30 
(1) 
2178 35 
(1) 
1918 29 
(1) 
474 39 
(2) 
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% staff 
experiencing 
physical violence 
from 
patients/relatives 
in previous 12 
months 
1139 14 (1) 1112 9 
(1) 
2531 13 
(1) 
1073 11 
(1) 
2157 17 
(1) 
1932 13 
(1) 
463 18 
(2) 
Intention to leave 
(Michie and West, 
2004) 
1144 3.41 
(0.03) 
1118 3.39 
(0.03) 
2508 3.50 
(0.02) 
1074 3.33 
(0.03) 
2158 2.99 
(0.02) 
1919 3.03 
(0.02) 
472 3.33 
(0.05) 
Staff job 
satisfaction (Michie 
and West, 2004) 
1155 3.46 
(0.02) 
1120 3.46 
(0.02) 
2550 3.56 
(0.01) 
1079 3.35 
(0.02) 
2185 3.25 
(0.02) 
1923 3.26 
(0.02) 
476 3.40 
(0.03) 
Quality of work life 
balance (Michie 
and West, 2004) 
1152 2.64 
(0.03) 
1116 2.60 
(0.03) 
2529 2.50 
(0.02) 
1074 2.75 
(0.03) 
2173 2.73 
(0.02) 
1916 2.66  
(0.02) 
476 2.63 
(0.05) 
Support from 
supervisors (Michie 
and West, 2004) 
1146 3.40 
(0.03) 
1120 3.48 
(0.03) 
2536 3.50 
(0.02) 
1072 3.36 
(0.03) 
2179 3.18 
(0.02) 
1917 3.21 
(0.02) 
473 3.33 
(0.04) 
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Organisational 
climate 
(Healthcare 
Commission, 2006; 
Michie and West, 
2004)) 
1137 3.32 
(0.02) 
1098 3.20 
(0.02) 
2516 3.19 
(0.01) 
1070 2.90 
(0.02) 
2155 2.82 
(0.02) 
1902 2.79 
(0.02) 
459 3.08 
(0.03) 
Response rate - 43% - 40% - 39% - 39% - 39% - 31% - 48% 
* The first six of these scores were percentages, simply reflecting the percentage of respondents who answered “yes” to a single question or a set of questions. The other 
five are on a scale of 1-5, and are based on the mean of between three and six questions, each of which was scored between 1 and 5 for each respondent. For four of these 
five scores (“quality of work-life balance”, “staff job satisfaction”, “support from supervisors” and “organisational climate”), the higher the score the better, although for 
“intention to leave”, lower scores are better. 
** Due to reorganisation this hospital only participated in one survey.  
Standard Error (SE) 
Shaded areas relate to post-intervention epochs.   
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Table 5.2: Staff survey scores in control and SPI1 hospitals at the two periods* 
 
 Control hospitals SPI1 hospitals 
Range 
at 
base-
line 
Difference 
in change 
(99% CI) 
P-value 
 N Survey 
1 
[2004] 
score 
(SE) 
N Survey 
2 
[2006] 
score 
(SE) 
Absolute  
% 
change 
N Survey 
1 
[2004/
2005]  
score 
(SE) 
N Survey 
2 
[2006/
2007]  
score 
(SE) 
Absolute  
% 
change 
   
% staff having well structured 
appraisals within previous 12 
months 
8046 39 
(1) 
7260 28 
(1) 
-10 6111 34 
(1) 
3993 27 
(1) 
-7 27-46 3 
(-2, 8) 
0.095 
% staff working in well 
structured teams 
8052 40 
(1) 
7279 37 
(1) 
-3 6088 38 
(1) 
3961 35 
(1) 
-2 34-52 1 
(-4, 6) 
0.510 
% staff witnessing potentially 
harmful errors or near misses 
in previous month 
8236 47 
(1) 
7520 39 
(1) 
-8 6242 48 
(1) 
4133 44 
(1) 
-4 41-56 5 
(-2, 11) 
0.068 
% staff suffering work related 
injury in previous 12 months 
8286 22 
(0) 
7372 19 
(0) 
-3 6246 21 
(1) 
4023 18 
(1) 
-3 18-26 0 
(-4, 3) 
0.854 
% staff suffering work related 
stress in previous 12 months 
8368 34 
(1) 
7457 33 
(1) 
-1 6340 34 
(1) 
4094 30 
(1) 
-4 29-39 -5 
(-12, 0) 
0.013 
% staff experiencing physical 
violence from 
patients/relatives in previous 
12 months 
8283 13 
(0) 
7482 11 
(0) 
-2 6290 15 
(0) 
4117 11 
(0) 
-3 9-18 -3 
(-8, 0) 
0.026 
Intention to leave (Healthcare 
Commission, 2006)
 
8263 3.36 
(0.01) 
7437 3.29 
(0.01) 
-0.08 6282 3.29 
(0.01) 
4111 3.21 
(0.01) 
-0.09 2.99-
3.51 
0.04  
(-0.03, 
0.10) 
0. 139 
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Staff job satisfaction 
 
(Healthcare Commission, 
2006) 
8357 3.47 
(0.01) 
7495 3.37 
(0.01) 
-0.10 6366 3.42 
(0.01) 
4122 3.34 
(0.01) 
-0.09 3.25-
3.57 
0.03  
(-0.02, 
0.08) 
0.13
2 
Quality of work life balance 
(Healthcare Commission, 
2006) 
8249 2.63 
(0.01) 
7436 2.72  
0.01) 
0.10 6330 2.61 
(0.01) 
4106 2.67 
(0.02) 
0.06 2.45-
2.80 
-0.05 
(-0.12, 
0.03) 
0.10
6 
Support from supervisors 
(Healthcare Commission, 
2006) 
8310 3.45 
(0.01) 
7477 3.41 
(0.01) 
-0.05 6334 3.36 
(0.01) 
4109 3.32 
(0.01) 
-0.04 3.18-
3.55 
0.02 
(-0.04, 
0.08) 
0.35
8 
Organisational climate 
(Healthcare Commission, 
2006) 
8302 3.11 
(0.01) 
7424 2.89 
(0.01) 
-0.22 6267 3.08 
(0.01) 
4070 2.93 
(0.01) 
-0.15 2.82-
3.32 
0.08 
(0.02, 
0.13) 
0.00
0* 
*The first six of these scores were percentages, simply reflecting the percentage of respondents who answered “yes” to a single question or a set of questions. The other 
five are on a scale of 1-5, and are based on the mean of between three and six questions, each of which was scored between 1 and 5 for each respondent. For four of these 
five scores (“quality of work-life balance”, “staff job satisfaction”, “support from supervisors” and “organisational climate”), the higher the score the better, although for 
“intention to leave", lower scores are better. To aid interpretation scores where a lower value is better are shown in italics. Range at baseline indicates the range of scores 
across control and SPI1 hospitals in the first survey to give some context for the level of change shown. The difference in change and corresponding confidence interval 
does not necessarily reflect the difference in absolute change because of the inclusion of covariates in the models tested. 
Standard Error (SE) 
Shaded areas relate to post-intervention epochs 
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Table 5.3: Staff survey scores in control and SPI2 hospitals at the two periods* 
 Control hospitals SPI2 hospitals 
Range at 
baseline 
Difference 
in change 
(99% CI) 
p-
value 
 N Survey 1 
[2006] 
score 
(SE) 
N Survey 2 
[2008] 
score 
(SE) 
Absolute 
% 
change 
N Survey 1 
[2006] 
score 
(SE) 
N Survey 2 
[2008] 
score 
(SE) 
Absolute 
% 
change 
   
% staff having well 
structured 
appraisals within 
previous 12 
months (Guzzo et 
al., 1985; West et 
al., 2006) 
3477 28 
(1) 
3429 28 
(1) 
-1 3783 28 
(1) 
3734 26 (1) -2 20-39 3 
(-3, 9) 
% staff working in 
well structured 
teams (Borrill et 
al., 2000) 
3498 36 
(1) 
3408 37 
(1) 
1 3781 38 
(1) 
3747 38 (1) 0 32-42 4 
(-4, 12) 
0.205 
% staff witnessing 
potentially harmful 
errors or near 
misses in previous 
month 
3602 37 
(1) 
3532 33 
(1) 
-4 3918 41 
(1) 
3851 40 (1) -1 32-47 -4 
(-10, 3) 
0.167 
% staff suffering 
work related injury 
in previous 12 
months 
3524 19 
(1) 
3490 16 
(1) 
-3 3848 19 
(1) 
3796 18 (1) -1 16-23 -2 
(-5, 2) 
0.182 
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% staff suffering 
work related stress 
in previous 12 
months 
3575 33 
(1) 
3532 27 
(1) 
-6 3882 32 
(1) 
3842 27 (1) -6 26-40 -1 
(-6, 5) 
0.670 
% staff 
experiencing 
physical violence 
from 
patients/relatives 
in previous 12 
months 
3598 1 
 (1) 
3536 11 
(1) 
-1 3884 11 
(1) 
3849 11 (1) 0 7-16 -1 
(-3, 3) 
0.645 
Intention to leave 
(Michie and West, 
2004)) 
3557 3.26 
(0.02) 
3544 3.40 
(0.02) 
0.14 3880 3.31 
(0.01) 
3865 3.42 
(0.01) 
0.11 3.07-3.50 -0.04 
(-0.12, 0.04) 
0.198 
Staff job 
satisfaction 
(Michie and West, 
2004) 
3593 3.34 
(0.01) 
3568 3.44 
(0.01) 
0.10 3902 3.40 
(0.01) 
3898 3.49 
(0.01) 
0.09 3.23-3.50 -0.02 
(-0.08, 0.04) 
0.422 
Quality of work life 
balance (Michie 
and West, 2004) 
3568 2.77 
(0.02) 
3536 2.56 
(0.02) 
-0.22 3868 2.68 
(0.02) 
3857 2.51 
(0.02) 
-0.17 2.46-2.97 0.05 
(-0.04, 0.14) 
0.142 
Support from 
supervisors 
(Michie and West, 
2004) 
3583 3.39 
(0.02) 
3551 3.56 
(0.02) 
0.17 3894 3.43 
(0.01) 
3869 3.61 
(0.01) 
0.18 3.22-3.53 0.00 
(-0.08, 0.07) 
0.889 
Organisational 
climate 
(Healthcare 
Commission, 2006; 
Michie and West, 
2004) 
3578 2.79 
(0.01) 
3551 2.87 
(0.01) 
0.08 3861 2.91 
(0.01) 
3886 2.92 
(0.01) 
0.01 2.52-3.07 -0.07 
(-0.14, 0.00) 
0.009 
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† 
Fairness and 
effectiveness of 
incident reporting 
procedures 
(Michie and West, 
2004) 
3555 3.36 
(0.01) 
3487 3.41 
(0.01) 
0.05 3861 3.41 
(0.01) 
3803 3.45 
(0.01) 
0.04 3.27-3.54 -0.01 
(-0.05, 0.04) 
0.664 
† 
Availability of 
hand washing 
materials (Michie 
and West, 2004) 
2939 4.58 
(0.01) 
3126 4.75 
(0.01) 
0.17 3231 4.51 
(0.01) 
3418 4.67 
(0.01) 
0.16 4.32-4.72 -0.01 
(-0.07, 0.04) 
0.587 
*
 The first six of these scores were percentages, simply reflecting the percentage of respondents who answered “yes” to a single question or a set of questions. The other 
seven are on a scale of 1-5, and are based on the mean of between three and six questions, each of which was scored between 1 and 5 for each respondent. For six of these 
seven scores, the higher the score the better, although for “intention to leave”, lower scores are better. To aid interpretation scores where a lower value is better are 
shown in italics. Range at baseline indicates the range of scores across SPI and control hospitals in the first survey to give some context for the level of change shown. The 
difference in change and corresponding confidence interval does not necessarily reflect the difference in absolute change because of the inclusion of covariates in the 
models tested. 
† 
These scores were not included in the SPI1 evaluation as they were not included   in survey 1. 
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5.4 Discussion 
In both the SPI1 and control hospitals the response rate declined from the first survey to the 
second survey, which was reflected in a national decrease in response rates among acute 
hospitals in England over the same period (from 57% to 52%) (Healthcare Commission, 2005; 
Healthcare Commission, 2007b).  However, response rates were somewhat lower in the non-
English hospitals, which may be due to the lack of the national profile for the survey outside 
England.  The SPI2 response rates remained stable between the two surveys for both control 
and intervention hospitals.  
Overall, the staff survey shows little change between the first and second survey in both 
control and SPI hospitals (both SPI1 and SPI2). Control and SPI hospitals were also mostly 
indistinguishable at baseline.   
The SPI had little impact on the culture of the organisation, as within both evaluations only 
one (“organisational climate”) of the 11 dimensions of staff satisfaction changed significantly 
over time but to a small degree.  However, this change favoured the intervention hospitals in 
the SPI1 evaluation; but within the SPI2 evaluation controls were favoured.   
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CHAPTER 6: EXPLICIT CASE-NOTE REVIEW 
TO MEASURE ERROR RATES/QUALITY OF 
CARE IN PATIENTS WITH ACUTE 
RESPIRATORY DISEASE  
6.1 Introduction 
Specific SPI targets included improvements to the monitoring of the acutely sick patient and 
a reduction in the number of medication errors (see 3.6.2.1 and 3.6.2.3).  An anamnestic 
method of measuring the effect of the SPI in these areas is by retrospective case-note 
review.  In this chapter I will describe an explicit method of review (adherence to 
predetermined standards of care) of patients admitted with acute respiratory disease.  The 
areas of review include both those specifically targeted by the SPI, and those that might 
plausibly be expected to improve if an overall shift in organisational systems and culture 
related to patient safety had occurred.   
6.2 Methods 
An overview of this sub study can be found in Figure 6.1.  This sub-study was conducted in 
both the SPI1 and SPI2 evaluations.  The case-notes collected as part of this sub-study are 
also utilised in the holistic review, measurement of adverse events and measurement of 
mortality within this cohort of patients.  These sub-studies are reported as separately in 
Chapters 8, 11 and 12.   
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Figure 6.1: An outline of the case-note review of patients admitted with acute respiratory 
disease 
 
6.2.1 Case-note selection criteria 
Patients over the age of 65 years with acute respiratory disease admitted to acute medical 
wards were selected as the focus for study for the following reasons: 
• improving recognition and response to acute deterioration in a patient’s 
condition was a specific SPI target, and patients admitted with acute respiratory 
disease are at high risk of such deterioration (Hillman et al., 2001; Smith et al., 
2006);  
• a number of specific evidence-based guidelines exist for this condition; 
What?
Case-note 
review** 
(explicit 
and holistic 
methods) 
to measure error 
rates, adverse 
events and 
mortality in acute 
medical care
Where?
4 SPI1
intervention & 18 
control* hospitals
9 SPI2
intervention & 9 
control hospitals
Who?
Patients over the 
age of 65
Acute respiratory 
disease
When (SPI1 evaluation)?
Data collection (“before”): Oct ‘03 – Mar ‘04
SPI1 intervention: Jan ‘05 - Sept ‘06
Data collection (“after”): Oct ’06 – Mar ‘07
When (SPI2 evaluation)?
Data collection (“before”): Oct ‘03 – Mar ‘04
Data collection (“before”): Oct ’06 – Mar ‘07
SPI2 intervention: Mar ‘07 – Sep ‘08
Data collection (“after”): Oct ’08 – Mar ‘09
*The controls for the SPI1 evaluation comprise of the pre-intervention data collected for the SPI2
evaluation. For a full explanation see section 3.2.
** The sub-studies for the explicit review, holistic review, adverse events and mortality are reported
separately in Chapters 7, 8, 11 and 12 respectively
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• there is a high incidence of co-morbidities in people aged over 65, making this a 
high-risk population where the opportunity for error is high and hence where 
there should be opportunity for improvement. 
6.2.2 Case-note assembly  
6.2.2.1 Case-notes collected for the SPI1 evaluation 
Case-notes from both the four intervention and 18 control hospitals from two time periods 
(Epoch 1 and Epoch 2) that preceded and followed the SPI1 intervention period (Figure 6.1) 
were collected. The number of SPI1 hospitals was fixed and the control observations were 
spread across a greater number of hospitals to provide a more robust sample. The aim was 
to analyse 100 case-notes from each SPI1 hospital per epoch (800 in total) and 15 from each 
control hospital per epoch (540 in total).  
Epoch 1 extended from October 2003 to September 2004 in the SPI1 hospitals and from 
October 2006 to September 2007 in Epoch 2, thereby largely controlling for any seasonal 
effects (due, for example, to staff changeovers at particular times of the year). As fewer 
patients were needed for each time period in control hospitals, the epoch only extended 
from October to March of the corresponding years.  
The case-notes from the first eight or nine patients who fulfilled the eligibility criteria (see 
6.2.4) were selected from each SPI1 hospital, in each month from each epoch. In the control 
hospitals, the first two or three of such cases were selected. 
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6.2.2.2 Case-notes collected for the SPI2 evaluation 
Case-notes from both the nine control and nine SPI2 hospitals from time periods that both 
preceded (Epochs 1 and 2) and followed (Epoch 3) the SPI2 intervention period were 
collected (Figure 6.1). The pre-implementation observations were spread over two epochs 
(Epoch 1 [October 2003 to March 2004] and Epoch 2 [October 2006 to March 2007]) so that 
the hospitals participating in the SPI2 evaluation could also serve as controls for the 
preceding SPI1 evaluation. Epoch 3 (October 2008 to March 2009) was therefore the post-
SPI2 period. (The temporal change between Epochs 1 and 2 was included as a fixed effect in 
the statistical models. Each six month time period was made to correspond across the 
calendar to control for seasonal effects). The aim was to analyse, using review against 
explicit criteria, 15 case-notes from each control and SPI2 hospital per epoch (810 in total).   
Epoch 1 extended from October 2003 to March 2004 in the SPI2 and control hospitals, and 
from October 2006 to March 2007 in Epoch 2, and from October 2008 to March 2009 in 
Epoch 3.   
6.2.3 Sample size  
The target sample size for both the SPI1 and SPI2 evaluations (540 and 810 case-notes 
respectively) would give 80% power to detect effects summarised in Table 6.1. For example, 
for a standard (such as measurement of respiratory rate at least 6 hourly) with a baseline 
compliance of 70%, the study is powered to detect an SPI associated improvement to 83% 
compliance, or a deterioration to 55% at p=0.05, two-tailed.  
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These calculations are appropriate for binary data analysis where each patient is associated 
with a single opportunity for error. However, the power available to analyse prescribing 
errors will tend to be considerably greater than that in Table 6.1 since the typical patient is 
associated with more than one medication prescription and thus has several opportunities 
for error. However, some actions, such as use of blood culture in people with evidence that 
they may have blood stream infection, were contingent (did not apply to the whole sample) 
and less power would be available in such cases.  
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Table 6.1: Detectable Effect Sizes, at 5% significance and 80% power for a sample of 800 
case notes split equally between epochs. For example if baseline compliance with a 
standard was 50% then an improvement to 65% or a deterioration to 35% would be 
detectable 
Baseline  
Proportion 
Modified proportions 
detectable with 80% power 
0.05 0.14 0.00 
0.10 0.21 0.02 
0.15 0.27 0.05 
0.20 0.34 0.09 
0.25 0.39 0.13 
0.30 0.45 0.17 
0.35 0.50 0.21 
0.40 0.56 0.25 
0.45 0.61 0.30 
0.50 0.65 0.35 
0.55 0.70 0.39 
0.60 0.75 0.44 
0.65 0.79 0.50 
0.70 0.83 0.55 
0.75 0.87 0.61 
0.80 0.91 0.66 
0.85 0.95 0.73 
0.90 0.98 0.79 
0.95 1.00 0.86 
 
6.2.4 Eligibility criteria 
Patients over 65 years of age and admitted with acute respiratory disease, primarily 
community-acquired pneumonia, exacerbation of chronic obstructive pulmonary disease 
(COPD) or acute asthma were included in the study (for rationale see 6.2.1).  
For each case-note, the admission of interest was photocopied and anonymised (with 
respect to the patient’s name, hospital name and year of admission) by medical-record 
 135 
 
clerks in each hospital. Photocopied notes were dispatched to Birmingham before being sent 
to reviewers. In Birmingham, anonymisation was quality assured; the notes were digitised; 
and the year of admission was removed so that reviewers would be blinded to the epoch 
from which the case-notes originated. 
The quality of anonymisation was audited by asking the reviewer to note if the hospital of 
origin, the year of origin and the patient name had been recognised.  
6.2.5 Explicit case-note review 
A set of explicit criteria to define medical care for respiratory patients was developed with 
reference to British Thoracic Society (BTS) guidelines (2001) and (2004), the British National 
Formulary [BNF (versions 53 (2007a), 54 (2007b) and 56 (2008)) – the editions that covered 
the study period] and expert opinion (consultant respiratory physicians from a teaching and 
a general hospital – see contributions). The areas of review and source of guidelines were:  
• quality of medical history-taking. Eleven items (Box 6.1) were identified as 
constituting the ideal history for a patient admitted with acute respiratory 
disease (expert opinion); 
• proportion of routine investigations (urea and electrolytes, chest x-ray and full 
blood count) ordered within 6 hours of a patient’s admission (expert opinion – 
see above); 
• observations and signs of patient deterioration. The completeness with which 
patients’ vital signs were recorded) was evaluated on admission and then for the 
 136 
 
first and subsequent 6 hour time periods (BTS). Vital sign data that were 
recorded in the case-notes constituted the numerator, while all vital signs that 
should have been recorded constituted the denominator; 
• appropriate clinical response for abnormal vital signs was measured (Table 6.3) 
(BTS);  
• investigating features of good care for specific classes of patients by: 
o calculating the CURB score to determine the severity of community 
acquired pneumonia and hence appropriate antibiotic selection (Box 
6.1) (BTS, BNF); 
o use of intravenous steroids for patients’ with acute exacerbations of 
asthma and COPD (BTS); 
o measurement of peak flow in asthma patients (expert opinion); 
o to exclude hypercapnia in COPD patients, by performing arterial 
blood gases, before prescribing/administering oxygen (BTS); 
o rates of prescribing errors. The following definition was used: 
“A clinically meaningful prescribing error occurs when, as a result of a prescribing 
decision or prescription writing process, there is an unintentional significant (1) 
reduction in the probability of treatment being timely and effective or (2) increase in 
the risk of harm when compared with generally accepted practice” (Dean et al., 
2000).  
Errors were identified using a previously developed pro forma (Barber et al., 2006) and 
categorised according to stage of the drug use process (Appendix B) (Cousins and Hatoum, 
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1991). SPI had identified reductions in the number of adverse effects related to 
anticoagulant therapy as a key aim so prescribing error in this area was investigated as a 
sub-category (as listed in section 2.8 of the BNF). Finally, medicines reconciliation on 
admission was also a target of the SPI (Table 3.2) and, therefore, failures to continue to 
prescribe medicines on the transition from primary to secondary care where no explanation 
for this was recorded in the notes were examined. 
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Box 6.1: Components of an "ideal" respiratory history 
• Duration of presenting symptoms 
• Normal (pre-morbid) exercise tolerance 
• Presence/absence of shortness of breath 
• Presence/absence of orthopnoea 
• Presence/absence of cough 
• Whether or not cough was productive (if present) 
• Smoking history taken 
• Presence/absence haemoptysis 
• Whether or not chest pain was present 
• Occupation/previous occupation 
• Pet ownership 
 
Table 6.2: Vital signs that should be recorded 
 
Admission 6 and 12 hours later 
Temperature   
Respiratory rate   
Cyanosis/oxygen saturation  - 
Presence of confusion/mental state (new onset)  - 
Pulse   
Blood pressure   - 
Oxygen saturation -  
  
Table 6.3: Appropriate clinical response for abnormal observations  
Abnormal vital sign Appropriate clinical response 
Oxygen saturation <90%, at any time Full blood gases within 2 hours 
Given oxygen (if not on oxygen) 
Doctor called or transferred to ICU (if on oxygen) 
Blood pressure systolic <90 mmHg At least next 6 hours, hourly observations 
Blood culture 
Sputum present Sputum culture 
Respiratory rate >20 breaths per minute at any 
time after admission 
Given oxygen (if not on oxygen) 
Doctor called (if on oxygen) 
Temperature over 38°C - any episode Blood culture 
Failure to improve within 48 hours or subsequent 
deterioration 
Review by consultant 
Repeat chest x-ray 
White cell counted/repeated 
Appropriate addition of further antibiotics 
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Box 6.2: Assessment of severity of community acquired pneumonia using the CURB score  
CURB score 
Confusion: new mental confusion (defined as an Abbreviated Mental Test score of 8 or less); 
Urea: raised >7 mmol/l; 
Respiratory rate: raised > 30/min; 
Blood pressure: low blood pressure (systolic blood pressure <90 mm Hg , diastolic blood pressure < 
60 mm Hg). 
 
Interpretation of CURB score 
• patients who have two or more “core” adverse prognostic features are at high risk of death and 
should be managed as having severe pneumonia; 
• patients who display one “core” adverse prognostic feature are at increased risk of death. The 
decision to treat such patients as having severe or non-severe pneumonia is a matter of clinical 
judgement, preferably from an experienced clinician. This decision can be assisted by considering 
“pre-existing” and “additional” adverse prognostic features. 
 
Influence on antibiotic therapy 
Non-severe community-acquired pneumonia  
Most patients can be adequately treated with oral antibiotics. Combined oral therapy with 
amoxicillin and a macrolide (erythromycin or clarithromycin) is preferred for patients who require 
hospital admission for clinical reasons. When oral treatment is contraindicated, recommended 
parenteral choices include intravenous ampicillin or benzylpenicillin, together with erythromycin or 
clarithromycin. 
 
Severe community acquired pneumonia  
Patients with severe pneumonia should be treated immediately after diagnosis with parenteral 
antibiotics. An intravenous combination of a broad spectrum β-lactamase stable antibiotic such as 
co-amoxiclav or a second generation (e.g. cefuroxime) or third generation (e.g. cefotaxime or 
ceftriaxone) cephalosporin together with a macrolide (e.g. clarithromycin or erythromycin) is 
preferred. 
All case-notes were reviewed by a qualified pharmacist over a period from November 2006 
to November 2009. Ideally reviews would be conducted in a random sequence once all 
records had been collected. However, due to the time taken to collect the case-notes and 
the reporting requirements this was not possible. Therefore, to control for any learning 
and/or fatigue effect on the part of the reviewer, the case-notes were scrambled to ensure 
that the notes were not reviewed entirely in series and in particular so that the same 
hospitals and epochs were not examined in series. 
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Inter-observer agreement on prescribing error was evaluated for the SPI1 evaluation only 
and was measured by assigning every tenth case-note to a second observer, who is also a 
qualified pharmacist, and who assessed cases in batches blinded to the others assessment, 
but compared and discussed results after each batch.  
6.2.6 Statistical methods 
Generalised linear mixed models were used to analyse the effect of the SPI intervention. 
Adjustment for the patient-level covariates age and sex was included in all analyses. Cubic 
polynomials in the time of review were used to adjust for learning/fatigue effects in the 
review process and were included in all analyses save that for mortality (see Chapter 12). 
Binary observations were modelled using mixed effects logistic regressions with a random 
component for variation between hospitals. Medication errors (per recorded prescription) 
were analysed with population-averaged negative binomial models with grouping by 
hospital, fitted using generalised estimating equations (GEE). Where the data were 
insufficient to support a full analysis as described here, the hospital effects were excluded 
from the model leading to logistic regression analyses (for binary data) and negative 
binomial regression models (for prescribing errors.) The calculations were performed in 
STATA 11.0. Statistical significance is claimed for p-values less than 0.01, and 99% confidence 
intervals are used throughout. Levels of inter-agreement were tested using the κ statistic.   
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6.2.6.1 Statistical methods used specifically in the SPI1 evaluation 
Fixed effects were included: (a) for differences in pre-intervention levels between control 
and SPI1 hospitals (“baseline comparisons”) (b) the temporal change experienced in the 
control hospitals between the pre-intervention period (Epoch 1) and the post-intervention 
period (Epoch 2); and (c) the effect of the SPI, interpreted as the difference between the 
temporal changes pre/post intervention experienced in the control and SPI1 hospitals. 
6.2.6.2 Statistical methods used specifically in the SPI2 evaluation 
Within all models, pre-intervention levels were estimated by pooling data from the first two 
epochs and post-intervention levels were estimated using data from the third epoch. Fixed 
effects were included: (a) for differences in pre-intervention levels between control and SPI2 
hospitals (“baseline comparisons”) (b) for temporal changes between Epochs 1 and 2 across 
all hospitals; (c) the temporal change experienced in the control hospitals between the pre-
intervention period (i.e. Epochs 1 and 2 pooled together) and the post-intervention period 
(Epoch 3); and (d) the effect of the SPI, interpreted as the difference between the temporal 
changes pre/post intervention experienced in the control and SPI2 hospitals. 
 142 
 
6.3 Results 
6.3.1 The sample 
6.3.1.1 Number of case-notes reviewed within the explicit review in the SPI1 
evaluation  
The smallest SPI1 hospital could not identify the target numbers of case-notes, leading to a 
slight shortfall in the intended SPI1 sample size of 400 case-notes in each epoch: 381 (Epoch 
1, before SPI1) and 380 (Epoch 2, after implementation of SPI1). The corresponding 
numbers for control hospitals are 236 case-notes in Epoch 1 and 240 in Epoch 2.  
6.3.1.2 Number of case-notes reviewed within the explicit review in the SPI2 
evaluation 
The intended sample size of 405 from the SPI2 hospitals was not met - 347 case-notes were 
reviewed. These case-notes were split approximately equally across the epochs: 116 from 
Epoch 1, 117 from Epoch 2 and 114 from Epoch 3. Control hospitals yielded 355 case-notes 
out of the intended sample size of 405: 120 from Epoch 1, 123 from Epoch 2 and 112 from 
Epoch 3.  
6.3.2 Effects associated with the review process 
Case-note reviews took place in the period November 2006 to August 2009. The review of 
SPI1 hospital case-notes was done first, and was 90% complete by August 2008. By contrast, 
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90% of the SPI2 and control hospital reviews were not carried out until after September 
2008 (as this was commissioned at a later date). In the intervention arm, randomisation of 
the order of review was only partial: on average, the review date for Epoch 1 was earlier 
than for Epoch 2, though there was considerable overlap between the dates of the two sets 
of reviews (see Figure 6.2). A cubic polynomial adjustment for the timing of the review was 
employed to minimise the potential for confounding between the SPI effect and any 
temporal effects associated with the date of review. These effects were found to be most 
significant in the analysis of prescribing errors and have been routinely incorporated into the 
results described in 6.3.8, 6.3.9 and 6.3.10 below. Elsewhere they were found to be 
significant for just two items not associated with prescribing error (see 6.3.4 below). 
Figure 6.2: Prescription error rates and date of review 
 
The rates of detected errors (per prescription) are represented by a locally smoothed version of the raw error-
rates (solid line) and also by the cubic polynomial (broken line) used in the analysis. Median dates of review 
(♦), and intervals showing when most (80%) of the reviews were done (←  →), are given for each combination 
of Arm and Epoch.  Date of review for Epoch 3 is not shown here but occurred during Dec 2008 to Nov 2009 
and learning/fatigue effects from this time have also been incorporated in the analysis.   
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6.3.3 Reliability  and anonymisation of case-notes within the SPI1 evaluation  
The comparison of prescribing error results between two observers showed substantial 
inter-observer agreement (Landis and Koch, 1977), with a κ value of 0.71 and 0.70 in Epochs 
1 and 2, respectively. Prescribing errors were used to assess reliability as it is the most 
difficult of the explicit review criteria to assess, being based on hundreds of potential errors 
in the BNF. 
During the review the primary reviewer was able to detect the hospital of origin in 1% of 
cases (11/1154), the epoch in 14% of cases (158/1154) and the patients’ name in 4% of cases 
(42/1154).  
6.3.4 Quality of medical history taking 
6.3.4.1 Within the SPI1 evaluation  
The effect of SPI is not apparent, and is not statistically significant for any item. The baseline 
comparisons showed no significant differences between control and SPI1 hospitals; neither 
is there significant evidence of temporal improvement for any item (see Table 6.5). 
There was some evidence of a temporal effect in the review process (learning/fatigue effect) 
for Item 2 (“Exercise Tolerance”), p<0.001 and for Item 9 (“Chest Pain”), p=0.002.  
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Several of the questions were asked less often for older patients. Age was a significant 
predictor for items 2, 3, 5, 6, 7 and 9 (p<0.001 in all cases), typically reducing the odds of the 
question being asked by about 5% per year of age. 
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Table 6.4: Medical history taking (% of patients asked) 
 
Control Hospitals (N=18) SPI1 Hospitals (N=4) 
 Epoch 1 Epoch 2 Epoch 1 Epoch 2 
Number of Patients 236 240 381 380 
     
 % SE % SE % SE % SE 
         
1. Duration of "presenting" symptom 94.5 1.5 94.6 1.5 94.5 1.2 95.5 1.1 
2. Normal exercise tolerance 32.6 3.1 34.9 3.1 32.5 2.4 37.1 2.5 
3. Presence/absence shortness of breath 89.8 2.0 92.1 1.7 93.2 1.3 93.9 1.2 
4. Presence/absence orthopnoea 28.0 2.9 28.7 2.9 24.1 2.2 20.3 2.1 
5. Presence/absence cough 89.8 2.0 90.4 1.9 84.8 1.8 89.2 1.6 
6. If cough, was it productive 82.6 2.5 86.3 2.2 81.6 2.0 88.2 1.7 
7. Smoking history taken 75.7 2.8 80.4 2.6 80.3 2.0 82.1 2.0 
8. Presence/absence of haemoptysis 23.7 2.8 25.7 2.8 26.0 2.2 27.4 2.3 
9. Chest pain (of any type) 61.3 3.2 68.6 3.0 74.8 2.2 71.8 2.3 
10. Occupation/previous occupation 39.7 3.2 38.1 3.1 63.5 2.5 63.9 2.5 
11. Pets 2.6 1.0 3.0 1.1 1.8 0.7 1.1 0.5 
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% over all items 56.6 58.6 59.8 61.0 
Entries are percentages with Binomial standard errors (SE).   Shaded areas relate to post-intervention epochs 
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Table 6.5: Medical history taking – differences between control and intervention hospitals, changes over time and the effect of SPI1  
 
Baseline Comparisons Changes in Controls Effect of SPI1 
    
 OR (99% CI) p-value OR (99% CI) p-value OR (99% CI) p-value 
       
1. Duration of "presenting" symptom 2.0 (0.5, 8.5) 0.207 0.8 (0.3, 2.4) 0.607 1.6 (0.4, 6.9) 0.414 
2. Normal exercise tolerance† 0.6 (0.2, 1.5) 0.158 1.2 (0.7, 2.0) 0.421 1.5 (0.7, 3.0) 0.178 
3. Presence/absence shortness of breath 2.1 (0.6, 7.7) 0.149 1.3 (0.6, 3.2) 0.388 0.9 (0.3, 3.1) 0.843 
4. Presence/absence orthopnoea 0.7 (0.3, 1.5) 0.230 1.0 (0.6, 1.8) 0.817 1.0 (0.5, 2.2) 0.966 
5. Presence/absence cough 0.4 (0.1, 1.1) 0.018 1.2 (0.5, 2.7) 0.610 1.9 (0.7, 5.3) 0.129 
6. If cough, was it productive 0.8 (0.3, 2.2) 0.533 1.5 (0.7, 3.0) 0.142 1.3 (0.5, 3.3) 0.453 
7. Smoking history taken† 1.0 (0.3, 3.1) 0.963 1.6 (0.8, 2.9) 0.060 0.8 (0.4, 1.9) 0.519 
8. Presence/absence of haemoptysis 1.1 (0.5, 2.4) 0.733 1.2 (0.7, 2.0) 0.505 0.9 (0.4, 1.9) 0.769 
9. Chest pain (of any type)† 1.1 (0.4, 2.6) 0.872 1.5 (0.9, 2.6) 0.031 0.7 (0.3, 1.5) 0.230 
10. Occupation/previous occupation† 1.6 (0.7, 3.7) 0.159 1.0 (0.6, 1.6) 0.939 1.1 (0.6, 2.2) 0.622 
11. Pets 0.3 (0.03, 1.6) 0.048 1.5 (0.3, 6.9) 0.502 0.6 (0.1, 6.1) 0.571 
† Denotes items with significant (p<0.010) between hospital variation within the arms of the study  
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6.3.4.2 Within the SPI2 evaluation  
Baseline comparisons showed no significant differences between control and SPI2 hospitals. 
An effect of SPI was not apparent and was not statistically significant for any of the items 
measured. For two items (“Exercise Tolerance” and “Occupation”) measured in relation to 
history taking there was significant evidence of an improvement overtime in both control 
and SPI2 hospitals (see Table 6.7). There was some evidence of a reviewer learning/fatigue 
effect for “Exercise Tolerance” (p<0.001) “Chest Pain” (p=0.010) and “Occupation” (p=0.001).  
Again, several of the questions were asked less often for older patients. Age was a significant 
predictor for items 3, 6 and 7 (p≤0.001 in all cases), typically reducing the odds of the 
question being asked by about 5% per year of age. 
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Table 6.6: Medical history taking (% of patients asked)   
 
Control Hospitals (N=9) SPI2 Hospitals (N=9) 
 Epoch 1 Epoch 2 Epoch 3 Epoch 1 Epoch 2 Epoch 3 
Number of Patients 120 123 112 116 117 114 
       
 % SE % SE % SE % SE % SE % SE 
             
1. Duration of "presenting" symptom 92.5 2.4 91.1 2.6 95.5 2.0 96.6 1.7 98.3 1.2 99.1 0.9 
2. Normal exercise tolerance 26.5 4.1 31.7 4.2 38.4 4.6 38.8 4.5 38.3 4.6 33.9 4.5 
3. Presence/absence shortness of breath 88.3 2.9 91.1 2.6 88.4 3.0 91.4 2.6 93.2 2.3 92.0 2.6 
4. Presence/absence orthopnoea 23.3 3.9 28.1 4.1 17.0 3.6 32.8 4.4 29.3 4.2 18.0 3.7 
5. Presence/absence cough 88.3 2.9 89.4 2.8 86.6 3.2 91.4 2.6 91.5 2.6 83.9 3.5 
6. If cough, was it productive 78.3 3.8 84.6 3.3 77.7 4.0 87.1 3.1 88.0 3.0 76.8 4.0 
7. Smoking history taken 73.9 4.0 81.3 3.5 66.1 4.5 77.6 3.9 79.5 3.7 74.1 4.2 
8. Presence/absence of haemoptysis 22.2 3.9 28.1 4.1 16.1 3.5 25.2 4.1 23.3 3.9 26.1 4.2 
9. Chest pain (of any type) 68.1 4.3 71.5 4.1 54.5 4.7 54.3 4.6 65.5 4.4 59.8 4.7 
10. Occupation/previous occupation 44.4 4.6 37.7 4.4 53.6 4.7 34.8 4.5 38.5 4.5 38.4 4.6 
11. Pets 3.4 1.7 3.3 1.6 0.9 0.9 1.7 1.2 2.6 1.5 6.3 2.3 
       
% over all items 55.7 58.2 54.1 57.5 59.0 57.4 
Entries are percentages with binomial standard errors. 
Shaded areas relate to post-intervention epochs. 
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Table 6.7: Medical history taking – differences between control and SPI2 hospitals, changes over time and the effect of SPI2 
 
Baseline Comparisons Changes in Controls Effect of SPI2 
    
 OR (99% CI) p-value OR (99% CI) p-value OR (99% CI) p-value 
       
1. Duration of "presenting" symptom 3.2 (0.7, 14.0) 0.040 1.6 (0.4, 7.3) 0.391 1.7 (0.07, 40.3) 0.672 
2. Normal exercise tolerance 1.4 (0.8, 2.4) 0.125 2.2 (1.1, 4.4) 0.005 0.7 (0.3, 1.7) 0.312 
3. Presence/absence shortness of breath 1.3 (0.5, 3.5) 0.480 0.8 (0.3, 2.3) 0.539 1.3 (0.3, 5.7) 0.701 
4. Presence/absence orthopnoea 1.3 (0.7, 2.5) 0.330 0.6 (0.3, 1.5) 0.159 0.9 (0.3, 2.6) 0.749 
5. Presence/absence cough 1.2 (0.5, 2.9) 0.506 0.7 (0.2, 1.8) 0.286 0.7 (0.2, 2.4) 0.407 
6. If cough, was it productive 1.4 (0.7, 2.9) 0.208 0.7 (0.3, 1.6) 0.307 0.7 (0.2, 2.1) 0.418 
7. Smoking history taken 1.1 (0.5, 2.1) 0.841 0.6 (0.3, 1.2) 0.061 1.5 (0.5, 4.0) 0.313 
8. Presence/absence of haemoptysis† 0.9 (0.4, 1.9) 0.686 0.6 (0.2, 1.4) 0.106 2.2 (0.7, 6.5) 0.061 
9. Chest pain (of any type) 0.6 (0.4, 1.1) 0.041 0.7 (0.4,1.4) 0.193 2.1 (0.9, 5.2) 0.028 
10. Occupation/previous occupation 0.9 (0.5, 1.7) 0.696 2.0 (1.0, 4.0) 0.010 0.6 (0.3, 1.5) 0.178 
11. Pets 0.9 (0.2, 4.7) 0.872 0.3 (0.02, 5.6) 0.299 8.3 (0.3, 210.0) 0.093 
†Denotes items with significant (p<0.010) between hospital variation within the arms of the study. 
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6.3.5 Observations and signs of patient deterioration 
6.3.5.1 Within the SPI1 evaluation  
Compliance in recording patient observations did improve markedly at both 6 and 12 hours 
after admission and this was statistically significant for all but one item.  Though both control 
and SPI1 hospitals improved, the improvement was greater in SPI1 hospitals (see Table 6.8) 
though statistically significant only for the recording of respiratory rate at 12 hours.  
.
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Table 6.8: Vital signs – percentage compliance with standards within the SPI1 evaluation 
 
Control Hospitals SPI1 Hospitals Changes in controls Effect of SPI1 
 Epoch 1 Epoch 2 Epoch 1 Epoch 2     
 % SE % SE % SE % SE OR (99% CI) p-value OR (99% CI) p-value 
On Admission             
1. Temperature 97.9 0.9 99.2 0.6 99.0 0.5 99.2 0.5 5.1 (0.3, 89.5)  0.144 0.2 (0.01, 8.5) 0.289 
2. Respiratory rate 96.2 1.3 98.8 0.7 90.8 1.5 98.4 0.6 4.7 (0.6, 36.5) 0.052 1.5 (0.2, 16.0) 0.677 
3. Cyanosis/Oxygen 
saturation 
98.7 0.7 98.8 0.7 97.6 0.8 99.2 0.5 1.7 (0.2, 18.2) 0.578 2.7 (0.1, 55.2) 0.385 
4. Confusion/Mental state 57.9 3.2 64.6 3.1 66.7 2.4 68.9 2.4 1.2 (0.7, 2.1) 0.307 1.2 (0.6, 2.6) 0.437 
5. Pulse 98.7 0.7 99.2 0.6 99.0 0.5 99.5 0.4 3.3 (0.2, 68.7) 0.306 0.5 (0.01, 23.7) 0.614 
6. Blood pressure 98.7 0.7 99.2 0.6 99.0 0.5 99.5 0.4 3.3 (0.2, 68.7) 0.306 0.5 (0.01, 23.7) 0.614 
At 6 Hours             
7. Temperature 62.4 3.2 73.8 2.8 75.9 2.2 86.1 1.8 1.7 (1.0, 2.9) 0.008 1.0 (0.5, 2.2) 0.976 
8. Respiratory rate 44.0 3.3 72.5 2.9 42.8 2.5 81.6 2.0 3.6 (2.1,6.2) < 0.001 2.0 (1.0, 4.2) 0.015 
9. Pulse 67.1 3.1 77.1 2.7 82.7 1.9 88.2 1.7 1.7 (1.0, 3.0) 0.012 1.0 (0.4, 2.3) 0.973 
10. Oxygen saturation 61.1 3.2 75.0 2.8 76.6 2.2 87.6 1.7 1.9 (1.1, 3.3) 0.002 1.3 (0.6, 2.8) 0.425 
At 12 Hours             
11. Temperature 58.5 3.2 70.3 3.0 70.6 2.3 82.4 2.0 1.8 (1.0, 3.0) 0.005 1.3 (0.6, 2.8) 0.314 
12. Respiratory rate 39.7 3.2 68.8 3.0 37.0 2.5 77.9 2.1 3.7 (2.2, 6.2) < 0.001 2.1 (1.0, 4.3) 0.008 
13. Pulse 61.5 3.2 73.8 2.8 75.3 2.2 83.2 1.9 1.9 (1.1, 3.2) 0.002 1.2 (0.5, 2.5) 0.618 
14. Oxygen saturation 55.6 3.3 73.3 2.9 64.0 2.5 81.8 2.0 2.3 (1.4, 3.9) < 0.001 1.4 (0.7, 2.9) 0.234 
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Routine Investigations             
15. Urea & Electrolytes 99.6 0.4 98.8 0.7 98.7 0.6 98.7 0.6 0.6 (0.02, 14.1) 0.665 0.8 (0.02, 39.5) 0.865 
16. Chest X-ray 96.6 1.2 97.9 0.9 94.5 1.2 93.7 1.2 2.4 (0.5, 11.8) 0.164 0.5 (0.1, 3.0) 0.291 
17. Full Blood Count 98.7 0.7 98.3 0.8 99.0 0.5 98.2 0.7 1.2 (0.1, 10.5) 0.789 0.2 (0.01, 5.4) 0.223 
Entries are percentages, with Binomial standard errors (SE) 
Shaded areas relate to post-intervention epochs 
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6.3.5.2 Within the SPI2 evaluation  
There is no significant evidence for an effect associated with SPI (Table 6.9 and Table 6.10). 
However, compliance in taking patient observations at 6 and 12 hours after admission also 
improved in both groups of hospitals when Epochs 1 and 2 are compared to Epoch 3. This 
was most evident for “Respiratory Rate” where practice continued to improve across all 
three epochs. In addition improvement took place between the first two epochs on these 
and most of the other 6 and 12 hour items (p<0.010 for all items except for 6 hour “Pulse”, 
for which p=0.016). 
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Table 6.9: Vital signs- percentage compliance with standards within the SPI2 evaluation 
 
Control Hospitals (N=9) SPI2 Hospitals (N=9) 
 Epoch 1 Epoch 2 Epoch 3 Epoch 1 Epoch 2 Epoch 3 
       
 % SE % SE % SE % SE % SE % SE 
On Admission             
1. Temperature 96.7 1.6 99.2 0.8 99.1 0.9 99.1 0.9 99.1 0.9 96.5 1.7 
2. Respiratory rate 95.8 1.8 99.2 0.8 100.0 0.0 96.5 1.7 98.3 1.2 100.0 0.0 
3. Cyanosis/Oxygen saturation 98.3 1.2 98.4 1.1 100.0 0.0 99.1 0.9 99.1 0.9 100.0 0.0 
4. Confusion/Mental state 53.3 4.6 71.5 4.1 74.1 4.2 62.6 4.5 57.3 4.6 80.7 3.7 
5. Pulse 98.3 1.2 99.2 0.8 100.0 0.0 99.1 0.9 99.1 0.9 100.0 0.0 
6. Blood pressure 98.3 1.2 99.2 0.8 100.0 0.0 99.1 0.9 99.1 0.9 100.0 0.0 
At 6 Hours             
7. Temperature 61.7 4.5 69.9 4.2 69.6 4.4 63.2 4.5 77.8 3.9 68.1 4.4 
8. Respiratory rate 40.8 4.5 69.1 4.2 72.3 4.2 47.4 4.7 76.1 4.0 77.9 3.9 
9. Pulses 69.2 4.2 73.2 4.0 75.0 4.1 64.9 4.5 81.2 3.6 79.6 3.8 
10. Oxygen saturation 61.7 4.5 71.5 4.1 74.1 4.2 60.5 4.6 78.6 3.8 79.6 3.8 
At 12 Hours             
11. Temperature 58.3 4.5 70.7 4.1 68.8 4.4 58.8 4.6 69.8 4.3 72.6 4.2 
12. Respiratory rate 35.0 4.4 69.9 4.2 73.2 4.2 44.7 4.7 67.5 4.3 78.8 3.9 
13. Pulse 63.3 4.4 76.4 3.8 75.0 4.1 59.6 4.6 70.9 4.2 79.6 3.8 
14. Oxygen saturation 54.2 4.6 75.6 3.9 74.1 4.2 57.0 4.7 70.9 4.2 79.6 3.8 
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Routine Investigations             
15. U & E 99.2 0.8 98.4 1.1 99.1 0.9 100.0 0.0 99.1 0.9 100.0 0.0 
16. Chest X-ray 96.7 1.6 97.6 1.4 97.3 1.5 96.5 1.7 98.3 1.2 100.0 0.0 
17. Full Blood Count 98.3 1.2 97.6 1.4 99.1 0.9 99.1 0.9 99.1 0.9 100.0 0.0 
Shaded areas relate to post-intervention epochs 
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Table 6.10: Vital signs– differences between control and SPI2 hospitals, changes over time and the effect of SPI2   
 
Baseline Comparisons Changes in Controls Effect of SPI2 
    
 OR (99% CI) p-value OR (99% CI) p-value OR (99% CI) p-value 
On Admission       
1. Temperature 2.2 (0.2, 21.1) 0.381 0.7 (0.02, 24.0) 0.823 0.1 (0.002, 4.1) 0.108 
2. Respiratory rate 0.7 (0.1, 3.9) 0.617 - - - - 
3. Cyanosis/Oxygen saturation 1.6 (0.1, 18.2) 0.605 - - - - 
4. Confusion/Mental state 0.9 (0.5, 1.7) 0.674 1.8 (0.8,3.7) 0.045 1.7 (0.6, 4.5) 0.187 
5. Pulse 1.1 (0.1, 14.9) 0.942 - - - - 
6. Blood pressure 1.1 (0.1, 14.9) 0.942 - - - - 
At 6 Hours       
7. Temperature 1.3 (0.7, 2.4) 0.323 1.4 (0.7, 2.8) 0.239 0.8 (0.3, 1.9) 0.457 
8. Respiratory rate 1.3 (0.7, 2.5) 0.281 2.1 (1.0, 4.3) 0.010 1.0 (0.4, 2.8) 0.907 
9. Pulse 1.1 (0.6, 2.1) 0.604 1.3 (0.6, 2.8) 0.327 1.2 (0.4, 3.3) 0.662 
10. Oxygen saturation 1.2 (0.7, 2.2) 0.433 1.4 (0.7, 3.0) 0.223 1.2 (0.4, 3.1) 0.703 
At 12 Hours       
11. Temperature 1.0 (0.6, 1.8) 0.934 1.2 (0.6, 2.4) 0.583 1.2 (0.5, 2.9) 0.685 
12. Respiratory rate 1.2 (0.6, 2.3) 0.524 2.4 (1.1, 5.0) 0.002 1.2 (0.4, 3.1) 0.713 
13. Pulse 0.8 (0.5, 1.4) 0.394 1.2 (0.6, 2.5) 0.510 1.5 (0.6, 4.1) 0.268 
14. Oxygen saturation 1.0 (0.6, 1.7) 0.953 1.4 (0.7, 2.9) 0.231 1.4 (0.5, 3.6) 0.430 
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Routine Investigations       
15. U & E 0.9 (0.03, 28.8) 0.944 0.6 (0.01, 27.7) 0.762 - - 
16. Chest X-ray 1.1 (0.2, 5.1) 0.904 0.7 (0.1, 5.6) 0.641 - - 
17. Full Blood Count 1.6 (0.2, 16.9) 0.609 1.7 (0.1, 40.4) 0.663 - - 
No items showed significant variation between hospitals within arms.  Blanks are associated with 100% compliance for which logistic regression analysis is 
impossible. 
 160 
 
6.3.6 Appropriate clinical response to abnormal vital signs  
6.3.6.1 Within the SPI1 evaluation  
The data are summarised in Table 6.11 and Table 6.12. There is wide variation in the 
denominators (N) for these items, reflecting the conditional nature of the responses. Mixed 
effects analysis was attempted for each item, but there were no significant effects between 
arms or between epochs, and no evidence for any effects associated with the SPI. The 
component of variation between hospitals was negligible in most cases, and achieved a p-
value less than 0.10 (= 0.09 in both cases) for only two items. 
For most items the data are sparse. No substantive conclusions are indicated.  
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Table 6.11: Appropriate clinical response – compliance with standards 
 
Control Hospitals (N=18) SPI1 Hospitals (N=4) 
 Epoch 1 Epoch 2 Epoch 1 Epoch 2 
 N % SE N % SE N % SE N % SE 
Oxygen saturation <90, at any time             
Full blood gases within 2 hours 15 60.0 12.6 20 60.0 11.0 130 36.9 4.2 100 54.0 5.0 
Given oxygen (if not on oxygen) 16 68.8 11.6 16 68.8 11.6 100 79.0 4.1 58 77.6 5.5 
Doctor called or transferred to ICU  
(if on oxygen) 
10 30.0 14.5 11 63.6 14.5 114 36.0 4.5 60 36.7 6.2 
Blood pressure systolic<90             
At least next 6 hours, hourly observations 21 19.0 8.6 27 14.8 6.8 36 25.0 7.2 35 20.0 6.8 
Blood culture 18 33.3 11.1 23 39.1 10.2 27 33.3 9.1 31 38.7 8.7 
Sputum present             
Sputum culture 141 39.0 4.1 150 47.3 4.1 215 47.0 3.4 256 51.6 3.1 
Respiratory rate >20 at any time after 
admission 
            
Given oxygen (if not on oxygen) 5 0.0 0.0 1 0.0 0.0 96 20.8 4.1 55 7.3 3.5 
Doctor called (if on oxygen) 8 0.0 0.0 3 33.3 27.2 27 7.4 5.0 18 16.7 8.8 
Temperature over 38° C - any episode             
If yes, blood culture  35 71.4 7.6 39 74.4 7.0 73 72.6 5.2 89 76.4 4.5 
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Failure to improve by 48 hours or subsequent 
deterioration 
            
Review by consultant 20 100.0 0.0 22 100.0 0.0 41 100.0 0.0 38 100.0 0.0 
Repeat chest x-ray 18 100.0 0.0 17 100.0 0.0 36 69.4 7.7 30 73.3 8.1 
White cell counted/repeated 19 100.0 0.0 22 100.0 0.0 41 95.1 3.4 37 97.3 2.7 
Appropriate addition of further antibiotics 16 93.8 6.0 11 100.0 0.0 31 64.5 8.6 24 66.7 9.6 
Follow up             
Clinical review arranged 6 weeks after 
discharge 
112 61.6 4.6 112 65.2 4.5 264 43.9 3.1 277 45.5 3.0 
 
The columns headed “N” represent the opportunities for error. The opportunities vary within categories, e.g. the reviewer may judge that it would have 
been inappropriate to call a doctor, or move a patient to ICU despite falling oxygen saturation, e.g. because death was expected.  
Entries are error rates as percentages of N, with Binomial standard errors. 
Shaded areas relate to post-intervention epochs 
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Table 6.12: Appropriate clinical response - differences between control and intervention hospitals, changes over time and the effect of SPI1 
 
Comparisons at Epoch 1 Change in Controls Effect of SPI1 
 SPI1/Control Epoch 2/ Epoch 1 Ratio of temporal changes 
 OR (99% CI) p-value OR (99% CI) p-value OR (99% CI) p-value 
Oxygen saturation <90, at any time       
Full blood gases within 2 hours 1.0 (0.2, 5.9) 1.000 0.6 (0.1, 4.9) 0.531 2.3 (0.2, 22.6) 0.333 
Given oxygen (if not on oxygen) 0.9 (0.1, 8.5) 0.893 0.8 (0.1, 7.2) 0.893 1.3 (0.1, 14.3) 0.763 
Doctor called or transferred to ICU (if on oxygen) 3.3 (0.3, 36.4) 0.201 1.9 (0.1, 29.3) 0.554 0.3 (0.01, 4.6) 0.223 
Blood pressure systolic <90       
At least next 6 hours, hourly observations 4.1 (0.2, 80.2) 0.223 0.6 (0.1, 5.1) 0.579 0.6 (0.04, 8.8) 0.627 
Blood culture 1.3 (0.1, 15.2) 0.794 1.3 (0.2, 7.5) 0.726 0.7 (0.1, 7.2) 0.651 
Sputum present       
Sputum culture 1.4 (0.5, 4.4) 0.391 1.4 (0.7, 2.6) 0.221 0.9 (0.4, 2.0) 0.651 
Respiratory rate >20 at any time after admission       
Given oxygen (if not on oxygen) - - - - - - 
Doctor called (if on oxygen) - - - - - - 
Temperature over 38° C - any episode       
If yes, blood culture  1.3 (0.2, 8.0) 0.754 1.0 (0.3, 4.2) 0.957 0.9 (0.1, 5.4) 0.865 
Failure to improve by 48 hours or subsequent 
deterioration 
      
Review by consultant - - - - - - 
Repeat chest x-ray - - - - - - 
White cell counted/repeated - - - - - - 
Appropriate addition of further antibiotics 1.1 (0.04, 
317.5) 
0.960 - - - - 
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Follow up       
Arrange clinical review within 6 weeks 0.9 (0.3, 2.2) 0.672 1.2 (0.6, 2.6) 0.461 0.7 (0.3, 1.8) 0.388 
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6.3.6.2 Within the SPI2 evaluation  
Again the data was sparse (Table 6.13 and Table 6.14), and formal analysis was possible for 
only three items. No significant conclusions were indicated. 
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Table 6.13: Appropriate clinical response  
 
Control Hospitals (N=18) SPI2 Hospitals (N=4) 
 Epoch 1 Epoch 2 Epoch 3 Epoch 1 Epoch 2 Epoch 3 
 N % SE N % SE N % SE N % SE N % SE N % SE 
Oxygen saturation <90 at any time                   
Full blood gases within 2 hours 13 61.5 13.5 10 50.0 15.8 0 - - 2 50.0 35.4 10 70.0 14.5 4 25.0 21.7 
Given oxygen (if not on oxygen) 12 66.7 13.6 7 57.1 18.7 1 0.0 0.0 4 75.0 21.7 9 77.8 13.9 2 50.0 35.4 
Doctor called or transferred to ICU (if 
on oxygen) 
8 25.0 15.3 6 50.0 20.4 0 - - 2 50.0 35.4 5 80.0 17.9 2 50.0 35.4 
Blood pressure systolic <90                   
At least next 6 hours, hourly 
observations 
7 28.6 17.0 8 25.0 15.3 8 50.0 17.7 4 50.0 25.0 6 16.7 15.2 2 100.0 0.0 
Blood culture 4 50.0 25.0 5 40.0 21.2 8 37.5 17.1 4 25.0 21.7 5 80.0 17.9 2 100.0 0.0 
Sputum Present                   
Sputum culture 70 41.4 5.9 72 48.6 5.9 69 24.6 5.2 71 36.6 5.8 78 46.2 5.7 62 29.0 5.8 
Respiratory rate >20 at  
any time after admission 
                  
Given oxygen (if not on oxygen) 3 0.0 0.0 0 . . 0 - - 2 0.0 0.0 1 0.0 0.0 0 - - 
Doctor called (if on oxygen) 5 0.0 0.0 1 100.0 0.0 0 - - 3 0.0 0.0 2 0.0 0.0 3 0.0 0.0 
Temperature over 38°C – any 
episode 
                  
If yes, blood culture 16 68.8 11.6 14 71.4 12.0 15 73.3 11.4 19 73.7 10.1 25 76.0 8.5 13 61.5 13.5 
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Failure to improve by 48 hours or  
subsequent deterioration 
                  
Review by consultant 11 100.0 0.0 12 100.0 0.0 10 100.0 0.0 9 100.0 0.0 10 100.0 0.0 3 100.0 0.0 
Repeat chest x-ray 10 100.0 0.0 9 100.0 0.0 9 100.0 0.0 8 100.0 0.0 8 100.0 0.0 3 100.0 0.0 
White cell counted/repeated 11 100.0 0.0 12 100.0 0.0 11 100.0 0.0 8 100.0 0.0 10 100.0 0.0 3 100.0 0.0 
Appropriate addition of further 
antibiotics 
9 100.0 0.0 5 100.0 0.0 8 75.0 15.3 7 85.7 13.2 6 100.0 0.0 2 50.0 35.4 
Follow up                   
Arrange follow up? 45 71.1 6.7 47 61.7 7.1 38 42.1 8.0 49 59.2 7.0 52 63.5 6.6 44 38.6 7.3 
Note: The columns headed “N” represent the opportunities for error. The opportunities vary within categories, e.g. the reviewer may judge that it would 
have been inappropriate to call a doctor, or move a patient to ICU despite falling oxygen saturation, e.g. because death was expected.  
Entries are error rates as percentages of N, with Binomial standard errors. 
Shaded areas relate to post-intervention epochs 
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Table 6.14: Appropriate clinical response – difference between control and SPI2 hospitals, changes over time and the effect of SPI2 (formal 
analyses for three items only, because of sparse data for other items)   
 
Baseline Comparisons Changes in Controls Effect of SPI2 
    
 OR (99% CI) p-value OR (99% CI) p-value OR (99% CI) p-value 
Sputum Present       
Sputum Culture 0.8 (0.4, 1.6) 0.411 0.5 (0.2, 1.2) 0.040 1.7 (0.5, 6.0) 0.250 
Temperature >38°C       
If Yes, Blood Culture 1.0 (0.2, 4.5) 0.969 0.9 (0.1, 7.1) 0.874 0.6 (0.04, 9.6) 0.636 
Appropriate Follow-up       
Clinical Review Arranged if appropriate 0.7 (0.3, 1.7) 0.343 0.3 (0.1, 1.0) 0.009 1.2 (0.3, 5.4) 0.698 
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6.3.7 Other features of good care for specific classes of patients  
6.3.7.1 Within the SPI1 evaluation  
The effect of SPI is not apparent, and is not statistically significant for any item (Table 6.15 
and   
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Table 6.16). The baseline comparisons showed no significant differences between control 
and SPI1 hospitals. However, it should be noted that the use of CURB score (a clinical 
prediction rule for predicting mortality from community-acquired pneumonia and infection 
at any site) has improved significantly in control hospitals over time, albeit from a very low 
base. 
A strong negative age-effect was apparent for item 3 (“severity of pneumonia”) yielding a 
reduction in odds of compliance of about 8% per year of age. 
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 Table 6.15: Features of good care for specific classes of patient  
 
Control Hospitals (N=18) SPI1 Hospitals (N=4) 
 Epoch 1 Epoch 2 Epoch 1 Epoch 2 
 N % SE N % SE N % SE N % SE 
             
1. Asthma or COPD: given steroids within 24 hrs 129 87.6 2.9 135 92.6 2.3 224 91.1 1.9 199 88.4 2.3 
2. Peak flow record 34 79.4 6.9 29 82.8 7.0 78 82.1 4.3 37 64.9 7.8 
3. Severity of pneumonia patients assessed 101 75.2 4.3 113 73.5 4.2 170 73.5 3.4 189 70.4 3.3 
4. Is this based on CURB score in notes? 102 2.0 1.4 111 23.4 4.0 170 2.4 1.2 189 8.5 2.0 
5. Was appropriate antibiotic treatment given? 100 93.0 2.6 110 95.5 2.0 169 94.7 1.7 189 93.1 1.8 
Shaded areas relate to post-intervention epochs 
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Table 6.16: Features of good care for specific classes of patient – differences between control and intervention hospitals, changes over time 
and the effect of SPI1 
 
Baseline Comparisons Changes in Controls Effect of SPI1 
 OR (99% CI) p-value OR (99% CI) p-value OR (99% CI) p-value 
1. Asthma or COPD given steroids within 24 hrs 1.6 (0.4, 5.9) 0.385 1.7 (0.6, 5.3) 0.219 0.7 (0.2, 2.9) 0.500 
2. Peak flow record† 1.0 (0.03, 30.2) 0.974 1.1 (0.1, 11.1) 0.896 0.6 (0.04, 8.2) 0.570 
3. Severity of pneumonia patients 1.7 (0.5, 5.2) 0.245 1.1 (0.4, 2.6) 0.854 0.8 (0.2, 2.4) 0.553 
4. Is this based on CURB score in notes? 0.7 (0.04, 11.7) 0.753 17.0 (2.3, 125.8) <0.001 0.3 (0.02, 3.4) 0.173 
5. Was appropriate antibiotic treatment given? 1.5 (0.2, 14.8) 0.626 2.0 (0.4, 10.8) 0.303 0.5 (0.1, 4.2) 0.383 
† Denotes items with significant between hospital components of variation within the arms of the study (p<0.01) 
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6.3.7.2 Within the SPI2 evaluation  
There is no significant evidence that the SPI had an effect (Table 6.17 and Table 6.18). Use 
of the CURB score again improved significantly over time (OR=7.3; 1.4 - 37.7), though from a 
very low base and differences were not statistically significant between control and SPI2 
hospitals. A negative age-effect (p<0.001) was apparent for item 3 (“severity of pneumonia”) 
yielding a reduction in odds of compliance of about 6% per year of age.  
.  
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Table 6.17: Use of steroids and antibiotics, CURB score and other standards applicable to specific cases – compliance with standards   
 
Control Hospitals (N=9) SPI2 Hospitals (N=9) 
 Epoch 1 Epoch 2 Epoch 3 Epoch 1 Epoch 2 Epoch 3 
 N % SE N % SE N % SE N % SE N % SE N % SE 
                   
1. Asthma or COPD given steroids 
within 24 hrs 
70 84.3 4.4 63 91.8 3.5 56 92.9 3.5 59 91.5 3.7 74 93.2 2.9 53 94.3 3.2 
2. Peak flow record 10 80.0 12.6 11 63.6 14.5 5 40.0 21.9 24 79.2 8.3 18 94.4 5.4 8 75.0 15.3 
3. Severity of pneumonia patients 
recorded in notes? 
52 73.1 6.2 68 70.6 5.6 57 77.2 5.6 49 77.6 5.9 45 77.8 6.3 60 70.0 6.0 
4. CURB score recorded in notes? 52 1.9 1.9 67 22.4 5.1 56 21.4 5.5 50 2.0 2.0 44 25.0 6.1 60 41.7 6.4 
5. Was appropriate antibiotic 
treatment given? 
51 94.1 3.3 68 92.6 3.2 53 96.2 2.6 49 91.8 4.0 42 100.0 0.0 55 94.5 3.1 
COPD: Chronic Obstructive Pulmonary Disease 
CURB: Confusion/Urea / Respiratory rate / Blood pressure score 
Shaded areas relate to post-intervention epochs 
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Table 6.18: Steroids and antibiotics, CURB score and other standards applicable to specific cases – differences between control and SPI2 
hospitals, changes over time and the effect of SPI2  
 
Baseline Comparisons Changes in Controls Effect of SPI2 
    
 OR (99% CI) p-value OR (99% CI) p-value OR (99% CI) p-value 
1. Asthma or COPD given steroids within 24 hrs 1.8 (0.6, 5.7) 0.183 0.9 (0.2, 4.8) 0.813 0.6 (0.05, 6.8) 0.568 
2. Peak flow record 1.1 (0.03, 40.9) 0.954 0.1 (0.001, 13.5) 0.255 29.7 (0.1, 15943) 0.165 
3. Severity of pneumonia patients recorded in notes? 0.9 (0.3, 3.2) 0.829 0.9 (0.3, 3.1) 0.821 0.7 (0.1, 3.0) 0.478 
4. CURB score recorded in notes? 1.4 (0.4, 4.9) 0.453 7.3 (1.4, 37.7) 0.002 2.1 (0.4, 11.1) 0.236 
5. Was appropriate antibiotic treatment given? 1.4 (0.2, 10.5) 0.676 1.5 (0.1, 15.7) 0.665 0.5 (0.02, 10.0) 0.519 
No items showed significant variation between hospitals within arms. 
COPD: Chronic Obstructive Pulmonary Disease 
CURB: Confusion/Urea / Respiratory rate / Blood pressure score 
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6.3.8 Prescribing error 
6.3.8.1 Within the SPI1 evaluation  
The results are presented in Table 6.19 and Table 6.20. There are more prescriptions per 
patient in the SPI1 hospitals (29.3), compared to the control hospitals (24.9) and a small 
increase (about 2 per patient) across epochs in both arms. Unadjusted analysis suggests an 
increases in error rate associated with the SPI of marginal significance (p=0.041). 
The rate of error detection was found to change with time in a systematic way as the (single) 
reviewer gained more experience with the semi-structured task of identifying medication 
errors from case-notes. Reviews took place in the period November 2006 to August 2009. 
The rate of detected errors of the case-note review was found to improve at first, peaking at 
around July/August 2008 but declined thereafter. The control hospital data was reviewed 
during the later period, when the detected error rate was declining. SPI1 hospitals were 
reviewed while it was increasing. In the intervention arm, randomisation of the order of 
review was only partial: on average, the review date for Epoch 1 was earlier than for Epoch 
2, though there was considerable overlap between the dates of the two sets of reviews. 
Thus there is the potential for confounding between the SPI effect and the date of review.  
After adjustment for date of review (which was highly significant, p<0.001) there are no 
significant differences between arms or epochs and no effect associated with SPI.  
(Examples of prescribing errors are given in Table 6.21).  
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Table 6.19: Prescribing errors 
 
Control Hospitals (N=18) SPI1 Hospitals (N=4) 
 Epoch 1 Epoch 2 Epoch 1 Epoch 2 
     
Number of patients* 233 239 381 378 
Number of prescriptions 5482 6207 10664 11538 
Prescriptions per patient 23.5 26.0 28.0 30.5 
Errors     
Total 596 564 1157 1530 
By type of error     
Counsel 1 0 0 2 
Monitor 0 0 1 1 
Need 56 95 114 190 
Dose 287 224 591 616 
Drug 23 13 46 55 
Formula 40 39 41 73 
Supply 189 193 364 593 
     
 Rate SE Rate SE Rate SE Rate SE 
Unadjusted Rates         
Error rate per prescription 0.115 0.010 0.093 0.008 0.111 0.012 0.132 0.014 
Rates adjusted for date of review         
Overall rate (all errors) 0.137 0.016 0.111 0.014 0.146 0.017 0.146 0.013 
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By type of error         
Need 0.015 0.003 0.023 0.004 0.014 0.002 0.018 0.002 
Dose 0.067 0.009 0.048 0.008 0.059 0.009 0.053 0.007 
Drug 0.007 0.002 0.004 0.002 0.003 0.001 0.004 0.001 
Formula 0.007 0.002 0.006 0.002 0.006 0.001 0.007 0.001 
Supply 0.035 0.006 0.029 0.005 0.069 0.011 0.077 0.010 
*Number of patients with medication charts available to review 
Shaded areas relate to post-intervention epochs 
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Table 6.20: Prescribing Errors – differences between control and intervention hospitals, changes over time and the effect of SPI1   
 
Baseline Comparisons Changes in Controls Effect of SPI1 
 Rate Ratio (99% CI) p-value Rate Ratio (99% CI) p-value Rate Ratio (99% CI) p-value 
Overall rate (all errors) 1.0 (0.6, 1.5) 0.789 0.8 (0.6, 1.1) 0.048 1.2 (0.9, 1.8) 0.138 
       
By type of error       
Need 1.0 (0.5, 1.9) 0.879 1.5 (0.9, 2.5) 0.045 0.8 (0.4, 1.6) 0.438 
Dose 0.9 (0.5, 1.5) 0.553 0.7 (0.5, 1.0) 0.011 1.2 (0.8, 1.9) 0.201 
Drug 0.3 (0.1, 0.8) 0.002 0.5 (0.2, 1.5) 0.123 2.7 (0.8, 9.7) 0.041 
Formula 0.8 (0.3, 2.2) 0.659 0.9 (0.5, 1.7) 0.598 1.4 (0.5, 3.4) 0.319 
Supply 1.8 (1.0, 3.1) 0.012 0.8 (0.6, 1.2) 0.179 1.4 (0.9, 2.3) 0.064 
Rate-ratios are estimated from a population-averaged Negative Binomial model 
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Table 6.21: Examples of prescribing errors relating to each stage of the drug use process 
found within the SPI1 evaluation 
Category of prescribing error Examples from case-notes reviewed 
Need for drug • Rabeprazole 10mg oral once a day was 
taken by patient before admission but 
was not prescribed during admission 
• Patient usually takes digoxin 125mcg 
oral once a day, but this was not 
prescribed on admission 
Selection of drug • Tiotropium 18mcg inhaler once a day 
prescribed at the same time as 
Combivent (salbutamol and ipratropium) 
inhaler 2 puffs four times a day. This is 
drug duplication as both of these drugs 
have the same pharmacological action 
• Patient is allergic to penicillin but was 
given one stat dose of 500mg oral 
amoxicillin 
Selection of dose • Doctor prescribed Combivent 
(salbutamol and ipratropium) inhaler 4 
puffs four times a day .This was a wrong 
dose (overdose) as the maximum should 
have been 2 puffs four times a day 
• Paracetamol 1g oral to be given “when 
required” prescribed without indicating 
the maximum daily frequency/dose 
Selection of formulation • Seretide 250 2 puffs inhaler twice a day 
prescribed without specifying whether 
evohaler or accuhaler 
• Dipyridamole 200mg orally twice a day 
prescribed without indicating that 
modified release formulation intended 
Provide information needed for supply • Co-amoxiclav 625mg three time a day 
prescribed without indicating the route 
of administration 
• Clopidogrel 75mg oral once a day 
prescribed and given without having a 
signature of prescriber 
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6.3.8.2 Within the SPI2 evaluation  
A reviewer learning/fatigue effect was significant (p=0.009) in the review of prescribing 
errors (Table 6.22 and Table 6.23), with a decreasing rate of error detection with time of 
review; this was allowed for in the analysis. No significant time effects for SPI arm, Time or 
SPI were detected (Table 6.23). 
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Table 6.22: Prescribing Errors 
 
Control Hospitals (N=9) SPI2 Hospitals (N=9) 
 Epoch 1 Epoch 2 Epoch 3 Epoch 1 Epoch 2 Epoch 3 
       
Number of patients† 120 122 112 113 117 114 
Number of prescriptions 2953 3269 2871 2529 2938 2656 
Prescriptions per patient 24.6 26.8 25.6 22.4 25.1 23.3 
Errors       
Total 345 298 216 251 266 167 
       
 Rate SE Rate SE Rate SE Rate SE Rate SE Rate SE 
Unadjusted Rates             
Error rate per prescription 0.120 0.017 0.092 0.013 0.076 0.012 0.106 0.015 0.088 0.013 0.060 0.010 
             
Rates adjusted for date of review             
Overall rate (all errors) 0.103 0.017 0.086 0.013 0.089 0.015 0.098 0.015 0.084 0.013 0.073 0.014 
             
By 5 most prevalent stages of the  
drug use process 
            
Need for drug therapy 0.006 0.002 0.018 0.003 0.018 0.004 0.014 0.003 0.011 0.002 0.015 0.002 
Selection of dose 0.057 0.009 0.031 0.005 0.032 0.006 0.039 0.006 0.039 0.006 0.030 0.006 
Selection of drug 0.002 0.001 0.002 0.001 0.001 0.001 0.004 0.001 0.002 0.001 0.001 0.001 
Selection of formulation 0.010 0.003 0.005 0.001 0.005 0.002 0.007 0.002 0.008 0.002 0.009 0.003 
Provide information needed for supply 0.029 0.006 0.029 0.005 0.035 0.007 0.032 0.006 0.026 0.005 0.025 0.006 
†The number of patients are those with medication charts available for review.  Shaded areas relate to post-intervention epochs 
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Table 6.23: Prescribing errors – differences between control and SPI2 hospitals, changes over time and the effect of SPI2  
 
Baseline Comparisons Changes in Controls Effect of SPI2 
    
 Rate Ratio (99% CI) p Rate Ratio (99% CI) p Rate Ratio (99% CI) p 
Overall rate (all errors) 1.0 (0.6, 1.5) 0.860 0.9 (0.6, 1.4) 0.662 0.9 (0.5, 1.5) 0.444 
       
By 5 most prevalent stages of the  
drug use process 
      
Need for drug therapy 1.0 (0.6, 1.6) 0.825 1.5 (0.7, 2.9) 0.157 0.8 (0.3, 2.1) 0.626 
Selection of dose 0.9 (0.6, 1.4) 0.595 0.8 (0.5, 1.3) 0.166 1.0 (0.5, 2.0) 0.982 
Selection of drug 1.2 (0.5, 2.9) 0.670 0.7 (0.1, 4.2) 0.643 0.7 (0.05, 9.3) 0.687 
Selection of formulation 1.1 (0.6, 2.0) 0.788 0.8 (0.3, 2.0) 0.506 1.6 (0.5, 5.3) 0.277 
Provide information needed for supply 1.0 (0.6, 1.8) 0.842 1.1 (0.7, 1.9) 0.556 0.7 (0.3, 1.5) 0.220 
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6.3.9 Anti-coagulant prescribing errors 
6.3.9.1 Within the SPI1 evaluation  
A specific breakdown of errors relating to anti-coagulant administration was carried out 
because this treatment was particularly stressed by IHI (Table 6.24 and Table 6.25). No 
differences were observed, but the denominators are small, especially in control hospitals.  
6.3.9.2 Within the SPI2 evaluation  
A total of ten errors were recorded. Six occurred in SPI2 hospitals before the introduction of 
the intervention, the other four in control hospitals in Epoch 3. The breakdown is shown in 
Table 6.26, but no further analysis was possible. 
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Table 6.24: Anti-coagulant prescribing errors 
 
Control Hospitals (N=18) SPI1 Hospitals (N=4) 
 Epoch 1 Epoch 2 Epoch 1 Epoch 2 
     
Number of patients* 52 93 167 224 
Number of prescriptions 83 132 274 362 
Number of Errors 1 5 25 32 
     
 Rate SE Rate SE Rate SE Rate SE 
Unadjusted Rates         
Error rate per prescription 0.011 0.012 0.038 0.018 0.088 0.024 0.089 0.022 
         
Rates adjusted for date of review         
Overall rate (all errors) 0.020 0.023 0.070 0.050 0.169 0.055 0.094 0.025 
* Number of patients receiving anti-coagulant therapy 
Shaded areas relate to post-intervention epochs 
 
Table 6.25: Anti-coagulant prescribing errors – analysis  
 
Baseline Comparisons Changes in Controls Effect of SPI1 
 Rate Ratio (99% CI) p-value Rate Ratio (99% CI) p-value Rate Ratio (99% CI) p-value 
Overall rate (all errors) 8.5 (0.4, 181.1) 0.071 3.1 (0.2, 56.7) 0.317 0.2 (0.01, 3.7) 0.146 
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Table 6.26: Anti-coagulant prescribing errors SPI2 
 
Control Hospitals (N=9) SPI2 Hospitals (N=9) 
 Epoch 1 Epoch 2 Epoch 3 Epoch 1 Epoch 2 Epoch 3 
       
Number of patients 28 42 62 31 64 74 
Number of prescriptions 43 61 92 54 92 99 
Number of errors 0 0 4 1 5 0 
Shaded areas relate to post-intervention epoch 
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6.3.10 Medicines reconciliation errors at admission 
6.3.10.1 Within the SPI1 evaluation  
The results can be found in Table 6.27 and Table 6.28. Again, there is no significant evidence 
that the SPI has an effect. The arms of the study are very similar at baseline and there is a 
tendency for this type of error to increase over epochs in both control and SPI1 hospitals.  
6.3.10.2 Within the SPI2 evaluation  
The results can be found in Table 6.29 and Table 6.30. Again, there is no significant evidence 
that the SPI has an effect (p=0.914). 
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Table 6.27: Reconciliation errors at admission  
 
Control Hospitals (N=18) SPI1 Hospitals (N=4) 
 Epoch 1 Epoch 2 Epoch 1 Epoch 2 
     
Number of Admissions* 203 188 380 377 
     
Admissions with Reconciliation Errors     
N 14 21 24 41 
% (SE) 6.9 (1.8) 11.1 (2.3) 6.3 (1.2) 10.9 (1.6) 
     
Mean Number of Errors when Error is present (SE) 1.6 (0.2) 2.2 (0.3) 2.3 (0.4) 2.1 (0.2) 
*Number of patients with admission medication charts available to review 
 
Table 6.28: Reconciliation errors at admission – differences between control and intervention, changes over time and the effect of SPI1   
 
Comparisons at Epoch 1 Change in Controls Effect of SPI1 
 SPI1/Control Epoch 2/ Epoch 1 Ratio of temporal changes 
 OR (99% CI) p-value OR (99% CI) p-value OR (99% CI) p-value 
       
Admission with Reconciliation 
Error 
1.1 (0.3, 4.3) 0.839 1.5 (0.6, 4.0) 0.241 0.8 (0.3, 3.0) 0.770 
Odds-ratios (OR) derive from a logistic model with random effects for hospitals, adjusted for the date of review 
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Table 6.29: Reconciliation errors at admission SPI2  
 
Control Hospitals (N=9) SPI2 Hospitals (N=9) 
 Epoch 1 Epoch 2 Epoch 3 Epoch 1 Epoch 2 Epoch 3 
       
Number of admissions 120 122 112 113 117 114 
       
Admissions with reconciliation errors       
N 8 14 10 7 8 6 
% (SE) 6.7 (2.3) 11.5 (2.9) 8.9 (2.7) 6.2 (2.3) 6.8 (2.3) 5.3 (2.1) 
       
Mean number of errors when error is present (SE) 1.4 (0.3) 2.1 (0.3) 2.2 (0.6) 2.9 (1.1) 2.3 (0.7) 2.3 (0.6) 
Shaded areas relate to post-intervention epochs 
Table 6.30: Reconciliation errors at admission – differences between control and SPI2, changes over time and the effect of SPI2   
 
Baseline comparisons Change in Controls Effect of SPI2 
   Ratio of temporal changes 
 
OR  (99% CI) p-value OR  (99% CI) p-value OR  (99% CI) p-value 
 
      
Admissions with reconciliation 
errors 
1.2 (0.3, 4.8) 0.727 1.5 (0.6, 3.8) 0.292 0.9 (0.3, 3.2) 0.914 
Odds-ratios (OR) derive from a logistic model with random effects for hospitals, adjusted for the date of review. 
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6.4 Discussion 
This sub-study was a substantial undertaking with 1,463 episodes of care reviewed by the 
retrospective explicit case-note review method.  Case-notes were reviewed with respect to 
areas that have been targeted by the SPI – observations of the deteriorating patient and 
prescribing errors (particularly anticoagulation prescribing and medicines reconciliation).  
Observations were also made in areas which might be expected to improve if the overall 
goal of strengthening the system and achieving cultural and organisational realignments 
around safety had been achieved, such as the quality of history taking, appropriate clinical 
response to abnormal vital signs (e.g. taking a blood culture if body temperature exceeds 
38°C) and other features of good care (e.g. prescribing steroids within 24 hours for asthma 
and COPD patients).   
At baseline there was no difference between SPI and control hospitals.  Observations of 
patients taken at 6 and 12 hours improved in both intervention and control hospitals over 
time in both evaluations.  There was only one measure in which the SPI1 intervention was 
significant (p=0.008) and that was the recording of respiratory rate at 12 hours.  Across all 
measures there was no difference between intervention and control hospitals for both 
evaluations and overall no SPI effect was observed.   
The observed prescribing error rates were quite high when compared with the only other 
study using the same methods in two hospitals (7.4 and 8.6%) (Barber et al., 2006). After 
adjustment for learning/fatigue effects the evaluation found no improvement in prescribing 
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over epochs, and there was no difference between control and intervention hospitals, thus 
suggesting that there was no SPI effect on prescribing error rates. 
Many prescribing errors are of a minor nature. The extent to which such minor errors are a 
surrogate for more serious errors, as implied by the Heinrich ratio, is contested (Dean et al., 
2005). Errors associated with anticoagulation therapy are potentially a particular cause of 
concern (Leape et al., 1991) and was therefore a specific SPI target. No trends towards 
fewer errors over time in anticoagulation therapy were found (and discovered only one 
adverse event associated with this class of drug, see Table 10.2). Medicines reconciliation 
was another key SPI target, but there was no trend towards improvements either over time, 
or between the SPI hospitals and controls. 
A number of clinical processes that were not specific SPI targets showed that there were no 
significant differences between control and SPI hospitals over time. For some measures – 
such as use of corticosteroids in COPD and asthma – this was because practice was already 
good at baseline and there was little room for further improvement. However, there was 
also no change in the quality of medical history taking or appropriateness of antibiotic 
selection, even though here there was room for improvement.  
An important methodological finding of this sub-study is the learning/fatigue effect observed 
on behalf of the reviewer, particularly with semi-structured items such as prescribing which 
requires piecing together disparate pieces of information in the case-notes.  If this had not 
be taken into account in the analysis prescribing errors would have increased overtime as 
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the reviewer became more adept at spotting this type of error and then decreased as the 
reviewer became weary of the process.  Ideally all case-notes would be collected and 
randomised for review so that this type of bias is spread over time and between intervention 
and control arms but for pragmatic reasons, such as in this instance this is not always 
possible and hence this type of adjustment needs to be made.  In hindsight, a panel of 
reviewers were required so that the review process was not channelled through an 
individual and to minimise bias of learning/fatigue further.   
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CHAPTER 7: HOLISTIC CASE-NOTE REVIEW 
TO MEASURE ERROR RATES/QUALITY OF 
CARE IN PATIENTS WITH ACUTE 
RESPIRATORY DISEASE 
7.1 Introduction 
In the previous chapter, I described the review of acute respiratory episodes of care using an 
explicit review method.  In this chapter, I will describe an alternative audit method utilising 
the same cases-notes – that of a semi-structured holistic (implicit) review.  In a structured 
holistic review, experts are presented with a series of pre determined questions designed to 
extract a complete assessment.  The differences between explicit and holistic reviews are 
described in Table 4.1.  However, holistic reviews can be considered as complimentary 
rather than an alternative to explicit reviews, as it reflects the full scope of clinical decisions 
that apply to a particular patient.   
7.2 Methods 
The case-note selection and eligibility criteria have previously been described in Chapter 6.  
This sub-study was conducted in both the SPI1 and SPI2 evaluation (Figure 6.1).  This review 
was undertaken by a specialist in general medicine, who has considerable experience in 
case-note review, and has investigated hospitals who were outliers on hospital mortality 
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statistics (Mohammed et al., 2008b).  To measure inter-observer reliability, a subset of case-
notes was independently re-evaluated by an experienced trainee in respiratory medicine.  
Using expert clinical judgement, an overall quality score was assigned, graded on a scale 
from 1 (unsatisfactory, an error had occurred) to 10 (very best care). A specific score for 
each of the three stages of care – (a) admission; (b) management; and (c) pre-discharge – 
was  allocated on a scale from 1 (unsatisfactory) to 6 (excellent care).  Reviewers classified 
errors and adverse events using standard definitions found in Box 7.1 (Brennan et al., 1991; 
Leape et al., 1991; Reason, 2000; Vincent et al., 2001; Wilson et al., 1995; Woloshynowych et 
al., 2003). 
Box 7.1: Definitions of error and adverse events  
Error: 
“Undesirable event in healthcare management which could have lead to harm or did so but which did 
not impact on duration of admission or lead to disability at discharge” 
“A failure to complete a planned action as it was intended or to adopt an incorrect plan” 
 
Adverse Event: 
“Unintended injury or complication” 
“Prolonged admission, disability at discharge or death” 
“Caused by healthcare management rather than the disease process” 
“Poor outcomes, some of which are the result of preventable actions or poor plans” 
The number of errors and adverse events (of all types, not just those relating to medication) 
were recorded for each patient; it was possible for a patient to have more than one error or 
adverse event.  
The results are presented as average numbers of errors per 100 patients. Average ratings 
and average numbers of errors were calculated for both control and intervention groups, for 
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all study epochs (with standard errors). Errors were further classified by broad categories 
(Table 7.1).   
Table 7.1: Classification of errors and adverse events  
Category Nature of the problem 
Diagnosis/Assessment 
Admission Error 
• Failure to diagnose promptly /correctly 
• Failure to assess patient's overall condition adequately 
(including comorbidities) 
Hospital-acquired infection • Hospital-acquired infection 
Technical/management • Technical problem relating to a procedure 
• Problem in management/monitoring (including nursing 
and other professional care) 
Medication/Maintenance/Test 
results 
• Failure to give correct/monitor the effect of medication 
• Failure to maintain correct hydration/electrolytes 
• Failure to follow up abnormal test 
Clinical reasoning • Obvious failure of clinical reasoning 
Discharge information • Information needed by GP not transferred at discharge 
for whatever reason 
Note, that a particular error/event could be assigned to more than one category. For example a test 
result showing severe hyperthyroidism was ignored and this error could be classified under 
“Medication/Maintenance/Test results” and “Discharge information”.  
 
7.2.1 Statistical methods 
No formal adjustments were made for multiple comparisons, although 99% confidence 
intervals are quoted in all cases. Inter-observer reliability was calculated  by ICC for the four 
scores. Inter-observer reliability was assessed between the two errors by using the κ 
statistic. 
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7.2.1.1 Statistical methods used specifically in the SPI1 evaluation 
Generalised linear mixed models with random effects for each hospital were used to 
estimate the difference in changes (although in one instance the random effect model did 
not converge so a fixed model was used instead).  
7.2.1.2 Statistical methods used specifically in the SPI2 evaluation 
A mixed modelling approach was used to test for differences in between Epochs 1 and 2, and 
Epoch 3. Random effects were included to allow for within hospital correlation, using an 
exchangeable correlation structure. Covariates included a binary variable “After” indicating 
whether the observation was before or after the intervention period; a binary variable 
“Intervention” indicating whether the hospital was a control or SPI2 hospital; a binary 
variable “Epoch 1 (or 2)” indicating whether the observation was from the pre-intervention 
phase; and an interaction between “After” and “Intervention”, to evaluate the estimated 
difference in change between the control and SPI2 hospitals (between Epoch 3 and the 
average of the pre-intervention epochs). All models were adjusted for age and sex of 
patients.  
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7.3 Results 
7.3.1 The sample 
7.3.1.1 Number of case-notes reviewed within the holistic review in the SPI1 
evaluation 
The number of case-notes reviewed by the holistic method differs, being higher than the 
number reviewed by the explicit review method (see 6.3.1). This is because the reviews were 
commissioned at different times. In the four SPI1 hospitals, 390 and 381 case notes were 
holistically reviewed from Epoch 1 and Epoch 2 respectively (roughly divided equally 
between the four hospitals). For the eighteen control hospitals, 243 and 246 case notes were 
reviewed from Epoch 1 and Epoch 2 (range 8 to 15 cases per hospital).  
7.3.1.2 Number of case-notes reviewed within the holistic review in the SPI2 
evaluation 
In the nine SPI2 hospitals, 359 case-notes were holistically reviewed (roughly divided equally 
between the nine hospitals). For the nine control hospitals, 366 cases notes were holistically 
reviewed (again roughly equally divided between the 9 hospitals). For both the control and 
SPI2 hospitals, roughly equal numbers of cases notes were reviewed from each of the three 
epochs (243 cases notes were reviewed from Epoch 1; 246 from Epoch 2; and 236 from 
Epoch 3). This means that a total of 489 cases notes were reviewed from the pre-
intervention period and 236 cases notes were reviewed from the post-intervention period. A 
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small number of case-notes analysed by explicit review did not get included in the holistic 
review, and vice-versa, due to logistical problems and time constraints. For this reason the 
homology between the two sets of notes is not complete. For example there were 31 deaths 
among the explicit case-notes reviewed, and 30 among the implicit case-notes.    
7.3.2 Reliability 
7.3.2.1 Agreement between reviewers within the SPI1 evaluation 
In total, 122 case notes were reviewed by both reviewers. Measures of reliability between 
the two holistic reviewers were, as expected for holistic reviews, low (Lilford et al., 2007) 
(ICC’s were 0.05 [99% CI: -0.13,0.23] for the admission rating; 0.19 [99% CI: -0.05,0.23] for 
the management rating; 0.21 [99% CI: -0.02,0.42] for the pre-discharge care rating; and 0.29 
[99% CI: 0.06, 0.49] for the overall care rating). The main reviewer tended to assign higher 
average ratings with more variability, whereas the second reviewer tended to assign lower 
average ratings with less variability. The inter-rater agreement measures between reviewers 
for identifying patients who had experienced an error as part of their overall care was low 
(κ= 0.15, se 0.08). 
7.3.2.2 Agreement between reviewers within the SPI2 evaluation 
Seventy-four case-notes were reviewed by two reviewers. Again, measures of reliability 
between the two holistic reviewers were low (Lilford et al., 2007) (ICC’s were 0.05 (99% CI: -
0.25, 0.34) for admission rating; 0.05 (99% CI: -0.25,0.34) for the management rating; 0.37 
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(99% CI: 0.08,0.60) for the pre-discharge care rating; and 0.31 (99% CI: 0.02, 0.56) for the 
overall care rating). Again the main reviewer tended to assign higher average ratings with 
more variability, whereas the second reviewer tended to assign lower average ratings with 
less variability. The errors identified by the two reviewers was small (κ = 0.08, se 0.09). 
7.3.3 Quality of care ratings 
7.3.3.1 Quality of care within the SPI1 evaluation 
The average scores during Epoch 1 (with standard errors) for admission, management and 
pre-discharge ratings were 5.0 (0.05), 4.2 (0.07) and 4.3 (0.07) respectively on a scale of 1 
(below best practise) to 6 (excellent care); and the average score for over all care was 7.4 
(0.06), on a scale of 1 (unsatisfactory) to 10 (very best care). Admission, management and 
pre-discharge care ratings were higher in the SPI1 hospitals compared with the control 
hospitals, during both Epoch 1 and Epoch 2 (Table 7.2), although not significantly so. 
However, the overall care rating was higher in the control hospitals during Epoch 1 (although 
again not significantly so), but similar during Epoch 2. In addition, all ratings tended to 
increase in Epoch 2 as compared with Epoch 1. This pattern was more consistent across 
intervention hospitals, where not only did all rating increase, but admission rating increased 
significantly between epochs (increase 0.28, p=0.001) However, differences in changes 
across control and SPI1 hospitals were not significant for any of the four ratings (Table 7.2). 
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7.3.3.2 Quality of care within the SPI2 evaluation 
The average quality of care scores during Epoch 1 (with standard errors) for admission, 
management and pre-discharge ratings were 4.89 (0.08), 4.15 (0.12), and 4.20 (0.12) 
respectively; and the average score for overall care was 7.56 (0.09).  During Epoch 1, all of 
the four quality of care ratings were higher in the SPI2 hospitals compared with the control 
hospitals (Table 7.3), although not significantly so. However, during both Epoch 2 and Epoch 
3, all four quality of care ratings were higher in the control hospitals compared to the SPI2 
hospitals (although again not significantly so). In the control hospitals, all ratings tended to 
increase with time; whereas in the SPI2 hospitals, all ratings decreased between Epoch 1 and 
Epoch 3, (although once again not significantly so). However, differences in changes across 
control and SPI2 hospitals were not significant for any of the four ratings (Table 7.3). 
An analysis of the differences between SPI2 hospitals, and control hospitals at baseline and 
changes between Epoch 3 was also conducted, the details of which can be found in 
Appendix C. 
7.3.4 Errors 
7.3.4.1 Error rates within the SPI1 evaluation 
The numbers of errors per 100 patients were lower in the SPI1 hospitals compared to the 
control hospitals, for both for Epoch 1 and Epoch 2 (Table 7.2). In the control hospitals, there 
was approximately one error for every two patients, whereas in the SPI1 hospitals there was 
 201 
 
circa one error for every three patients. The numbers of errors decreased in Epoch 2 (for 
both the control and SPI1 hospitals), although this difference was not significant. Again 
differences in changes across control and SPI1 hospitals were not significant for errors. 
A total of 425 errors were identified (Table 7.4). The most frequent categories of errors 
related to “diagnosis, assessment or admission”, or were errors relating to “poor clinical 
reasoning”. Errors relating to poor clinical reasoning were more frequent in the control 
hospitals (in both Epoch 1 and Epoch 2), and although they decreased in the control 
hospitals in Epoch 2, they increased in the SPI1 hospitals in Epoch 2. Rates of other errors 
also differed between control and SPI1 hospitals and between Epoch 1 and Epoch 2, 
although no differences in changes were significant.  
7.3.4.2 Error rates with the SPI2 evaluation 
Over all hospitals and all epochs, the average number of errors observed was 41 (se 2.17) 
per 100 patients, which equates to approximately one error in every 2.5 case-notes 
reviewed. In the control hospitals, the average number of errors per 100 patients decreased 
over the three epochs from 52.4 (se 5.6) errors per 100 patients in the first epoch to 30.7 (se 
5.3) in the third epoch (Table 7.5). Whereas, in the SPI2 hospitals, the average number of 
errors per 100 patients was relatively stable over epochs: from 35.9 (se 4.9) in the first 
epoch to 38.5 (se 5.0) in the third. Again differences in changes in average number of errors 
before and after the intervention across control and SPI2 hospitals were not significant (Rate 
Ratio 1.47; 0.74-0.90). 
 202 
 
A total of 153 errors were identified in the control hospitals and 145 errors identified in the 
SPI2 hospitals (Table 7.5). The most frequent categories of errors related to “diagnosis, 
assessment or admission”, or were errors relating to “poor clinical reasoning”. Errors relating 
to both these types were more frequent in the control hospitals in Epoch 1, but were less 
frequent during Epochs 2 and 3. Rates of other errors also differed between control and SPI2 
hospitals and between Epoch 1 and Epoch 2, although no differences in changes were 
significant.  
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Table 7.2: Holistic review: changes in ratings and numbers of adverse events and errors between control and SPI1 hospitals 
 
Control Hospitals SPI1 Hospitals Difference in change 
 Epoch 1 Epoch 2 Epoch 1 Epoch 2 (99% CIs)* 
      
Number of Patients 243 246 390 381  
      
 Ave SE Ave SE Ave SE Ave SE  
Quality Ratings          
Admission Rating† 4.9  0.08 4.9  0.08 5.0 0.07 5.3 0.05 0.23 (-0.14, 0.60) 
Management Rating† 4.2 0.12 4.1 0.12 4.3 0.10 4.6 0.09 0.35 (-0.19, 0.90) 
Pre-discharge Rating† 4.2  0.11 4.2  0.10 4.3 0.08 4.4 0.08 0.06 (-0.42, 0.54) 
Overall Care Rating‡ 7.6  0.09 7.6  0.09 7.4 0.08 7.6 0.07 0.27 (-0.17, 0.70) 
          
Errors/ Adverse Events Rate SE Rate SE Rate SE Rate SE  
Number Errors per 100 patientsФ 44.44  3.8 42.3  3.8 29.7 2.5 24.4 2.3 -2.42 (-17.99, 13.31) 
Number Adverse Events per 100 
patientsФ 
2.9 1.2 4.8 1.3 6.2 1.2 3.7 1.1 -3.92 (-10.39, 2.55) 
% of Preventable Adverse Events  0 - 30 13 28 9 36 11 -22 (-67, 30) 
*Difference in changes are estimated from a mixed effects model (see methods for details) 
†Score scale: 1 (below best practice) to 6 (excellent care) 
‡Score scale: 1 (unsatisfactory) to 10 (very best care) 
ФPatients could experience more than one error and more than one adverse event 
Shaded areas relate to post-intervention epochs 
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Table 7.3: Holistic review: changes in ratings and numbers of adverse events and errors between control and SPI2 hospitals (standard errors 
in parenthesis)   
  Control Hospitals SPI2 Hospitals Difference in Change 
(99% CIs)
* 
  Epoch 1 Epoch 2 Epoch 3 Epoch 1 Epoch 2 Epoch 3  
Number of patients 126 126 114 117 120 122   
Quality Ratings         
Admission Rating† 4.76 (0.13)  4.94 (0.12)  4.97 (0.10) 5.03 (0.10)  4.93 (0.11)  4.87 (0.10) -0.26 (-0.77, 0.24) 
Management Rating† 3.98 (0.17) 4.18 (0.17) 4.29 (0.16) 4.35 (0.16) 4.03 (0.17) 4.25 (0.16) -0.18 (-0.92, 0.56) 
Pre-discharge Rating† 4.13 (0.16) 4.25 (0.14) 4.32 (0.13) 4.28 (0.15) 4.16 (0.15) 4.25 (0.14) -0.10 (-0.74, 0.54) 
Overall Care Rating‡ 7.42 (0.13) 7.62 (0.12) 7.77 (0.11) 7.72 (0.11) 7.46 (0.12) 7.47 (0.11) -0.41 (-0.94, 0.11) 
Errors / Adverse Events       Rate Ratios 
Number Errors Ф 52.4 (5.6) 39.7 (5.2) 30.7 (5.3) 35.9 (4.9) 45.0 (5.7) 38.5 (5.0) 1.47 (0.74, 2.90) 
Number Adverse Events Ф 4.76 (2.21) 3.97 (1.74) 3.51 (1.73) 0.85 (0.85) 5.00 (1.99) 0 (--)  
* Differences in changes are estimated from a mixed effects model (see methods for details) and represent a difference in change between Epoch 3 and 
Epochs 1 and 2.  
† Score scale: 1 (below best practice) to 6 (excellent care) 
‡ Score scale: 1 (unsatisfactory) to 10 (very best care) 
Ф The numbers of errors and numbers of adverse events are per 100 patients (patients could experience more than one error and more than one adverse 
event) 
Shaded areas relate to post-intervention epochs 
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Table 7.4: Rates (per 100 patients) of errors identified by broad category of error – holistic review   
 
Control Hospitals SPI1 Hospitals Effect of SPI1 
 Epoch 1 Epoch 2 Epoch 1 Epoch 2  
      
Number of Patients 243 246 390 381  
      
Number of Errors
* 111 104 116 94  
     Rate Ratio (99% CI) 
Rate of Errors 44.4 (3.8) 42.3 (3.8) 29.7 (2.5) 24.4 (2.3) 0.87 (0.52, 1.44) p=0.48 
      
 Rate SE Rate SE Rate SE Rate SE  
Diagnosis/ Assessment/  
Admission Error  
54.3  5.0 48.8  4.7 31.8  3.1 27.8  3.1 1.02 (0.64, 1.65) p=0.90 
Hospital-acquired infection 0  0  0.26  0.26 1.05  0.52 - 
Technical/ management 7.4  1.7 8.9  1.8 3.3  0.9 2.4  0.8 0.60 (0.15, 2.43) p=0.35 
Medication/Maintenance/  
Follow-up 
23.5  3.1 16.7  2.6 18.7  2.2 15.2  2.0 1.20 (0.59, 2.42) p=0.51 
Clinical reasoning 30.9  3.0 28.5  2.9 10.5  1.6 16.5  1.9 1.83 (0.92, 3.63) p=0.02 
Discharge information 11.9  2.1 15.4  2.3 10.3  1.5 9.4  1.5 0.75 (0.31, 1.81) p=0.41 
*Errors can be of multiple categories 
Shaded areas relate to post-intervention epochs 
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Table 7.5: Rates per 100 patients of errors identified by broad category of error (Standard errors are in parenthesis) SPI2 
 
Control Hospitals SPI2 Hospitals Rate Ratio 
 Epoch 1 Epoch 2 Epoch 3 Epoch 1 Epoch 2 Epoch 3 (99% CIs)* 
Number of patients 126 126 114 117 120 122  
        
Number of errors 67 50 36 44 54 47  
         
Diagnosis/ Assessment/  
Admission Error 
63.49 (7.18) 42.86 (6.00) 36.84 (6.74) 44.44 (6.91) 55.00 (7.28) 46.72 (6.60) 1.34 (0.72, 2.51) 
Hospital-acquired infection 0 0 0.87 (0.87) 0 0 0 Not estimable 
Technical/ management 10.32 (2.72) 9.52 (2.63) 9.65 (2.78) 4.27 (1.88) 8.33 (2.53) 5.74 (2.11) 0.94 (0.21, 4.28) 
Medication /Maintenance/  
Follow-up 
24.60 (4.46) 16.67 (3.52) 8.77 (2.66) 22.22 (4.22) 16.67 (3.80) 17.21 (3.43) 2.13 (0.69, 6.53) 
Clinical reasoning 36.50 (4.30) 27.78 (4.00) 20.18 (3.78) 24.79 (4.01) 29.17 (4.17) 27.87 (4.08) 1.65 (0.72, 3.77) 
Discharge information 12.70 (2.98) 14.29 (3.13) 9.65  (2.78) 11.11 (2.92) 16.67 (3.42) 13.93 (3.15) 1.43 (0.44, 4.68) 
Errors can be of multiple categories 
* Differences in changes are estimated from a mixed effects model (see methods for details) and represent a difference in change between Epoch 3 and 
Epochs 1 and 2. 
Shaded areas relate to post-intervention epochs 
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7.4 Discussion 
This sub-study sought to measure, by using a semi-structured holistic review, the quality of 
care and the error rates of the case-notes collected in Chapter 7.  Overall quality of care 
ratings remained stable over time in intervention and control hospitals in both evaluations.  
Error rates were lower in SPI1 hospitals (one error for every three patients) compared to 
controls (one error for every two patients), and in both arms the number of errors decreased 
in Epoch 2.  Whilst in SPI2 evaluation the intervention hospitals had a similar error rate as 
control hospitals (one error for every 2.5 patients) before the SPI was implemented. But 
after SPI implementation the error rate remained stable in the SPI2 hospitals, but decreased 
in control hospitals.  In both evaluations the most frequent categories of error related to 
“diagnosis, assessment or admission” or error relating to “poor clinical reasoning”, possibly 
reflecting the cognitive difficulty of these tasks (Croskerry, 2009).   
Moreover, for both the quality of care measures and error rates there was no difference 
between control and intervention hospitals for both the SPI1 and SPI2 evaluations.  These 
results concur with the explicit review in that there was no added benefit of the SPI. 
In previous studies, using this method of assessment (Lilford et al., 2007), reliability was low 
between the reviewers for both quality of care measures and error rates.  This low reliability 
could be due to differences in clinical experience - the principal reviewer was a senior 
consultant general physician with a particular interest in biochemistry, whilst the second 
reviewer was a soon to be consultant respiratory physician.  Elstad et al., (2010) have 
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recently concluded that “physicians overtime gain complex social, behavioural and intuitive 
wisdom as well as the ability to compare the present day patient against similar past 
patients”.   
It is possible that reliability of the reviewers in a holistic review could be improved through 
further training, but perhaps it should be accepted that low reliability is inherent in this 
method, as each reviewer through their own personal experience, heuristics and biases will 
formulate an “internal” proforma of good care – the type of variation that can provide 
richness to a review but alas is lacking here.   
A weakness of this sub-study was the failure to record the date of review, as it plausible that 
semi-structured holistic review was also susceptible to learning/fatigue effect observed in 
the explicit review.  In the explicit review, this effect only became obvious during the 
analysis stage at which point it was too late to include this important piece of information in 
this sub-study.   
Another flaw of this sub-study, as with the explicit review, was channelling such a large 
review through an individual as a reviewer is prone to fatigue.  If this study was to be 
repeated, I would ensure that there was a panel of reviewers with similar clinical experience.   
Furthermore this type of review is expensive, and in light of these results there seems little 
added value in conducting a holistic review to illicit quality of care ratings and error rates 
over an implicit review.   
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CHAPTER 8: ERROR RATES AND QUALITY 
OF PERI-OPERATIVE CARE 
8.1 Introduction 
A specific target of the SPI was to improve peri-operative care (see 3.6.2.5), and this sub-
study seeks to measure adherence to pre defined standards of care by using explicit case-
note review methodology.   
8.2 Methods 
This sub-study is summarised in Figure 8.1.   
Figure 8.1: An outline of the case-note review of surgical patients 
 
What?
Case-note 
review 
(explicit 
method) 
to measure error 
rates in peri-
operative care
Where?
9 SPI2
intervention 
& 9 control 
hospitals
Who?
Patients over the 
age of 18 
Hip replacement & 
open cholectomy
When?
Data collection (“before”): Oct ‘06 – Mar ‘07
SPI2 intervention: Mar ‘07 – Sept  ’08
Data collection (“after”): Oct ‘08 – Mar ‘09
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8.2.1 Case-note selection 
Patients over the age of 18 years, undergoing major surgical operations of two types (total 
hip replacement and open colectomy see (Figure 8.1) were selected for the following 
reasons: 
• improving peri-operative care was a specific SPI2 target; 
• specific guidelines apply to this group of patients; 
• it was believed that compliance with the guidelines was poor. 
A set of explicit criteria for peri-operative care was developed using clinical guidelines from 
IHI (Institute for Healthcare Improvement, 2007) British Orthopaedic Association (British 
Orthopaedic Association, 2006) and the National Institute for Health and Clinical Excellence 
(NICE) (National Institute for Health and Clinical Excellence, 2008; National Institute for 
Health and Clinical Excellence, 2010) and by eliciting expert opinion.  The areas of review are 
as follows: 
• administration of prophylactic antibiotics prior to inclusion; 
• the use of prophylactic Deep Vein Thrombosis (DVT) treatment (unless 
contraindicated), which included pharmacological intervention (unfractionated 
or low molecular weight heparins) and/or mechanical interventions, such as anti-
thromboembolism stockings, foot pumps and sequential compression devices; 
• intra-operative temperature monitoring (on at least one occasion); 
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• the use of “advanced methods” of pain control (epidural anaesthesia and/or 
patient controlled analgesia) for post-operative pain control. Types of 
anaesthesia administered were also investigated, as there is evidence to suggest 
that using neuraxial blocks (spinal and epidural) with sedation only or in 
combination with a general anaesthetic helps with early post-operative pain 
control and recovery. Likewise there is an evidence base to support the use of 
patient controlled analgesia (PCA). The quality criterion was that on least one of 
the modalities (neuraxial block or PCA) should be used. 
Within the SPI intervention, the IHI advocate the removal of hair by clipping (not shaving); 
as this standard is not routinely recorded this was not included as a process measure for the 
evaluation.  
8.2.2 Case-note assembly 
Case-notes were selected from nine control and nine SPI2 hospitals. In this case there was a 
single pre-intervention epoch (corresponding to Epoch 2, i.e. October 2006 to March 2007) 
for comparison with the post-intervention epoch (corresponding to Epoch 3, i.e. October 
2008 to March 2009). The intention was to analyse ten case-notes from each epoch (five of 
each surgical operation type) to yield a total sample of 360. To control for seasonal effects, 
the case-notes were spread across each time period (approximately two per month). The 
anonymisation procedures used in the sub-study dealing with the management of the 
acutely sick respiratory patients was followed (see 6.2.2).  
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All case-notes, were reviewed by a single medically trained reviewer over a period from 
November 2009 to January 2010. The first 20 cases were read jointly by another senior team 
member, and each one was discussed for training purposes. The notes were partially 
scrambled over epochs to assess, and if necessary control for, learning/fatigue effects. Inter-
rater agreement was measured using 27 case-notes reviewed by a second reviewer, a 
surgical trainee.  
8.2.3 Sample size calculation 
Sample size calculation was performed after analysing results for 42 case-notes. There was 
high compliance (>90%) with the venous thrombo-prophylaxis and antibiotic criteria, such 
that there was little headroom for post intervention improvement. Thus the sample size 
calculation was based on intra-operative temperature monitoring, where compliance was 
about 40% at baseline, (i.e. there was plenty of headroom for improvement in response to 
SPI). Assuming that control hospitals experience an improvement from 40% to 50% 
compliance over the study period, the sample (n=360) was sufficient to detect an additional 
25% to 30% improvement in association with SPI at 80% power, see Figure 8.2 and Table 
8.1.  
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Figure 8.2: Sample sizes for 80% power (at 5% significance)  
 
Table 8.1: Sample sizes for 80% power (at 5% significance)  
Effect Size (%) Total number of cases 
needed for 80% power 
15 1,364 
20 764 
22.5 600 
25 484 
30 328 
35 236 
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8.3 Results 
8.3.1 Sample, reviewer reliability and headline message 
There was a shortfall in the target number of 360 case-notes, and were only able to retrieve 
242 notes; 127 were from admissions for total hip replacements and 115 from admissions 
for open colectomies. A second reviewer examined 27 case-notes. Percentage agreement 
and Kappa statistics are given in Table 8.2. These figures indicate low agreement on whether 
the temperature had been monitored (59%). For all other items the reviewers agreed on at 
least 85% of the cases. 
No significant SPI effects were observed for any of the four clinical standards examined and 
the before/after comparison if anything, leaned towards the control hospitals. The hospitals 
were similar at baseline except with respect to intra-operative temperature monitoring 
where controls had more headroom for improvement. The results relating to the individual 
criteria are given in Table 8.3 and the outcomes of the mixed effects logistic regressions are 
given in Table 8.4.  
8.3.2 Pain relief 
Hospital staff identified contraindications to either epidural or self-administered analgesia in 
15 of 242 cases. The existence of the contraindication was confirmed by the reviewers in all 
of these 15 cases with an additional contraindication in a patient identified by one of the 
reviewers. Two-hundred and twenty-six patients were thus eligible for modern analgesic 
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methods and 199 (88%) received such care. There was little headroom for improvement and 
there were no differences between control and SPI2 hospitals at either baseline or over 
time.  
8.3.3 Prophylactic antibiotics 
These were given in 235 of 242 cases (97%). While the breakdown across arms and epochs is 
summarised in Table 8.4, the full logistic regression analysis was not feasible because of the 
100% compliance in the control hospitals at Epoch 2. 
8.3.4 Temperature monitoring 
There was marked but non-significant increase in compliance over epochs in both control 
and SPI2 hospitals with little difference in rate of improvement (OR 1.8; 0.4-7.6). There is 
evidence of heterogeneity between hospitals.  
8.3.5 DVT prophylaxis 
Anticoagulation prophylaxis was given in 239 of the 242 cases (99%). Two of these 239 were 
contra-indicated for prophylaxis. It was correctly withheld in one further contra-indicated 
case, and in two cases where no contra-indications were recorded.  
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Table 8.2: Reviewer agreement in the peri-operative case-note  
 Appropriate Pain Relief Prophylactic Antibiotics Temperature Monitored DVT prophylaxis 
% Agreement 85% 93% 59% 96% 
Kappa* 0.46 - 0.24 - 
*Blank entries for Kappa indicate that one reviewer put all cases in the same category 
Table 8.3: Rates of compliance with peri-operative care standards   
 
Control Hospitals (N=9) SPI2 Hospitals (N=9) 
 Pre-intervention Post-intervention Pre-intervention Post-intervention 
Number of Patients 51 43 79 69 
     
 % SE % SE % SE % SE 
Advanced method of pain relief* 94.0 3.4 94.9 3.6 85.3 4.1 82.5 4.8 
Peri-operative antibiotic given† 94.1 3.3 100.0 - 97.5 1.8 97.1 2.0 
Temperature Monitored‡ 16.0 5.2 30.2 7.1 29.1 5.1 41.2 6.0 
Appropriate DVT prophylaxis†ф 100.0 - 100.0 - 98.7 1.3 100.0 - 
* Hospital staff identified 15 cases with contra-indications to this standard, all of which were corroborated by the reviewers. The data relates to the 227 
eligible patients 
† Logistic regression impossible because 100% in one cell 
‡ Evidence of heterogeneity between hospitals at baseline 
Ф Three cases had contra-indications yielding a denominator of 238. It was withheld in only two cases where no contra-indications were present but wrongly 
administered in two cases where there was a contra-indication 
Shaded areas relate to post-intervention epochs 
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Table 8.4: Peri-operative review: changes in the level of compliance between SPI2 and control hospitals and the effect of SPI2 
 
Baseline Comparisons Changes in Controls Effect of SPI2 
 (SPI/Control) (Epoch 2/Epoch 1)  
 OR (99% CI) p-value OR (99% CI) p-value OR (99% CI) p-value 
Advanced method of pain relief 0.3 (0.03, 2.6) 0.148 1.0 (0.1, 17.2) 0.978 0.6 (0.03, 18.4) 0.820 
Peri-operative antibiotic given 0.8 (0.06, 11.5) 0.862 - - - - 
Temperature monitored* 1.8 (0.5, 6.5) 0.227 1.8 (0.4, 7.6) 0.279 0.9 (0.1, 5.2)  
*Temperature monitoring is subject to significant (p=0.01) variation between hospitals within the arms of the study. 
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8.4 Discussion 
The retrospective explicit case-note review of peri-operative care demonstrated 
considerable compliance to the measures of interest with very little or no headroom for 
improvement.  Eighty-eight percent of patients eligible for analgesics received them; 97% of 
patient received appropriate prophylactic antibiotics and 99% of patients received DVT 
prophylaxis.   
There was good agreement on all items between reviewers aside from intra-operative 
temperature monitoring.  Hospitals were similar at baseline apart from temperature 
monitoring.  There was no observed additive benefit of the SPI.   
When these results have been shared with others there is a disbelief that these results are 
correct particularly the levels of compliance for DVT prophylaxis.  However, it is supported 
by the literature – in 2005 two surgical mortality audits (covering the period 1994 to 2002 
and 2002 to 2004) reported the increasing use of DVT prophylaxis and a decreasing number 
of DVT adverse events (Semmens et al., 2005; Thompson et al., 2005).  This result is further 
strengthened by a retrospective case-note review to measure the prevalence of DVT 
prophylaxis, which measured 100% compliance within orthopaedics in eight English hospitals 
(Campbell et al., 2001).   
Another reason why the reader maybe sceptical of the results is that if compliance for 
prophylactic antibiotics is so high why has there not been an equally dramatic decrease in 
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surgical site infection a rates (Health Protection Agency, 2009).  This could be due to the fact 
that the peri-operative bundle alone is not sufficient to reduce surgical site infections.  There 
is evidence by Stulberg and colleagues (Stulberg et al., 2010) that compliance to surgical 
infection control processes such as the peri-operative care bundle are not associated with a 
significantly lower probability of infection.   
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CHAPTER 9: INDIRECT MEASURE OF HAND 
HYGIENE 
9.1 Introduction 
Improvement in hand hygiene was a specific aim the SPI intervention. Within the UK there 
has also been a national initiative to improve hand hygiene amongst acute hospital 
employees - the “cleanyourhands” campaign (National Patient Safety Agency, 2010).  This 
initiative consisted of actions to make alcohol hand rub (AHR) available at the bedside, 
monthly updated posters on wards and a patient empowerment component to encourage 
patients to ask staff to clean their hands. The campaign was rolled out in England and Wales 
between December 2004 to June 2005 and continues to date. Since hand hygiene was also a 
SPI target, the hypothesis that SPI would have an additive effect was tested.   
9.2 Methods 
This sub-study was conducted in the SPI2 evaluation only and is outlined in Figure 9.1.   
The success of this campaign was measured by the National Observational Study to Evaluate 
the “cleanyourhands” campaign (NOSEC) (Stone et al., 2007). As part of their study, monthly 
data from NHS Logistics for soap and AHR consumption (litres) was collected as an indirect 
measure of hand hygiene compliance. Data were available on a monthly basis for the period 
July 2004 to September 2008. This spanned a “before” period (July 2004 to February 2007) 
and a period concurrent with the intervention (March 2007 to September 2008). To adjust 
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for potential variations in consumption due to hospital size, these data, which were available 
at hospital level and were expressed as a rate (in litres) per 1,000 bed occupied days. Bed 
occupancy days were based on yearly averages spanning financial years (Department of 
Health, 2010).  
Figure 9.1: An outline of the indirect measure of hand hygiene sub-study 
 
9.2.1 Statistical methods 
Population averaged (marginal) models were used to assess the effects of the intervention 
on soap and AHR consumption. To allow for decays in correlations (within hospitals) over 
time, an auto-regressive (AR 3) correlation structure was included. Results are based on the 
identity scale as this allows estimation of difference in change. Covariates within the models 
What?
Indirect 
measure 
of hand 
hygiene
Where?
SPI2
intervention 
& control 
hospitals
How?
Soap and AHR consumption
When?
Data collection (“before” and “during”): Jul ‘04 to Sept ‘08
SPI2 intervention: Mar ‘07 – Sept  ’08
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included an indicator variable denoting intervention or control hospital and time as a 
continuous variable (from one to maximum number of temporal observations available). The 
effect of time was modelled as a polynomial function (cubic) as there was an indication that 
change in rates were non-linear. Finally, a fixed effect interaction between time and 
intervention allowed assessment of whether the change in rates of infection differed 
between control and SPI2 hospitals.  
Both models were fitted in STATA using the GEE population averaged class of models. For 
the before and after comparisons, estimates of differences in differences (as estimated by 
the GEE models) are presented along with 99% confidence intervals. For the temporal 
models, smoothed estimates of outcomes over the study period are presented in graphical 
format, along with p-values for tests of significant differences in changes between control 
and SPI2 hospitals. Models were weighted with a suitably appropriate denominator (either 
number of events or standard deviation of outcome for summary data). 
9.3 Results 
9.3.1 Data available 
Data on soap and AHR (in litres) were available for nine and eight of the control hospitals 
and for seven and six of the SPI2 hospitals respectively.  
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9.3.2 Soap and alcohol hand rub consumption 
The median rate of soap consumption over all hospitals and all time periods was 50 litres per 
1,000 bed days (IQR: 32, 71) and the median rate of AHR consumption was 44 litres per 
1,000 bed days (IQR: 29, 61). Averaging over all time periods (July 2004 to September 2008) 
the median rate of soap and AHR consumption was higher in the SPI2 hospitals compared to 
the control hospitals: the median rate of soap consumption in the SPI2 hospitals was 53 
litres (IQR: 30, 79) compared to 46 litres (IQR: 34, 65) in the control hospitals; and the 
median rate of AHR consumption was 49 litres (IQR: 31, 79) compared to 43 in the control 
hospitals (IQR: 34 ,65). 
Rates of both soap and AHR consumption increased in both control and SPI2 hospitals over 
the study period (Table 9.1). For example, in the control hospitals the median rate of soap 
consumption increased from 43 litres (IQR: 32, 54) in the period before the intervention to 
63 litres (IQR: 35, 86) in the period during the intervention; and in the SPI2 hospitals this rate 
similarly increased from 49 litres (IQR: 30, 64) to 71 litres (IQR: 5, 102). Smoothed estimates 
of rates of increase of consumption of both products, as estimated by the GEE population 
averaged model, are presented in Figure 9.2 and Figure 9.3.  
The rate of increase in rates of consumption of both soap and AHR (i.e. the difference of the 
differences) were similar between control and SPI2 hospitals and were not significant 
(p=0.760 and p=0.889 respectively, Appendix D, Table A1), reflecting the fact that rates of 
consumption of both products was higher in the SPI2 hospitals through-out the study, and 
not only after the intervention phase.  
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Table 9.1: Soap and AHR consumption - median and inter-quartile ranges for control and 
intervention hospitals, pre- and post-intervention period (total hospital consumption rates 
per 1,000 bed days) 
 
Control Hospitals SPI2 Hospitals 
 *Pre-intervention 
(N=9) 
Post-intervention 
(N=8) 
Pre-intervention 
(N=7) 
Post-intervention 
(N=6) 
Soap 43 (33,54) 63 (35,86) 49 (30,64) 75 (5,102) 
AHR 34 (12,45) 56 (45,67) 39 (28,74) 60 (42,96) 
*Before period is July 2004 to February 2007 and after (during) period is March 2007 to September 
2008;  units are litres per 1,000 bed days 
Shaded areas relate to the post-intervention epoch 
 
Figure 9.2: Rate of soap consumption per 1,000 bed days over time in control and SPI2 
hospitals   
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Figure 9.3: Rate of alcohol hand rub (AHR) consumption per 1,000 bed days over time in 
control and SPI2 hospitals 
 
9.4 Discussion 
The use of hand hygiene consumables was higher in the SPI2 hospitals compared to controls 
and consumption of these items has increased in all study hospitals overtime.  However, 
there is no difference in the rate of change between the intervention and control hospitals 
and no SPI effect is observed. 
If the premise is accepted that the measurement of soap and AHR can be used as an indirect 
measure of hand hygiene then perhaps this finding this should not come as a surprise.  At 
the time of the SPI there was a large-scale resource intensive drive to improve hand hygiene 
- the “cleanyourhands” campaign (National Patient Safety Agency, 2010) and in addition the 
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Health Protection Agency (2010a), the Department of Health (2006) and WHO (2010) have 
all released guidance on this matter.  The issue of hand hygiene has also entered the 
mainstream - posters to wash hands are commonly seen and AHR is now readily available to 
the general public.   
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CHAPTER 10: ADVERSE EVENTS DETECTED 
IN ACUTE MEDICAL CASE-NOTES 
10.1 Introduction 
SPI1 aimed to make a 50% reduction in the total number of adverse events (Health 
Foundation, 2006; Shirley, 2008), whilst, in SPI2 the aim was tempered to a 30% reduction.  
This sub-study aimed to measure the adverse event rate amongst the patients with acute 
respiratory disease on medical wards.   
10.2 Methods 
The incidence of patient harm caused by medication was measured as part of the explicit 
review (Chapter 7). Whilst the holistic review also measured adverse events both overall and 
by degree of preventability (Chapter 8); and results are presented in the chapter as total 
adverse events per 100 patients. This sub-study was conducted in both the SPI1 and SPI2 
evaluations and utilises the case-notes collected in Chapter 7 (see Figure 6.1).   
The results are presented as average numbers of adverse events per 100 patients. Average 
ratings and average numbers of adverse events were calculated for both control and 
intervention groups, for in all study epochs (with standard errors). Adverse events were 
further classified by broad categories (Table 7.1), and categorised into four levels of 
preventability. (Definitely preventable; preventable on balance of probabilities; not 
preventable on the balance of probabilities; and definitely not preventable). 
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10.2.1 Additional review of deaths within the SPI2 evaluation 
Within the SPI2 evaluation, as a further quality control procedure, each death was re-
analysed by a second reviewer (“blinded” to epoch and group) who had been trained in 
anaesthesia and in public health and who had experience as a reviewer of deaths for the 
National Enquiry into peri-operative deaths. This was conducted after the completion of the 
data collection. 
10.2.2 Statistical methods 
No formal adjustments were made for multiple comparisons, although 99% confidence 
intervals are quoted in all cases. Inter-observer reliability between reviewers was assessed 
by using the κ statistic. 
10.3 Results 
10.3.1 Findings of the SPI1 evaluation  
The holistic review estimated an adverse event rate of about four per 100 patients treated 
(there were 56 adverse events overall), which is comparable to the published literature 
(Table 7.2) (Brennan et al., 1991; Leape et al., 1991; Vincent et al., 2001; Wilson et al., 1995). 
The inter-rater agreement for identifying patients who had experienced an adverse event 
was low (κ = 0.25 se 0.09). 
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The rate of adverse events per 100 patients was higher in the SPI1 hospitals compared with 
the control hospitals in Epoch 1, but the reverse was the case for Epoch 2 (Table 7.2). The 
number of adverse events per 100 patients decreased during Epoch 2 in the SPI1 hospitals, 
while the number of adverse events increased during Epoch 2 in the control hospitals (Table 
7.2). However, once again differences in changes were not significant. A trend in favour of 
the SPI1 hospitals was observed for five of the six categories of adverse events (Table 10.1): 
but no difference in change was significant.  
For approximately one quarter of the adverse events, there was strong or certain evidence 
that the event was preventable (Table 10.2). At around 1.3% (16/1260), this is a somewhat 
lower rate of adverse events than reported for hospital inpatients elsewhere (Vincent et al., 
2001).  Four patients died where there was more than 50% probability that death resulted 
from an adverse event. In two cases the reviewer felt that the death was definitely caused 
by the error (untreated, documented hyperkalaemia and failure to recognise adrenal crisis) 
and in two further cases that it was more likely than not (wrong choice of antibiotic and 
insulin overdose).  
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Table 10.1: Rates per 100 patients of adverse events identified by broad category of adverse events   
 
Control Hospitals (N=18) SPI1 Hospitals (N=4) Difference in change 
 Epoch 1 Epoch 2 Epoch 1 Epoch 2 (99% CIs) 
      
Number of Patients 243 246 390 381  
      
Number of Adverse Events* 7 11 24 14  
      
Category of adverse event Rate SE Rate SE Rate SE Rate SE  
Diagnosis/ Assessment/  
Admission Error 
2.47 1.00 2.44 0.99 6.67 1.59 3.67 1.16 -2.79 (-9.83, 4.26) 
Hospital acquired infection 0.82 0.58 2.03 0.90 3.08 0.88 1.57 0.64 -2.62 (-6.74, 1.50) 
Technical/ Management 0.41 0.41 1.22 0.70 0.51 0.36 0.52 0.37 -0.79 (-3.19, 1.60) 
Medication/ Maintenance/ 
 Follow-up 
0.41 0.41 0.81 0.57 2.05 0.71 0.52 0.37 -1.97 (-5.01, 1.07) 
Clinical reasoning 0.41 0.41 0 - 2.05 0.72 0.79 0.45 -0.87 (-3.79, 2.05) 
Discharge information 0.82 0.58 0 - 0.26 0.26 1.04 0.52 1.63 (-0.62, 5.65) 
          
         Rate Ratio (99% CI) 
Rate of Adverse Events 2.9 1.2 4.8 1.3 6.2 1.2 3.7 1.1 0.40 (0.09, 1.84) p=0.12 
*A single adverse event may occupy more than one category 
Shaded areas relate to post-intervention epochs 
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Table 10.2: Preventable adverse events identified as being strongly* or certainly 
preventable out of the 1260 case notes reviewed in the SPI1 holistic review   
 Control Hospitals SPI1 Hospitals 
Epoch 1 1. Given oxygen and became 
unrousable from carbon dioxide 
(CO2) retention requiring ICU 
admission 
1. Loss of consciousness due to 
hypoglycaemia caused by an overdose 
of insulin to control hyperkalaemia 
(patient died) 
  2. Supra-ventricular tachycardia in patient 
with untreated hypokalaemia (patient 
died) 
  3. Wrong choice of antibiotic for severe 
community-acquired pneumonia. 
(patient died) 
  4. Deterioration in breathlessness because 
nurse omitted scheduled use of 
nebuliser 
  5. Sent home with severe uninvestigated 
anaemia. Symptoms likely and very high 
risk † 
  6. Started on treatment for 
hypothyroidism despite equivocal test 
result (and in wrong dose) 
  7. Bronchospasm could have been avoided 
or lessened had beta blocker been 
stopped 
   
Epoch 2 1. Loss of consciousness due to 
hypoglycaemia caused by an overdose 
of insulin to control hyperkalaemia* 
1. Collapse due to adrenal crisis because 
corticosteroids were not prescribed for 
patient with known Addison’s disease. 
(patient died) 
 2. Delay in administration of vitamin K 
leading to haematoma 
2. Failure to treat MRSA and GP not 
informed on discharge. No absolute 
evidence of harm but very high risk 
 3. Breathlessness increased, requiring 
transfer to High Dependency Unit, 
following failure to administer 
prescribed antibiotics 
3. Severe anaemia not investigated and GP 
not informed. No harm in hospital but 
very high risk and symptoms likely † 
  4. Bronchospasm could have been avoided 
or lessened had beta blocker been 
stopped 
  5. Failure to inform GP of the risk of CO2 
retention by giving patient oxygen † 
*More likely than not on the balance of probabilities. †There is no absolute evidence of harm in 
these cases but patients were discharged in clear danger and this influenced the reviewer.  Shaded 
cases relate to patients who died 
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10.3.2 Findings of the SPI2 evaluation  
Over all hospitals and all epochs, the main reviewer identified 22 adverse events among the 
725 case-notes: the average number of adverse events observed was 3.03 per 100 patients. 
The inter-rater agreement for identifying patients who had experienced an adverse event 
was low (κ = 0) 
In the control hospitals the average number of adverse events per 100 patients decreased 
over the three epochs from 4.76 (se 2.21) adverse events per 100 patients in the first epoch, 
to 3.51 (se 1.73) in the third epoch. In contrast, in the SPI2 hospitals, the average number of 
adverse events per 100 patients increased between the first and second epoch from 0.85 (se 
0.85) to 5.00 (se 1.99); and decreased to zero in the third epoch. Again differences in 
changes in numbers of adverse events across control and SPI2 hospitals were not significant 
(Rate Ratio=1.47; 0.74 - 2.90). Classifications by type of adverse event are presented in Table 
10.3. Small numbers of identified adverse events preclude informative comparisons. 
Three medication related adverse events were found on holistic review. At around 0.004% 
(3/725), this is also a somewhat lower rate than reported elsewhere (Vincent et al., 2001). 
10.3.2.1 Additional review of deaths within the SPI2 evaluation 
The principal reviewer identified strong or certain evidence of preventability in four of the 22 
adverse events (i.e. 0.5% of cases overall). These four adverse events occurred in the pre-
intervention epochs described in Table 10.2 
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The first reviewer did not find over 50% probability of death in any of the 91 deaths included 
among holistic reviews. However, the second reviewer found two further deaths that were 
preventable on the balance of probabilities (both among control hospitals) in Epoch 3. One 
was due to brachycardia in a patient with hypokalaemica, and another due to delay in 
diagnosis of femoral artery thrombosis. This reviewer also found three deaths with strong 
evidence of probability in earlier epochs. A breakdown of deaths by level of preventability 
and reviewer is given in Table 10.4.   Due to such small numbers of deaths being assessed as 
preventable, these percentages were not analysed between control and SPI2 hospitals and 
they serve to shed light on mortality estimates.  However, breakdown of deaths by level of 
preventability and reviewer is given in Table 10.4. 
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Table 10.3: Rates (per 100 patients) of adverse events among patients admitted with acute respiratory disease  
 
Control Hospitals SPI2 Hospitals Difference in Change 
 Epoch 1 Epoch 2 Epoch 3 Epoch 1 Epoch 2 Epoch 3 (99% CIs)* 
Number of patients 126 126 114 117 120 122  
        
Number of errors 6 5 4 1 6 0  
        
Diagnosis/ Assessment/ 
Admission Error 
3.97 (1.75) 1.59 (1.12) 2.63 (1.95) 0.85 (0.85) 3.33 (1.65) 0 -1.98 (-8.18, 4.23) 
Hospital-acquired infection 2.38 (1.36) 1.59 (1.12) 1.75 (1.24) 0 2.50 (1.43) 0 -1.03 (-5.78, 3.74) 
Technical/management 0.79 (0.79) 1.59 (1.12) 0.88 (0.88) 0 0.83 (0.83) 0 -0.10 (-3.48, 3.28) 
Medication/Maintenance/ 
Follow-up 
0 0 0 0.85 (0.85) 1.67 (1.17) 0 -1.27 (-3.88, 1.33) 
Clinical reasoning 0 0 0 0.85 (0.85) 0 0 -0.42 (-1.94, 1.09) 
Discharge information 0.79 (0.79) 0 0 0.85 (0.85) 0 0 -0.02 (-2.17, 2.11) 
Errors can be of multiple categories 
* Differences in changes are estimated from a mixed effects model (see methods for details) and represent a difference in change between Epoch 3 and 
Epochs 1 and 2. 
Shaded areas relate to post-intervention epochs 
 235 
 
Table 10.4: Preventable deaths in acute medical wards across the study epochs 
Epoch Control Hospitals SPI2 Hospitals 
Number 
of 
deaths 
within 
holistic 
review 
Preventable 
deaths: 
≥50%** 
1
st
 reviewer 
Preventable 
deaths: 
≥50% 
2
nd
 reviewer 
Preventable 
deaths: 
<50%* 
1
st
 reviewer 
Preventable 
deaths:  
<50% 
2
nd
 reviewer 
Number 
of 
deaths 
within 
holistic 
review 
Preventable 
deaths: 
≥50% 
1
st
 reviewer 
Preventable 
deaths: 
≥50% 
2
nd
 reviewer 
Preventable 
deaths: 
<50% 
1
st
 reviewer 
Preventable 
deaths: 
<50% 
2
nd
 reviewer 
1 17 0 1† 1 0 9 0 0 0 0 
2 24 0 1† 2 0 11 0 1† 0 0 
3 23 0 2 2‡ 1‡ 7 0 0 0 0 
*Preventable deaths <50%: substandard practice was present that could have led to death but the probability that it did so was less than 50%; 
**Preventable deaths ≥50%: substandard practice led to death on the balance of probabilities. 
†These deaths (both associated with CO2 retention in patients denied non-invasive ventilation – one of whom was given 60% oxygen) were not detected by 
the reviewer SPI1 evaluation (see Table 10.2)   
‡ The reviewers identified different cases, with no overlap. 
Shaded area relates to post-intervention epochs 
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10.4 Discussion 
For this sub-study agreement between the reviewers was again low, and possible reasons 
and methods for improvement have been discussed in Chapter 8.   
Within the SPI1 evaluation there were a total number of 56 adverse events that equated to 
4 adverse events per 100 patients.  Whilst with the SPI2 evaluation there were 22 adverse 
events which is equivalent to 3.03 adverse events per 100 patients.  These findings are 
comparable to the Harvard Medical Practice study (Brennan et al., 1991; Leape et al., 1991) 
but lower than a previous UK adverse event retrospective review, which reported an overall 
adverse event rate of 10.8% and adverse event rate within general medicine of 8.8% 
(Vincent et al., 2001).  No difference in change was significant in either evaluation and hence 
no SPI effect was observed.   
For the SPI1 evaluation 28% (16/56) of the adverse events were preventable and in the SPI2 
evaluation this was 18% (4/22).  In both evaluations the adverse event rate is much lower 
than previously reported in the UK (47% were preventable in total, whilst 75% were 
preventable in general medicine (Vincent et al., 2001).  It is tempting to say that through 
improving quality of care observed in Chapter 7 preventable adverse events have decreased 
since the publication of earlier reports and during the period of both phases of the SPI.  
However, I am reticent in making such conclusions - the numbers of adverse events are small 
and the review was conducted for one episode of care (previous studies have reviewed the 
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whole patient case-note) such that it is unknown if further adverse events occurred post 
discharge and during subsequent readmissions.  
A novel methodological approach conducted in this sub-study was the review of preventable 
mortality; although it does not provide any meaningful information on preventability it does 
provide an insight on how quality of care could be measured in future. 
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CHAPTER 11: RATES OF MORTALITY 
AMONG ACUTE MEDICAL CARE PATIENTS 
11.1 Introduction 
Mortality rates across pre- and post-intervention epochs among patients whose case-notes 
were selected for review in Chapter 7 were compared.  This was because it was feasible and 
because, arguably, a higher signal to noise ratio would be expected among this group, which 
not only was especially well placed to benefit from specific SPI interventions, but also tends 
to have high mortality. 
11.2 Methods 
The case-notes were collected as part of the sub-study described in Chapter 7 and this sub-
study utilises the same statistical methods (see 6.2.6).  This sub-study was undertaken in 
both the SPI1 and SPI2 evaluation.   
11.3 Results 
11.3.1 Mortality within the SPI1 evaluation 
The analysis was adjusted for age, sex and the number of co-morbidities, though only age 
was significant (p<0.001). The odds of death increased by 8% (CI 5% - 11%) per year of 
patient age. 
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The effect of SPI is not significant. The baseline comparisons showed no significant 
differences between control and SPI1 hospitals; neither is there significant evidence of 
temporal change in the control hospitals (Table 11.1 and Table 11.2). 
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Table 11.1: Mortality rates 
 
Control Hospitals (N=18) SPI1 Hospitals (N=4) 
 Epoch 1 Epoch 2 Epoch 1 Epoch 2 
     
Number of Patients 236 240 381 380 
Deaths 27 39 63 49 
% Mortality (SE) 11.4 (2.1) 16.3 (2.4) 16.5 (1.9) 12.9 (1.7) 
Age: Mean (SD) 77.6 (7.6) 79.7 (7.7) 77.4 (7.6) 78.2 (8.0) 
% Female 58.5 52.1 50.4 51.8 
Co-morbidities: Mean 2.8 3.1 3.3 3.8 
Shaded areas relate to post-intervention epochs 
 
Table 11.2: Analysis of mortality rates   
 
Baseline Comparisons Changes in Controls Effect of SPI1 
 Odds Ratio (99% CI) p-value Odds Ratio (99% CI) p-value Odds Ratio (99% CI) p-value 
Mortality (adjusted for Age, Sex, 
Number of co-morbidities) 
1.9 (0.6, 5.6) 0.149 1.4 (0.7, 2.9) 0.274 0.5 (0.2, 1.4) 0.085 
 
 241 
 
11.3.2 Mortality within the SPI2 evaluation 
Crude mortality was higher in the control hospitals than in the SPI2 hospitals (OR 0.7; 0.2-
2.1) (Table 11.3), but neither this, nor any other effect – including that of the SPI – was 
significant at the pre-determined 1% level after adjustment for age of patient (OR 0.3; 0.068-
1.4) (although the result was just significant [p=0.043] at the 5% level). Sex and number of 
co-morbidities were also included as patient-level covariates, though only age was significant 
(p<0.001). The mortality rate increased by 10.3% (CI 6.8%-15.1%) per year of patient age.  
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Table 11.3: Mortality among acute medical care patients whose case-notes were reviewed  
 
Control Hospitals (N=9) SPI2 Hospitals (N=9) 
 Epoch 1 Epoch 2 Epoch 3 Epoch 1 Epoch 2 Epoch 3 
       
Number of Patients 120 123 112 116 117 114 
Deaths 18 24 24 9 15 7 
% Mortality (SE) 15.0 (3.3) 19.5 (3.6) 21.4 (3.9) 7.8 (2.5) 12.8 (3.1) 6.1 (2.3) 
Age: Mean (SD) 77.6 (7.7) 81.1 (7.9) 79.6 (8.0) 77.7 (7.6) 78.1 (7.1) 80.6 (7.8) 
% Female 63.3 53.7 53.6 53.4 50.4 52.6 
Co-morbidities: Mean 2.9 3.1 2.6 2.8 3.0 2.9 
Shaded areas relate to post-intervention epochs 
 
Table 11.4: The effect of SPI2 on the mortality among acute medical care patients   
 
Baseline Comparisons Changes in Controls Effect of SPI2 
    
 Odds Ratio (99% CI) p-value Odds Ratio (99% CI) p-value Odds Ratio (99% CI) p-value 
Mortality (adjusted for Age, Sex, 
Number of co-morbidities) 
0.7 (0.2, 2.1) 0.391 1.4 (0.6, 3.1) 0.320 0.3 (0.08, 1.4) 0.043 
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11.4 Discussion 
Age, as can be expected is a significant predictor of death with the odds of dying increasing 
by 8% and 10% per year of patient age in the first and second evaluations respectively.  
Again there is no SPI effect for either the SPI1 or the SPI2 evaluations, however, it should be 
noted that if significance was set at the 5% level then the result for the SPI2 evaluation 
would just be significant (p = 0.043).  Too much emphasis should not be put on this as it is 
inevitable that a study carrying out multiple tests will throw up a significant value at this 
level (Bland and Altman, 1995), hence the reason for raising the threshold of significance to 
the 1% level.  In addition this finding is not supported by other items measured in case-note 
review (Chapters 7, 8 and 11), which have all measured no SPI effect.    
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CHAPTER 12: INTENSIVE CARE UNIT (ICU): 
MORTALITY, MORBIDITY AND LENGTH OF 
STAY 
12.1 Introduction 
Data from the Case Mix Programme (CMP) was accessed (Harrison et al., 2004) so that the 
effectiveness of the SPI critical care bundles (see 3.6.2.6) could be measured.  The CMP is a 
comparative audit run by the Intensive Care National Audit and Research Centre (ICNARC). 
This programme collects patient outcomes from adult, general critical care units (intensive 
care and combined intensive care/high dependency units) covering England, Wales and 
Northern Ireland. Critical care units volunteer to join and collect standardised datasets (case 
mix, patient outcome and activity data) on patients admitted to their unit. These data are 
submitted to ICNARC for validation and analyses. 
12.2 Methods 
This sub-study was undertaken in the SPI2 evaluation only and is summarised in Figure 12.1.   
To provide information relevant to the effectiveness of the critical care bundles data from 
the Case Mix Programme (CMP) (Harrison et al., 2004) was accessed.  The CMP is a 
comparative audit run by the Intensive Care National Audit and Research Centre (ICNARC). 
This programme collects patient outcomes from adult, general critical care units (intensive 
care and combined intensive care/high dependency units) covering England, Wales and 
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Northern Ireland. Critical care units volunteer to join and collect standardised datasets (case 
mix, patient outcome and activity data) on patients admitted to their unit. These data are 
submitted to ICNARC for validation and analyses.  
Data for the ICUs for all the study hospitals were available on a monthly basis for six months 
prior to the SPI (from October 2006 to March 2007) and for six months after the 
intervention (from October 2008 to March 2009). Mortality data were available on the 
observed numbers of deaths and the risk-adjusted number of deaths, both of which were 
used to calculate observed to expected mortality ratios. Information was also available on 
the mean length of stay (LOS) in the unit, along with standard deviation. Finally data were 
available on the mean risk prediction scores: the APACHE II score (Harrison et al., 2006) and 
the ICNARC score (Harrison et al., 2007), for patients admitted directly from a ward (along 
with standard deviation). 
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Figure 12.1: An outline of the ICU outcomes sub-study 
 
 
12.2.1 Statistical methods 
For data on intensive care outcomes a mixed modelling population averaged approach was 
again used to provide information relevant to the effects of the intervention. However, since 
these data were only available for a single six month period prior to the intervention and for 
a single six-month period after the intervention (continuous time series data throughout the 
study period were not available), these data were modelled using a simple difference of 
difference model (i.e. not including time as a continuous variable and not including an auto-
regressive component). Covariates within the model included an indicator variable denoting 
control or SPI2 hospital and an indicator variable, denoting before or after the intervention. 
What?
ICU 
outcomes
Where?
SPI2
intervention 
& control 
hospitals
How?
Mortality, morbidity and length of stay 
collected by ICNARC
When?
Data collection (“before”): Oct ‘06 – Mar ‘07
SPI2 intervention: Mar ‘07 – Sept  ’08
Data collection (“after”): Oct ‘08 – Mar ‘09
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Correlations within hospitals were incorporated using an exchangeable correlation structure. 
Adjustment was made for the morbidity covariates, mean APACHE II score and mean ICNARC 
physiology score. Finally, a fixed effect interaction between intervention and before/after 
period allowed assessment of whether the change in outcomes between the before and 
after the intervention period differed between control and SPI2 hospitals.  
All models were fitted in STATA using the GEE population averaged class of models. For the 
before and after comparisons, estimates of differences in differences (as estimated by the 
GEE models) are presented along with 99% confidence intervals. Full results from fitted GEE 
models are provided in Appendix D. 
12.3 Results 
12.3.1 Data available  
Data on mortality, length of stay and several other outcome measures for intensive care 
units were available for 16 hospitals, eight of which were control hospitals and eight of 
which were SPI2 hospitals. Data were supplied to ICNARC by seven control and seven SPI2 
hospitals for the pre-intervention period (Epoch 1) and for six control hospital and eight SPI2 
hospitals post-intervention period (Epoch 2) (there were some hospitals which did not 
provide data for both periods). 
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12.3.2 Observed to expected mortality 
The median observed to expected mortality ratio over all hospitals and all time periods was 
1.06 (IQR: 0.93, 1.28). Averaging over all time periods (July 2004 to September 2008) this 
ratio was lower in the SPI2 hospitals compared to the control hospitals: the median 
observed to expected mortality ratio in the SPI2 hospitals was 0.98 (IQR: 0.90, 1.15) 
compared to 1.18 (IQR: 1.01, 1.32) in the control hospitals. 
The rate of observed to expected mortality increased in the control hospitals over the study 
period (Table 12.1). For example, in the control hospitals before the intervention period, the 
median observed to expected mortality ratio was 1.14 (IQR: 0.99, 1.32) and this rate 
increased to 1.24 (IQR: 1.02, 1.33) in the six months after the intervention. Whereas, in the 
SPI2 hospitals, the observed to expected mortality ratio decreased over the two periods: 
during the first six month period the observed to expected mortality ratio was 1.04 (IQR: 
0.90, 1.15) and during the last six month period this decreased to 0.97 (IQR: 0.90, 1.15). At 
the end of the follow-up period (March 2008), the rate of observed to expected mortality 
was higher in the control hospitals. However, the adjusted difference-in-differences 
between control and SPI2 hospitals after adjustment, was not significant at the 99% level 
(p=0.25, Table 12.1).  
12.3.3 Median length of stay 
The median length of stay was 125 hours (IQR: 96,153) over all hospitals and all time 
periods. Averaging over all time periods (July 2004 to September 2008) the median length of 
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stay was lower in the SPI2 hospitals compared to the control hospitals: the median length of 
stay was 103 hours in the SPI2 hospitals (IQR: 82,132) compared to 146 hours in the control 
hospitals (IQR: 123, 183). Based on this, control ICUs may have been dealing with a different 
case-mix from the SPI2 ICUs. 
Length of stay increased in the control hospitals over the study period (Table 3.16): during 
the pre-intervention period the median length of stay was 144 hours (IQR: 117, 174) and this 
increased to 147 hours (IQR: 126,185) in the post-intervention period. In the SPI2 hospitals 
the median length of stay remained similar between the pre- and post-intervention periods: 
during the pre-intervention period the median length of stay was 102 (IQR: 82,130) and 
during the post-intervention period the median length of stay was 103 hours (IQR: 81, 137) 
in the six month period October 2007 to March 2008. Once again, differences in the rate of 
changes in length of stay were not significant (p=0.60, Table 12.1).  
12.3.4 APACHE II and ICNARC risk prediction scores 
Over all time periods and over all hospitals the median APACHE score was 20.0 (IQR: 17.8, 
21.8) and the median ICNARC score was 22.1 (IQR: 19.5, 22.1). These scores were similar 
between control and SPI2 hospitals and were similar between pre- and post-intervention 
periods (Table 12.1). Tests for differences in differences were not significant (p=0.45 and 
p=0.16, Table 12.1). 
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Table 12.1: Intensive care outcomes– median and inter-quartile ranges for control and SPI2 hospitals, pre- and post-intervention period  
 
Control Hospitals SPI2 Hospitals Difference-in-difference 
Intensive and Critical Care 
Outcomes* 
Pre-intervention 
(N=7) 
Post-intervention 
(N=7) 
Pre-intervention 
(N=6) 
Post-intervention 
(N=8) 
Change (99% CI) p-value 
Adjusted Mortality Ratio 1.14 (0.99,1.32) 1.24 (1.02,1.33) 1.04 (0.90,1.15) 0.97 (0.90,1.15) 0.09 (-0.11,0.29) 0.25 
Mean LOS (hours) 144 (117,174) 147 (126,185) 102 (82,130) 103 (81,137) 5.86  
(-22.78,34.50) 
0.60 
Mean APACHE II Score  20.4 (17.7, 22.6) 19.0 (17.1, 20.8) 21.1 (19.1, 23.0) 20.3 (17.8, 21.8) -0.83 (-3.63,1.98) 0.45 
Mean ICNARC Score 22.3 (19.5, 26.3) 20.7 (18.0, 23.5) 22.6 (21.2, 25.3) 22.2 (19.7, 25.1) -2.26 (-6.39,1.87) 0.16  
* Before period is October 2006 to March 2007 and after period is October 2008 to March 2009 
LOS: Length of Stay 
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12.4 Discussion 
Over the study period observed to expected mortality decreased in the SPI2 hospitals but 
increased in control hospitals.  This may be explained by the differing LOS between control 
and intervention hospitals.  In the control hospitals the median LOS was 146 hours 
compared to 103 hours in the SPI2, which indicates a different case-mix of patients.  
However, the differences for observed mortality and LOS between control and intervention 
sites were not significant and no SPI effect was observed.  There was also no SPI effect in 
the APACHE II and ICNARC risk prediction scores.   
This result should not be surprising as concurrent to the SPI2 intervention the Department 
of Health were recommending similar interventions to the critical bundles described in 
section 3.6.2.6 (Department of Health, 2007).  It is also possible that discrete areas such as 
the ICU are readily able to adopt and maintain these types of interventions.  In 2006 
(Pronovost et al., 2006a) described a large and sustained reduction (66%) in rates of 
catheter-related bloodstream infections.  This was maintained throughout an 18-month post 
intervention period.  A recent follow up to this study has reported this drop has been 
conserved (Pronovost et al., 2010).   
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CHAPTER 13: C. DIFF AND MRSA 
INFECTION RATES  
13.1 Introduction 
The Health Protection Agency (HPA) collects mandatory HCAI data from all acute hospitals in 
England and Wales and as several components of the SPI intervention (see 3.6.2.4) are 
related to infection control the numbers of C. diff and MSRA bacteraemia associated 
diarrhoea in the study hospitals was obtained.   
13.2 Methods 
This sub-study was undertaken in the SPI2 evaluation only and is summarised in Figure 13.1. 
Several components of the SPI intervention are related to infection control. All numbers of 
C. diff and MSRA bacteraemia associated diarrhoea in the study hospitals, were obtained 
from the Health Protection Agency (HPA), which collects mandatory HCAI data from all acute 
tr hospitals in England and Wales.  
The C. diff and MRSA data relate to both community and hospital-based infections (i.e. they 
include cases diagnosed within the first 48 hours of stay) in patients older than 65 years. C. 
diff data were available quarterly for the period January 2004 to June 2009; and MRSA data 
were available from April 2001 to September 2009. These data therefore spanned a pre-
intervention period (April 2001 or January 2004 to March 2007), a period concurrent with 
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the intervention (April 2007 to September 2008) and a post-intervention period (October 
2008 to June 2009 or September 2009). To adjust for potential variations in numbers of 
cases due to hospital size, these data were expressed as a rate per 1,000 bed occupancy 
days for C. diff infections; and as a rate per 100,000 bed occupancy days for the MRSA 
infections. Bed occupancy days were based on yearly averages spanning financial years 
(Department of Health, 2010).   
Figure 13.1: An outline of the sub-study to measure HCAI rates 
 
13.2.1 Statistical methods 
Population averaged (marginal) models were used to used to assess the effects of the 
intervention on rates of C. diff and MRSA infections. To allow for decays in correlations 
What?
HCAI
infection 
rates
Where?
SPI2
intervention 
& control 
hospitals
Who?
C. diff and MSRA infections in patients 
>65 years submitted to the HPA
When?
C. Diff data collection (“before”, “during” and “after”):  Jan ‘04 to June ’09
MSRA data collection (“before”, “during” and “after”):  Apr ‘01 to Sept ’09
SPI2 intervention: Mar ‘07 – Sept  ’08
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(within hospitals) over time, an auto-regressive (AR 3) correlation structure was included. 
Model fits were compared between log and identity scales, and results presented here are 
based on the identity scale (as this allows estimation of difference in change). Covariates 
within the models included an indicator variable denoting control or SPI2 hospital and time 
as a continuous variable (from one to maximum number of temporal observations available). 
The effect of time was modelled as a polynomial function (cubic) as there was an indication 
that change in rates were non-linear. Finally, a fixed effect interaction between time and 
intervention allowed assessment of whether the change in rates of infection differed 
between control and SPI2 hospitals.  
Both models were fitted in STATA using the GEE population averaged class of models. For 
the before and after comparisons, estimates of differences in differences (as estimated by 
the GEE models) are presented along with 99% confidence intervals. For the temporal 
models, smoothed estimates of outcomes over the study period are presented in graphical 
format, along with p-values for tests of significant differences in changes between control 
and SPI2 hospitals. Full results from fitted GEE models are provided in Appendix D.  
13.3 Results 
13.3.1 Data 
Data on numbers of C. diff and MRSA cases were available for all 18 hospitals.  
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13.3.2 C. diff 
Over all time periods, the median C. diff infection rate was 1.14 cases per 1,000 bed 
occupied days (IQR: 0.77, 1.64). Averaging over all time periods, the median rate of C. diff 
infection was similar between the control and SPI2 hospitals: the median C. diff infection 
rate was 1.15 (IQR: 0.88, 1.55) in the control hospitals and 1.10 (IQR: 0.67, 1.73) in the SPI2 
hospitals.  
The median C. diff infection rate decreased over the study period in both the control and 
SPI2 hospitals (Table 13.1). In the control hospitals, in the period before the intervention the 
median C. diff infection rate was 1.26 (IQR: 0.95, 1.67) and this decreased to 0.77 (IQR: 0.56, 
1.02) in the period after the intervention. In the SPI2 hospitals, in the period before the 
intervention, the median C. diff infection rate was 1.37 (IQR: 0.65, 1.99) and this decreased 
to 0.66 (IQR: 0.50, 0.88) in the period after the intervention. Differences in changes were not 
significant between control and SPI2 hospitals (p=0.652, Appendix D, Table A4). Smoothed 
estimated rates of C. diff infection per 1,000 bed occupied days, by control and SPI2 
hospitals, are presented in Figure 13.2.  
13.3.3 MRSA 
Over all time periods, the median MRSA infection rate was 14.75 cases per 100,000 bed 
occupancies (IQR: 8.93, 21.98). Averaging over all time periods the median rate of MRSA 
infection was similar between the control and intervention hospitals: the median MRSA 
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infection rate was 14.87 (IQR: 9.36, 21.63) in the control hospitals and 14.58 (IQR: 8.85, 
22.77) in the SPI2 hospitals.  
The median MRSA infection rate decreased over the study period in both the control and 
SPI2 hospitals (Table 13.1). In the control hospitals, in the period before the intervention the 
median MRSA infection rate was 17.40 (IQR: 12.01, 23.04) and this decreased to 4.31 (IQR: 
2.26, 8.18) in the period after the intervention. In the SPI2 hospitals, in the period before the 
intervention, the median MRSA infection rate was 17.76 (IQR: 11.60, 24.43) and this 
decreased to 6.77 (IQR: 4.89, 10.65) in the period after the intervention. Differences in 
changes were not significant between control and SPI2 hospitals (p=0.693, Appendix D, 
Table A4). Estimated smoothed rates of MSRA infection per 100,000 bed occupied days, by 
control and SPI2 hospitals, are presented in Figure 13.3.  
Table 13.1: Rates of C.diff (per 1,000 bed days ) and MRSA infections (per 100,000 bed 
days) 
 
Control hospitals 
(N=9) 
SPI2 hospitals 
(N=9) 
 Pre-intervention  Post-intervention Pre-intervention Post-intervention 
C. diff† 1.26 (0.95,1.67) 0.77 (0.56,1.02) 1.37 (0.65,1.99) 0.66 (0.50,0.88) 
MRSA‡ 17.41 (12.02,23.04) 4.31 (2.26,8.18) 17.76 (11.60,24.43) 6.77 (4.89,10.65) 
† Before period is April 2004 to March 2007 and after period is October 2008 to June 2009 
‡ Before period is April 2001 to March 2007 and after period is October 2008 to September 2009 
Inter-quartile range is shown in parenthesis  
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Figure 13.2: Rate of Clostridium difficile (C. diff) cases per 1,000 bed days in control and 
SPI2 hospitals   
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Figure 13.3: Rate of Methicillin-resistant Staphylococcus aureus (MRSA) cases per 100,000 
bed days in control and SPI2 hospitals   
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13.4 Discussion 
Over the study period there is a dramatic fall in C. diff and MRSA infection rates in both 
control and SPI2 hospitals. In control hospitals median C.diff rates fell from 1.26 to 0.77 per 
1000 bed occupied days and MRSA fell from 17.40 to 4.31 per 100, 000 bed occupied days.  
Whilst in SPI2 hospitals C.diff rates fell from 1.37 to 0.66 per 1000 bed occupied days and 
MRSA fell from 17.76 to 6.77 per 100, 000 bed occupied days.  There was no significant 
difference between control and intervention hospitals. 
The data presented here are cases diagnosed within the first 48 hours of stay, which includes 
both community and hospital HCAI (the HPA has recently started to separate community and 
hospital infections but these were not available for the time period of interest for the 
evaluation) and it is assumed that the fall in infection rates is attributed to the hospital.  This 
assumption is taken as the hospital setting has been the target of the majority infection 
control measures and, thus, it would be highly improbable that the observed reduction was 
due to a fall in infection rates within the community setting.   
Regardless, no SPI effect is observed and this could be due to prevailing interest in HCAI and 
there prevention.  To this end the HPA was established in 2003 (before the SPI) and to date 
continues to report falling C.diff and MSRA rates in England and Wales (Health Protection 
Agency, 2010b).   
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CHAPTER 14: PATIENT SURVEY 
14.1 Introduction 
Since quality of care and avoidance of adverse events are important to patients, 
improvements in practice might plausibly affect patients’ views of their care (Cleary and 
Edgman-Levitan, 1997).  Their views were assessed by means of a patient survey. 
14.2 Methods 
This sub study was undertaken in both the SPI1 and SPI2 evaluation and is outlined in Figure 
14.1  All English hospitals participate in an annual patient survey, and for purposes of the 
evaluation the same survey was administered in the non-English hospitals using the same 
methods as those used in the Care Quality Commission’s National NHS Acute Inpatient 
Survey in England (Care Quality Commission and Picker Institute, 2010).  Each hospital 
identified a random list of 850 eligible patients who had been consecutively discharged in 
the period June to August. Patients were eligible if they were 16 years or older (in the 2004 
this was raised to 18 years as there was a concurrent survey of the experiences of young 
patient aged 0-17 years of age), had at least one overnight stay, and were not admitted to 
maternity or psychiatric wards. 
Of the fifty core questions five were identified for analysis (Box 14.1): three overall 
satisfaction scores and two related to cleanliness.  The details of these scores can be found 
in Appendix E. 
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Figure 14.1: A summary of the patient survey sub-study 
 
14.2.1 Statistical methods used in the SPI1 evaluation  
The dates of the surveys were aligned with those of the staff surveys (see 5.2), and the same 
control hospitals were selected. Methods similar to those for the staff survey were used in 
the analysis, except that only organisational level data were available for control hospitals. 
An organisational level analysis was therefore conducted using a two-way ANOVA (the 
factors being SPI1 versus control hospital, and survey 1 versus survey 2). Organisation-level 
scores in the SPI arm were formed by averaging all respondents’ scores within each hospital. 
What?
Patient 
surveys
to measure  
patient 
satisfaction
Where?
4 SPI1
intervention & 18 
control* hospitals
9 SPI2
intervention & 9 
control hospitals
Who?
850  inpatients over the age of 16 years
When (SPI1 evaluation)?
Data collection (“before”): 2004†/2005
SPI1 intervention: Jan ‘05 - Sept ‘06
Data collection (“after”): 2006/2007
When (SPI2 evaluation)?
Data collection (“before”): 2006
SPI2 intervention: Mar ‘07 – Sep ‘08
Data collection (“after”): 2008
*The controls for the SPI1 evaluation comprise of the pre-intervention data collected for the SPI2
evaluation. For a full explanation see section 3.2.
† In the English hospitals the sample consisted of patients over the age of 18, as during the same year an
additional survey of the experiences of young patients (ages 0 to 17 years) was carried out.
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14.2.2 Statistical methods used in the SPI2 evaluation  
Data were collected in October to December 2006 (pre-intervention) and October to 
December 2008 (post-intervention). Methods similar to those for the staff survey were used 
in the analysis; except that the control variables included were sex, age, length of stay and 
whether the admission was emergency or elective (control variables were not available for 
the SPI1 analysis above).   
Box 14.1: Patient survey questions deemed relevant to the SPI 
Overall, how would you rate the care you received?  
1. How would you rate how well the doctors and nurses worked together?  
2. Overall, did you feel you were treated with respect and dignity while you were in the 
hospital? 
3. How would you rate how well the doctors and nurses worked together? 
4. In your opinion, how clean was the hospital room or ward that you were in?  
5. How clean were the toilets and bathrooms that you used in hospital?  
14.3 Results 
14.3.1 Findings of the patient survey in the SPI1 evaluation  
The response rate for the first survey was 54% (1961 of 3624 returned) in the four SPI1 
hospitals; for the second it was 53% (1720/3397). In the 18 control hospitals there was a 
greater drop, from 63% to 53%. Table 14.1 shows the values of the five survey scores in each 
of the four SPI1 hospitals for the two surveys, along with details of response rates. Table 
14.2 shows the changes in both control and SPI1 hospitals on each of the five scores 
identified, along with the differences between the groups in these changes and associated 
99% confidence intervals. 
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At baseline there were no statistically significant differences between control and SPI1 
hospitals on any of the scores. One of the survey scores showed a significantly different 
change between the control and SPI1 hospitals. The rating of cleanliness of toilets and 
bathrooms decreased in the control hospitals, from 79 to 77 points, whereas this increased 
in SPI1 hospitals, from 74 to 76 points (p=0.009). It is noteworthy that there was apparently 
a baseline difference between the two groups of hospitals here, and although this difference 
was not statistically significant (p=0.115), the SPI1 hospitals were still slightly poorer than 
the control hospitals in survey 2 despite the change. None of the other four scores showed 
any significantly different changes between the two groups.  
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Table 14.1: Patient survey scores in SPI1 hospitals at the two periods   
 
Hospital 1 Hospital 2 Hospital 3 Hospital 4 
 Survey 1 Survey 2 Survey 1 Survey 2 Survey 1 Survey 2 Survey 1 Survey 2 
Overall, how would you rate the care you 
received? 
71 70 81 79 76 78 80 78 
Overall, did you feel you were treated with 
respect and dignity while you were in the 
hospital? 
84 82 90 89 87 84 91 88 
How would you rate how well the doctors and 
nurses worked together? 
72 70 79 78 74 75 79 77 
In your opinion, how clean was the hospital 
room or ward that you were in? 
77 76 83 82 79 78 78 80 
How clean were the toilets and bathrooms that 
you used in hospital? 
70 71 78 79 73 74 77 78 
Response rate 56% 46% 71% 59% 49% 53% 49% 45% 
Shaded areas relate to post-intervention epoch 
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Table 14.2: Patient survey scores in control and SPI1 hospitals at the two periods   
 
Control hospitals SPI1 hospitals Range at 
baseline 
Difference 
in change 
(99% CI) 
p-value 
 Survey 1 Survey 2 Absolute  
% change 
Survey 1 Survey 2 Absolute  
% change 
   
Overall, how would you rate the care 
you received? 
79 77 -2 77 76 -1 71-83 1 (-1, 3) 0.330 
Overall, did you feel you were treated 
with respect and dignity while you 
were in the hospital? 
89 87 -1 88 86 -2 84-91 -1 (-2, 1) 0.269 
How would you rate how well the 
doctors and nurses worked together? 
78 76 -2 76 75 -1 72-82 1 (-1, 3) 0.135 
In your opinion, how clean was the 
hospital room or ward that you were 
in? 
82 80 -1 79 79 0 71-89 1 (-1, 4) 0.288 
How clean were the toilets and 
bathrooms that you used in hospital? 
79 77 -2 74 76 1 69-86 3 (0, 6) 0.009 
Shaded areas relate to post-intervention epochs 
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14.3.2 Findings of the patient survey in the SPI2 evaluation  
For the first survey, the overall response rate was 62% (4328 of 7010 valid questionnaires 
returned) in the nine SPI2 hospitals; for the second it was slightly lower at 55% (3762/6810). 
In the nine control hospitals, the response rates were 61% (4262/6791) and 57% 
(3973/6913) respectively. Table 14.3 shows the changes in both control and SPI2 hospitals 
on each of the five scores identified, along with the differences between the groups in these 
changes and associated 99% confidence intervals. All five scores improved over the study 
period in both the control and SPI2 hospitals. None of the five scores showed any 
significantly different changes between the two groups.  
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Table 14.3: Patient survey scores in control and SPI2 hospitals at the two periods  
 Control hospitals SPI2 hospitals 
Range 
at 
baseline 
Difference 
in change 
(99% CI) 
p- 
value 
 N Survey 
1 score 
(SE) 
N Survey 
2 score 
(SE) 
Absolute 
% 
change 
N Survey 
1 score 
(SE) 
N Survey 2 
score 
(SE) 
Absolute 
% 
change 
   
Overall, how would 
you rate the care 
you received? 
4200 82 
(0.4) 
3913 85 
(0.3) 
4 4277 80 
(0.4) 
3705 84 
(0.3) 
4 75-87 1 
(-1, 3) 
0.292 
Overall, did you feel 
you were treated 
with respect and 
dignity while you 
were in the hospital? 
4111 78 
(0.4) 
3807 82 
(0.4) 
4 4167 76 
(0.4) 
3604 80 
(0.4) 
3 65-85 0 
(-2, 2) 
0.702 
How would you rate 
how well the doctors 
and nurses worked 
together? 
4182 87 
(0.4) 
3878 88 
(0.4) 
1 4220 88 
(0.4) 
3677 89 
(0.4) 
1 83-91 0 
(-2, 2) 
0.597 
In your opinion, how 
clean was the 
hospital room or 
ward that you were 
in? 
4113 75 
(0.4) 
3870 77 
(0.4) 
2 4201 77 
(0.4) 
3645 78 
(0.4) 
1 70-80 -1 
(-3, 1) 
0.141 
How clean were the 
toilets and 
bathrooms that you 
used in hospital? 
4141 76 
(0.4) 
3877 78 
(0.4) 
2 4220 78 
(0.4) 
3665 79 
(0.4) 
1 70-82 -1 
(-3, 1) 
0.204 
Shaded areas relate to post-intervention epoch 
 268 
 
14.4 Discussion 
Within the SPI1 evaluation response rates declined in the control hospitals but remained 
stable in intervention hospitals.  Whilst in the SPI2 the response rates declined in both 
control and intervention hospitals.   
There was one significant finding in the SPI1 evaluation – that of cleanliness of toilets, which 
decreased in control hospitals but increased in SPI1 hospitals.  However, this finding should 
be treated with caution as the survey in 2004 which was implemented in English hospitals (1 
SPI1 hospital and all control hospitals) differed in its inclusion criteria than proceeding 
surveys [the survey implemented in 2005 (pre-intervention) in non-English SPI1 hospitals 
and all hospitals post intervention) (see Figure 14.1).  The remaining scores remained stable, 
and there was no significant difference between control and intervention hospitals.   
In the SPI2 evaluation no SPI effect was observed and patient satisfaction improved in all 
hospitals in the measures of interest.  It is interesting to observe that two of the patient 
survey questions relate to cleanliness and over the study period there has been an increase 
in the use of hand hygiene consumables (see Chapter 10) and a decrease in HCAI rates (see 
Chapter 15).   
Unfortunately no direct comparisons can be made with the NHS Inpatient Survey (Care 
Quality Commission and Picker Institute, 2010) (from which this data originates from) as 
different methods have been used for the analysis.  The NHS Inpatient Survey reports on the 
 269 
 
proportions of responses (Garratt, 2009) in each category found in Appendix G, whilst in this 
evaluation an average score has been calculated.  However, the findings of the SPI2 
evaluation reflect the NHS Inpatient survey which reports a significant rise in the proportion 
of patients reporting the highest category of satisfaction in the survey questions deemed 
relevant to the SPI (Garratt, 2009).    
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CHAPTER 15: OVERALL DISCUSSION 
In this chapter I will provide a recap and discussion of the main findings of the evaluation of 
SPI.  I will then go onto conclude this chapter by answering the research question:  which 
study design provides a robust method of evaluation of complex patient safety 
interventions? 
15.1 Main findings of the evaluation 
Commentaries five years after the publication of two key reports on patient safety in 2000 
were characterised by some despair at the apparent lack of progress in the US (Leape and 
Berwick, 2005). Taken in the round, the quantitative data collected in this evaluation seem 
to tell the story of an improving NHS. Whilst the staff survey shows little change between 
epochs, the patient survey shows improvement across all five dimensions pre-specified for 
the study, suggesting better patient experience. There was even an improvement in medical 
history-taking. Despite the high mortality rate in the sample of case notes, the adverse event 
rate was low. There were encouraging trends in the quality of patient care. Firstly, the 
baseline performance across hospitals was over 90% on many criteria relating to quality, 
leaving very little headroom for improvement. For example, over 90% of patients with an 
acute exacerbation of obstructive airways disease received steroids when indicated and the 
rates of peri-operative prophylaxis against venous thrombosis and wound infection 
approached 100%. Secondly, where there was scope for improvement, many examples of 
improved, and none of worsening, practice were found. Both the vigilance of monitoring 
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vital signs on acute medical wards and the use of severity scoring have seen sharp significant 
increases and there was a strong upward trend in the incidence of intra-operative 
temperature monitoring. Rates of hand-washing have increased (if consumption of cleansing 
materials is accepted as a surrogate) and the incidence of C. diff and MRSA infection has 
plummeted. 
15.1.1 Participant experience 
The stakeholder interviews and focus groups, conducted in the SPI1 evaluation 
demonstrated that the SPI was greeted enthusiastically at a strategic level in hospitals 
where it was delivered (see Appendix B). However the ethnography within the same 
evaluation suggests that staff at the sharp end of medical wards generally had only a vague 
idea of the intervention and few had direct experience of most of its components, except in 
the area of recognising and responding to the deteriorating patient (see Appendix C).  A 
similar picture emerges from the staff survey. Control and SPI hospitals were mostly 
indistinguishable at baseline and within both evaluations only one of the 11 dimensions of 
staff satisfaction changed significantly over time (but to a small degree) – on the item 
relating to organisational climate. Within the SPI1 evaluation the results favoured the 
intervention; however, this is reversed in the SPI2 evaluation as the controls improved the 
most. Taken together, these findings suggest that the impact of SPI at medical ward level 
was at best modest. 
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15.1.2 Controls versus SPI 
There was one significant finding in the SPI1 evaluation and that was the recording of vital 
signs at 12 hours.  However, on the whole the quantitative data suggests that it is difficult to 
detect an additive SPI effect. Statistically significant observations were made but not 
between the two groups of hospitals (apart from the one previously mentioned. 
Quantitative evaluation of response to specific SPI targets (items 1a, b, c; 2a, b; 3a; 4 a, b. c, 
d in Table 3.2) overall yielded a null result, thereby corroborating the qualitative finding of 
apparently low impact of the programme on the sharp end of practice. The important SPI 
aim of improving response to acutely ill patients, including the quality of the recording of 
vital signs, improved markedly and significantly during the study periods in both evaluations, 
but a similar improvement was also observed in the control hospitals. This is likely to be due 
to contemporaneous policy shifts and other external imperatives encouraging better 
detection and response to deteriorating patients. The use of the CURB score also improved 
markedly, but from a very low base. 
Prescribing error rates are very sensitive to the methodology (Dean et al., 2005) used to 
make the measurements. Inter-observer reliability was good. Overlapping observation 
periods between epochs, enabled the detection of learning and fatigue effects and hence we 
were able to allow for these in the analysis. Although there was a high rate of prescribing 
error, very few of these errors resulted in adverse events for patients; with so few events 
due to prescribing error, this endpoint cannot reliably be used to confirm or refute an SPI 
effect. 
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One anomaly is the drop in mortality among the acute medical cases in the SPI2 hospitals 
and an unexplained rise in the control hospitals, such that in the SPI2 evaluation the 
difference-in-differences would have been just significant if the p<0.05 threshold had been 
selected a priori. However, this finding does not align well with either the explicit review of 
the quality of care or the adverse event tally observed among those same case-notes and it 
is unlikely that failure to implement SPI was causative of an increase in mortality among 
respiratory patients in control hospitals. The analysis of cases of those who had died show 
no differences in avoidable deaths across the intervention vs. control hospitals (see Table 
10.4) 
Dramatic improvements in use of hand-washing materials and in infection rates produced 
near mirror image results. The NHS seems responsive to the need to change in certain ways 
and it is hard to discern any additive effect of the SPI initiative. Overall, there is little 
evidence that good or improved quality and safety in participating NHS hospitals can be 
reliably attributed to an additive effect of the SPI. 
15.1.3 Interpretation  
A large number of different observations have been made. Many of these observations 
relate to specific SPI objectives such as the patient at risk of deterioration, infection control, 
peri-operative care and intensive care. Statistically significant observations were made but 
not between the two groups of hospital. This broadly null additive effect of SPI (for both 
SPI1 and SPI2 intervention phases) on patient care should not, however, be translated into a 
conclusion that there was evidence of no effect. While a null result can never be proven, this 
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is a greater problem for quality initiatives, where small effect sizes may nevertheless be cost-
effective, than it is for studies of clinical effectiveness. It can however be translated, less 
problematically, into the conclusion that any effect was not large, where large is defined in 
terms of observed confidence limits. To put this idea in another way, the results are 
compatible with effects on many end points of a magnitude that lies below the threshold 
that can be detected statistically in a study of this size.  
These results will be disappointing to anyone who thought that the effects would be 
dramatic. The SPI was introduced as a radical initiative that would have profound effects 
and which would “reduce adverse event rates in hospitals by 50%” (Health Foundation, 
2006; Shirley, 2008). However, the results suggest that much more temperate claims should 
be made in future. It must also add to the doubts that have already been expressed about 
whether the “Saving 100,000 lives” campaign was responsible for (all of) the observed 
reduction in mortality in participating hospitals in the USA (Wachter and Pronovost, 2006).  
The findings will come as less of a surprise to observers who start from the premise that it is 
difficult to achieve improvements in the quality of care and reduce error rates through 
generic management initiatives, however enthusiastically they are welcomed at strategic 
level. Creating deep-seated, systemic cultural change in organisations, by means of an 
external initiative with a modest budget over a limited time scale may be viewed as almost 
quixotic by more sceptical observers. It was found that the principles and practice of SPI had 
limited penetration at the medical ward level. The quantitative results are consistent with 
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this finding. More disappointingly, there was a failure to find an intervention effect on more 
specific targets such as monitoring vital signs or medicines reconciliation.  
Lack of a measured additive SPI effect might be explained in several ways: 
First, improvements may have occurred at a magnitude that eluded statistical detection. For 
example, the sample was large for the case-note review of acute respiratory patients, with 
over 1,400 cases it had sufficient statistical power to detect material changes in actions that 
should affect all patients (e.g. regular monitoring of all vital signs). Power was lower for 
contingent actions that only applied to smaller sub-groups (i.e. for patients whose condition 
deteriorated). The English threshold under which an intervention is judged cost-effective is 
about £30,000 (€33k; $46k) per quality adjusted life year (QALY). The SPI would, therefore, 
need to save fewer than seven lives within SPI1 hospitals with a mean duration of five years 
to justify the investment of about £775k (€860k; $1.2 million) per SPI1 hospital (ignoring 
discounting and assuming disability-free life). It would not be possible to exclude an effect of 
this magnitude in a study of any feasible size; with many hundreds of deaths taking place in 
each hospital in each year the signal would be lost in the noise.  
Second, there may have been improvements in aspects of safety targeted by individual 
hospitals. For example, care of cardiovascular disease was identified for special attention in 
some hospitals. It is a priori likely that such initiatives, if vigorously pursued, would result in 
improvement. However the study was not designed simply to answer the question – “Can a 
clinical practice ever be improved as a result of specific managerial intervention?” The 
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answer to this question is clearly “yes”- many spectacular examples, including the Michigan 
study of prevention of central line infections (Pronovost et al., 2006a), can be found in the 
literature. The question in this thesis concerned the average effect that may be expected 
among a series of practices aimed at improving patient safety, some specific and some more 
generic, that were specified in the study protocol in advance of the data collection.  
A third explanation might lie in programme design. It is possible that organisational 
interventions of this type are simply not highly efficacious and that alternative approaches, 
such as initiatives focused on professional networks, could be more powerful, as suggested 
in a study of motivations to change in a maternity context (Wilson et al., 2002).  
Fourth, it is possible that the design and implementation of the SPI might have not been 
optimal. Looking back over the evaluations of both programmes, and following many 
conversations with those responsible for this and other interventions with similar aims, it 
was suggested that the method by which vertical and horizontal spread of SPI might have 
been achieved was incompletely specified.  
While senior stakeholders stressed the bottom-up nature of the intervention (see Appendix 
B), this was not how it was perceived by most ward staff (see Appendix C). Although there 
were examples of PDSA cycles triggered by clinical staff, these were not replicated on a scale 
where the benefits were likely to show up in an independent quality audit based on 
predefined criteria. Despite the enthusiasm and broad understanding of the principles 
underlying the SPI at a strategic level, the programme and organisational theories of change 
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may not have been sufficiently explicit, and more pre-intervention work may have identified 
more precisely how it would work and under what conditions. It is also possible that the SPI 
needed a longer time scale or greater intensity to achieve change and for its improvements 
to show up in the kinds of observations we made. There is some evidence from the 
qualitative studies that the scale of the task was seen as daunting, and that the resource 
implications and degree of organisational re-gearing that was required had been under-
estimated.  The intensity of the intervention may not have been sufficient to engender large-
scale change (e.g. SPI1 hospitals received £775k [€860k; $1.2 million] spent over 18 months 
in hospitals with annual budgets of £150 to £300 million [€167m - €334m; $230m – $460m] 
might simply be too small a “dose”, especially when little of that money made its way to the 
sharp end of practice). The techniques used may have low effectiveness in general use. For 
example one element of the IHI approach, the use of FMEA, has recently been challenged 
(Bowles, 2003; Shebl et al., 2009). It may also be the case that the impact of measures such 
as WalkRounds, safety briefings, and SBAR may be too diffuse to have discernible impacts. 
A combination of a more explicit programme theory and organisational theory of change 
might have focused more attention on ensuring clinical engagement, encouraged an earlier 
recognition that the intervention was broad relative to resource, and identified that effects 
were likely to be localised in response to "dose" of intervention. In that case, a more focused 
and less ambitious intervention, and somewhat narrower evaluation, might have ensued.  
A fifth explanation for the absence of a measured additional effect of SPI might lie in the 
extent of the policy-level programmes and initiatives that were largely contemporaneous 
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with the SPI.  These shared some of its goals, principles and methods, and were targeting 
several of the same clinical processes as the SPI, for example, the “cleanyourhands” 
campaign ran continuously from late 2004/2005 onwards, promoting the same goal of 
improved hand hygiene as the SPI. Similarly, improving recognition and response to 
deterioration in hospitalised patients (an SPI goal) became a focus of policy attention, and 
guidelines on recognition and response to acutely ill patients were issued by NICE in 2007 
(National Institute for Health and Clinical Excellence, 2007). Perhaps most significantly, 
several initiatives were explicitly modelled upon IHI techniques and principles, which began 
to have increasing impact on policy-making at around the time that the SPI was launched 
(and it is possible that this was not a coincidence). For example, the Department of Health’s 
Saving Lives programme, beginning in June 2005 with a revised version in 2007 (Department 
of Health, 2007), included a self-assessment tool for hospitals to assess their managerial and 
clinical performance, and a set of “High Impact Interventions” that were similar to the IHI 
bundles and were aimed at several clinical processes also targeted by the SPI. In addition, 
the Health Act 2006 introduced new legislation on mandatory requirements on prevention 
and control of HCAIs.   
It is further relevant that many of these policy initiatives had already been anticipated by 
significant consensus within professional societies and Medical Colleges about the 
appropriate measures to be adopted, and thus enjoyed considerable professional legitimacy 
– a crucial factor in promoting safe and effective practice (Dixon-Woods, 2010).  
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Moreover, the hypothesis examined in this study is that SPI would add value to changes that 
were happening anyway. It is the marginal value of SPI over independent temporal change 
that is interesting. The possibility of such temporal effects underscores the need for 
contemporaneous controls in conducting external, summative, evaluations of service 
delivery interventions (Brown et al., 2008c); any changes may otherwise be falsely attributed 
to the intervention. 
Finally, it is possible that any additional effects associated with SPI may simply not be 
detected yet. The difference between the control hospitals and the SPI2 hospitals was that 
the SPI2 hospitals benefited from a specific organisational intervention designed to promote 
the building of improvement skills into systems of care. Any SPI effect may be in the form of 
“stickiness”; SPI hospitals may potentially be better equipped to show sustained 
improvements after the policy spotlight has moved elsewhere. If, however, no differences 
can be detected in the longer term, the role of organisational interventions of this type in 
promoting safety will require further examination. 
Patient safety is difficult (Dixon-Woods, 2010) and achieving change is likely to be a 
marathon rather than a sprint. Any detectable effects of such interventions may take some 
time to surface and their effective implementation requires clarity about the theories of 
change underlying the programme, recognition of the scale of resource and organisational 
support required to make patient safety efforts work, and improved understanding of how 
practitioners, middle managers and organisational systems can be better supported in the 
face of daunting complexity and multiple priorities. 
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15.1.4 Theory building 
In the previous section certain ideas that might explain the mostly null comparative results 
obtained in the evaluation of SPI were discussed. These covered the scope of the 
intervention (the dose may have been too small), the ambitious time scale, and certain 
features of the intervention, such that it was not fully “owned” by middle grade staff. The 
observation that the NHS has adopted certain good practices over the same time scale as 
the initiative suggests a further, rather more radical idea; the originators of SPI, along with 
many opinion formers in management, are working with the wrong theory. The current 
theory is largely built around the concept of organisations and the pivotal role they are 
thought to play in “driving up quality”. However, when the NHS wishes to change practice, it 
generally works with professional affiliations such as intensive care societies and Medical 
Colleges. Research into why evidence based guidelines were adopted or ignored in a 
maternity care context showed that staff were influenced almost entirely through 
personal/professional networks and hardly at all via the management route (Wilson et al., 
2002).  That, is not to say that hospitals do not have an essential role to play, but the idea 
put forward is that this role is enabling, not generative, in the main. In this respect medical 
services (and perhaps other highly professionalized groups) may differ from many industries 
where the hegemony of the organisation can drive change more directly. From the 
perspective of the evaluation the changes observed across 18 hospitals in our sample are 
unlikely to have resulted from concerted and simultaneous management action; this might 
be expected in the SPI hospitals, but it is unlikely that this would be mimicked 
simultaneously in the board rooms of control institutions. The idea put forward here is that 
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health services may have learned precisely the wrong lesson by adopting certain ideas and 
mind sets from managers and theorists with an industrial background.  
15.1.5 Next steps  
There are two dangers to be avoided: The first danger is despair and resort to nihilism. The 
corresponding danger is to privilege positive results over null results. Objective proof shorn 
of subjective interpretations is even more difficult to come by in the evaluation of service 
delivery interventions, than in other branches of science. Yet null results remain valuable; 
face validity is not enough. It is important to recognise that hospitals did report effects from 
SPI participation, including heightened managerial awareness of and commitment to patient 
safety, and organisational learning about how to implement patient safety improvement 
efforts in the future. The intervention did register in the hospitals even if it did not penetrate 
deeply enough. The challenge is to build on these observed effects. The staff interviewed 
theorised about the way forward. They proposed offering more support to the middle layer 
of management, and engaging clinical leaders at earlier stages and encouraging clinical 
ownership as a way of securing success in the future. Reducing the number of areas to be 
tackled, and avoiding areas where there is scientific contestation or dispute about whether 
something is an important problem were also seen as critical. It was clear that hospitals had 
learned that addressing issues of legitimacy was a key task. They had identified that 
introducing initiatives that generated more “paperwork” were unlikely to secure 
cooperation from stretched ward staff, and that large scale resourcing and structural 
support may be needed to implement many patient safety efforts successfully. 
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The results of the ethnographic sub-study (see Appendix C) have started to shed light on a 
fundamental dilemma in many aspects of management. Managers are held accountable for 
the quality of services yet quality is more likely to improve if based on initiatives arising from 
staff caring for patients. The task of managers might thus be seen as providing the 
conditions that might foster bottom-up change and exerting a subtle form of leadership that 
inspires without disempowering (or perhaps even by making frontline staff feel they were 
the objects not subjects of inspiration). Although the SPI intervention clearly intended to 
achieve this effect, it seems that success overall was limited. In contrast, the Veterans Health 
Administration “QUERI System” (Quality Enhancement Research Initiative) (Stetlet et al., 
2008) is held up as an example of a successful programme that has managed to orchestrate 
a genuinely bottom-up process. This programme is militantly clinician-based, and built 
around ideas agreed by clinicians working with managers and researchers in QUERI tasks 
groups; effort, focus and resources are placed in finding out where practice is sub-standard 
and then tackling the specific causes one by one. There is evidence that such a focused 
approach spills over into other targets not specifically identified for action, the so-called 
“halo-effect” (Eccles et al., 1996; Francis and Perlin, 2006).  It can be hypothesised that 
Donabedian’s chain (Donabedian, 1980) is a two way street, where efforts to strengthen the 
front line of practice influence culture as much as culture influences the front line. Far from 
abandoning the topic of safety improvement or decrying the SPI initiative, the results point 
to promising and reasonable hypotheses about how to catalyse a more truly holistic 
approach to safety. 
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15.2 Lessons for the study design of future evaluations 
In this thesis, I have described the evaluation of a large, highly complex patient safety 
intervention, which sought to generically strengthen the hospital system whilst improving 
frontline activities.  In comparison to the interventions retrieved from the literature search 
in Chapter 2, none were as complex as the SPI and the evaluation of SPI mirrored its 
complexity.  It was a multi-centre, before and after study, using non-randomised controls 
and mixed-methods.  This approach has relative strengths and weaknesses and is discussed 
below.   
15.2.1 Strengths and weaknesses  
The study was based on a before and after design with contemporaneous controls (Brown et 
al., 2008b). Such a design is not as robust as a cluster randomised trial. However, despite 
some notable exceptions (Landon et al., 2007), most quality improvement reports lack 
contemporaneous controls (see Chapter 2); such a design would evidently have been 
misleading in this case since the sharp improvement of monitoring of vital signs, the use of a 
formal scoring system, intra-operative temperature monitoring and a reduction in infection 
rates in the intervention hospitals could have been incorrectly attributed to the SPI. 
A limitation of the SPI1 evaluation was that controls were matched with SPI2 hospitals. 
Hospitals were selected for SPI because they were perceived to have contained positive 
features (see 3.2). Results might have been biased because: (i) SPI hospitals might have had 
less headroom for improvement; and (ii) controls might have had higher than average 
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performance, particularly since half were also selected as future SPI2 intervention hospitals. 
Results might have been biased in favour of SPI because: (i) intervention hospitals were 
selected, not chosen at random (the reverse of the possible bias mentioned above); (ii) while 
both control and intervention hospitals gave consent for the evaluation, this may have had a 
differentially motivating effect in intervention hospitals (a kind of Hawthorne effect that 
could not be avoided by randomisation).  
In addition, the matching between the SPI2 hospitals and the controls was also far from 
perfect (the algorithm for selecting controls can be found in section 4.3).  At the time of 
choosing controls, size was based on the number of staff at trust level.  When this was 
revisited after the evaluation with bed numbers at the hospital level (the level of analysis 
used in this study) there was one discrepancy in a matched pair (pair 9 in Table 4.3), in which 
the number of beds in the control hospital was double that of the intervention, thus 
confirming imperfect matching. 
The location (urban/rural) is also an important indicator of the quality of care (Keeler et al., 
1992) and thus an important consideration when matching between control and 
intervention hospitals.  In this evaluation, a value judgement was made on the location of 
the hospital but more sophisticated methods do exist.  Ideally patients of a hospital would 
be assigned to their “neighbourhood” (for example, ward, local authority, lower level super 
output areas) and then the attributes of variables of interest, such as location would be 
applied.  The proportions of these variables then determine the attribute of that hospital i.e. 
urban or rural.    
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As well as using a more refined method of matching other attributes should be considered , 
for example, income deprivation scores (Noble M et al., 2008).  The score is effectively a 
proportion of people in a neighbourhood who live in a household with less than 60% of the 
national median income and/or are in receipt of one of a number of means tested welfare 
benefits. 
One advantage of contemporaneous controls is that the groups can be compared at 
baseline. There were differences at baseline for some observations (most notably hospital 
mortality rate within the SPI2 evaluation) but not for others. Baseline rates on the staff and 
patient surveys were similar and there is little to distinguish the two groups of hospitals on 
the explicit reviews in either acute medical or surgical patients; none of the 17 vital sign 
criteria differed significantly between the two groups of hospitals for example. Thus most of 
the comparisons that were made were based on end points where no material differences 
were evident across the groups compared. 
These potential biases against controls would have been scientifically more worrisome had 
the results not been mostly null. Overall there do not appear to be material differences in 
performance between control and SPI hospitals at baseline; most observations are similar 
and where statistically significant differences exist, these are of small magnitude. The data 
do not support the idea that the SPI hospitals had such excellent practice at baseline 
compared to controls that they were jeopardised in the comparison. 
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Source data for most end points was collected by independent researchers working across 
the various hospitals and a supply chain of anonymised case-notes was set up for this 
purpose. However certain data was collected in the participating hospitals (infection rates 
and data from the ICU) and this could lead to bias in the comparative study if hospital-based 
observers were motivated to show SPI in a good (or bad) light. However, any bias must have 
affected both sets of hospitals approximately equally since the comparative results are null. 
Moreover it is unlikely that the observed dramatic reductions in infection rates across all 
hospitals are the result of “gaming” given the statutory duty to report certain infections 
when they are identified in the laboratory.  
A particular strength of the study arises from possibilities for “triangulation”, i.e. some of the 
observations (qualitative and quantitative) act as a kind of internal control for others. While 
the funding envelope did not permit qualitative studies to be built into the SPI2 design (as in 
SPI1), the study did provide the following internal controls: 
• findings on use of hand-washing materials and two different types of infection 
support the hypothesis of general improvement in this area; 
• the observation that vital signs were recorded with increasing diligence while use 
of risk scoring was also used more frequently supports the idea that patients at 
risk of deterioration are being taken more seriously; 
• mortality rates on the acute medical wards could be triangulated, not only by an 
audit of compliance with process standards, but also by scrutinising each death 
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in the sample to see if it could have been caused by poor care (only two of the 30 
deaths in the post-intervention period were preventable). 
Further evidence on this point could have been established by examining the incidence of 
unsuspected cardiac arrest (“crash calls”) but found that this information is not yet collected 
in a consistent way. The evaluation of SPI1 included qualitative observations which can 
provide yet a further form of internal control. However the study sponsor felt that 
theoretical saturation had already been reached in the first evaluation. For example, 
ethnographic sub-studies within the SPI1 evaluation did indeed confirm that ward staff had 
taken the importance of close observations of sick patient increasingly to heart. 
Within the literature review none of the studies that made before and after comparisons 
with contemporaneous controls used the “difference-in-difference” method, a method of 
calculating sample sizes which is based on a clusters propensity to change (see 2.1.3.2).  This 
approach allows sufficient power with a smaller sample and its utilisation within this 
evaluation is unique.  Perhaps with wider dissemination it will encourage future evaluations 
of complex patient safety interventions to use more robust methods as sample size 
considerations can be smaller than currently thought.   
15.3 Conclusion 
In this thesis I have described a robust study design to evaluate complex patient safety 
interventions.  The evaluation has taken a mixed method approach, using both quantitative 
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and qualitative methods.  All quantitative observations have been made with 
contemporaneous controls and uniquely a “difference-in-difference” method was used.   
The approach has been vindicated – measures of fidelity, intervening variables, process and 
outcome, supported by qualitative methods – and has provided a wealth of information of 
the effectiveness of the intervention and theories as to why the intervention worked the 
way it did.  This evaluation has been commended by Pronovost et al., (2011) as “a model for 
the field” and way in which future evaluations should be conducted.   
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Appendix B:  Strategic stakeholder interviews 
B.1 Introduction 
The potential importance of the “blunt end” (the source of the resources and constraints 
that shape the working environment) in influencing the “sharp end” (where practitioners 
care for patients) is well recognised (Cook and Woods, 1994). In addition, it is important to 
identify the theory of change, i.e. a theory of how and why an initiative works (Mason and 
Barnes, 2007; Sullivan and Stewart, 2006) and knowing whether the intervention was 
implemented as intended (see 4.1.2.1).  If strategic stakeholders (people in senior positions) 
do not understand and share the same theory of change then the implementation of a 
complex organisational intervention is likely to be suboptimal.  How strategic stakeholders 
understood and responded to the SPI as a programme of change was investigated by means 
of strategic stakeholder interviews.   
B.2 Methods 
This sub-study was undertaken in SPI1 hospitals only and an overview can be found in Figure 
B.1. 
Participants were recruited from all four SPI1 hospital sites by asking hospital contacts 
involved in the SPI to identify people in particular roles, including chief executive, medical 
director, senior nurses, senior pharmacists, and others involved at a strategic level with 
implementation of SPI1.  Interviews were also conducted with a small number of “external” 
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stakeholders at the Health Foundation and IHI who had been involved in commissioning and 
designing the SPI (they were responsible for the commissioning and designing both SPI1 and 
SPI2 intervention phases).   
Figure B.1: An outline of the strategic stakeholder interview sub-study 
 
An experienced senior researcher conducted telephone interviews by using a semi-
structured prompt guide.  The interviews intended to identify:  
• what participants saw as the aims of intervention; 
• what theory of change participants were working with; 
• barriers and facilitators they saw to change; 
• participants’ views on the acceptability and validity of the SPI. 
What?
Strategic 
stakeholder 
interviews
to assess the if 
the intervention 
was 
implemented as 
intended
Where?
4 SPI1
intervention 
hospitals
Who?
60 senior hospital 
stakeholders 
5 “external” 
stakeholders
When?
SPI1 intervention: Jan ‘05 – Sept  ’06
Data collection:  Nov ‘05 – Nov ’06
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Participants were allowed to describe the SPI in their own terms and responses were tape-
recorded and transcribed verbatim by an external contractor. The transcripts were subject to 
two separate analyses. Firstly, the analysis of all transcripts was based on the constant 
comparative method (Glaser and Thomson, 1967).  “Open” codes to describe each unit of 
meaning were initially generated.  Through comparison across transcripts, the open codes 
were developed into higher-order thematic categories and subcategories to provide 
frameworks for coding, assisted by NVivo software. 
Secondly, the responses given by transcripts by hospital (not commissioning) stakeholders 
were quantified. These transcripts were read by three independent reviewers who scored 
each individual’s interview (on a 1-10 scale) for level of knowledge displayed and level of 
enthusiasm exhibited. Inter-observer agreement was tested using the ICC statistic. Pearson’s 
correlation coefficient was used to measure association between enthusiasm and 
knowledge. 
B.2.1 Ethical considerations 
It is good research practice to attribute quotes to the person that made them, for example, 
"participant 21, medical director, hospital 1”, as it enables the reader to make a judgement 
on if the findings of the research are representative and based on the opinion of more than 
one person.  However, as the SPI had a high public profile participants would be easily 
identifiable, so to preserve anonymity and not to contravene the ethical approval granted 
for this study, direct quotes have not been attributed.   
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B.3 Results 
Sixty strategic-level hospital stakeholder interviews were conducted over the period 
November 2005 to November 2006.  Fourteen participants were in very senior strategic 
positions, including at each hospital the chief executive, the medical director, and the 
nursing director, and at least one clinical director.  Other participants included 36 staff in 
senior managerial positions at the “front-line”, including consultant grade doctors, nurses 
and pharmacists.  The remaining six participants were in mid-level managerial positions 
(such as theatre managers and patient safety co-ordinators).  Although some hospital 
participants had been directly involved in the competitive bidding process for their trust to 
participate in the SPI programme, most had not.  Five “external” stakeholders, all at senior 
position in their organisation were also interviewed.  Despite the interviews being taken 
over a year they suggested a high degree of congruence between participants.   
B.3.1 Aims of the SPI 
All hospital participants spoke of the initiative as aiming to address patient safety problems, 
particularly by reducing the number of adverse incidents and making the hospital 
environment safer.  
It's trying to improve patient care generally, but specifically to try to reduce the number 
of adverse events. I think with a bit of hard work and persistence to institute it, it could 
embed quite well in the NHS and it would be a healthy mechanism for maintaining 
standards and improving standards. (Consultant)  
 
If we can't make patients safe in hospital … then we're wasting our time. … So I strongly 
recommend it and I think it is transformational. (Head of Nursing) 
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Seven participants described SPI solely in terms of cultural change and 11 solely in terms of 
changes to systems, but most (n=42) described SPI in terms of changes both to culture (such 
as increasing awareness or changing attitudes) and to systems, practices and processes, 
particularly in increasing consistency and monitoring and implementing evidence-based 
practice.  
it is … about us looking at how we change the culture and the way that people think so 
that everybody realises this isn't an extra add-on to their day-job which probably at the 
moment some staff do perceive, but actually this is how we do business here and safety 
is our first and foremost, you know, ethos. (Patient Safety Manager) 
 
It's trying to look at the high risk areas and actually assessing whether our processes are 
reliable at the moment and if they're actually putting patients at increased risk, and 
trying to identify ways to improve those processes. (Pharmacist)  
 
Fifty-three hospital participants expressed positive attitudes towards the SPI during their 
interview, although 19 of these also made statements that indicated a muted positive or 
ambivalent attitude. Less positive attitudes included expressions of scepticism (n=10) or 
feeling apprehensive, overwhelmed or confused by the initiative (n=17). These more 
negative accounts tended to be descriptions of how the interviewees had felt when the 
initiative had first been introduced; many of those interviewed later in the study described 
having developed more positive attitudes over time. Four hospital participants described 
feeling only negatively about the initiative. Thus, for the most part, strategic stakeholders 
saw the SPI as a legitimate and promising response to the problems of patient safety.  
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B.3.2 How will it work? 
When asked to describe how the SPI would work, five hospital participants explicitly stated 
that they were unable to give an account of any specific element of the SPI, and a further 
two appeared to have very little knowledge of the initiative. However, most of the accounts 
from hospital stakeholders appeared to demonstrate a shared understanding of the main 
elements of the initiative. In many cases, hospital stakeholders' accounts demonstrated a 
high degree of symmetry with “external” stakeholders, as these extracts illustrate in their 
emphasis on the need for standardisation of practice as a way of improving safety:  
[we] believe very strongly that by the application of our model of the rapid cycle and the 
reliability principles that we're going to have less variability and more reliable processes 
to ensure that the care is delivered the way that we would want it to be delivered. (IHI, 
“external” stakeholder) 
 
It's about standardisation. A lot of these things, over the years consultants have 
developed their own particular practices and of course that's a problem if you've got 
juniors going from one consultant to another, they get a bit confused in the end and so it 
doesn't happen. So it's about bringing everyone together and making an agreement 
about what the process is than then making sure it happens. (Pharmacist)  
 
An example of the shared understanding among strategic stakeholders could be found in 
hospital stakeholders' descriptions of the PDSA cycle, which was described as a critical 
element of the SPI in the “external” stakeholder accounts and in the learning sessions. Most 
(n=41) hospital participants offered a reasonable description of PDSA, with 22 explicitly using 
the term PDSA, although accounts varied considerably in their precision. For many, a key 
element of their theory of change relating to PDSA could be summarised as “seeing is 
believing”, and an emphasis on how involving staff could lead to ownership and hence to 
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effective changes in practice. Again, there was considerable symmetry between “external” 
stakeholders and hospital stakeholders in their accounts.  
it's based on the IHI's own kind of interpretation of … approaches to quality 
improvement which are based around what they call these PDSA cycles which is a [way] 
of getting people into making relatively small tests of change—doing the measurements, 
introducing the improvements, reviewing and then moving on and building that up over 
time to give everybody involved a sense of purpose and confidence. (Health Foundation, 
“external” stakeholder) 
 
so there's a kind of planning stage on how it's gonna work and then they start doing it in 
a small group of patients first one patient as far as I know and then looked at how it's 
going and then roll it out to three patients, five patients and then everybody. (Health 
Professional in Haematology)  
 
In addition to identifying the principal elements of the design of the SPI programme, 
participants often identified very specific strands or components of the initiative. These 
included leadership (n=37), interventions relating to general ward (n=35), intensive/critical 
care (n=34), peri-operative/theatres (n=40), medication/drug errors (n=45) and hospital-
acquired infections (n=33). Participants also spoke about how the initiative worked in terms 
of practices that have been adopted, including SBAR (n=15), early warning and critical 
response system (n=29), safety briefings (n=15) and multidisciplinary teams (n=12). (See 
Chapter 2 for details of these elements of the intervention).   
B.3.3 Securing implementation 
Participants' accounts highlighted factors that they believed would facilitate the 
implementation of the initiative. For hospital stakeholders, these included good leadership 
in the trust (n=43), motivation and commitment of staff (n=41), the existing culture or 
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structure of the trust (n=42), resources (n=18), taking a bottom-up approach and ensuring 
local ownership (n=15), good information and communication (n=22), education and training 
(n=9), sharing of experiences with others involved in SPI (n=9), and evidence that the 
initiative works in practice (n=14). Many (n=42) talked of factors specific to their 
organisation that were already in place as providing “fertile ground” for SPI to embed. Such 
factors included people being receptive to change, a good track record with clinical and risk 
management, good communication, high levels of awareness and an open culture. 
Well I think it is more likely to work here. Because I think we have a culture of openness, 
freely admitting mistakes, good communication. We're regarded I suspect as a can-do 
organisation. … I think we're an organisation that readily accepts change. (Medical 
Director) 
 
I think that it's a very positive and supportive organisation … so it's not seen as 
something that's being brought in from the top. It's hopefully being seen as a genuine 
culture change. (Clinical Director) 
 
However, most (n=57) hospital stakeholders also described barriers to the initiative's 
successful implementation. For these stakeholders, success was seen as depending to a large 
extent on how far other stakeholders in the organisation—particularly those at the sharp 
end—could be mobilised around the initiative. Participants cited difficulties in changing 
attitudes and culture, and particularly in getting front-line staff to realise that their current 
practice was not necessarily safe practice; reconciling (new) standardised practices with 
clinical autonomy; problems in getting people to do things properly (due to lack of 
knowledge, education, engagement or time); lack of ownership; lack of leadership; 
difficulties communicating within multidisciplinary teams; and people not believing the 
evidence. 
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you do have that element where you know individuals would think that they work safely. 
So you know kind of like, “Well I always make sure my patient is safe”. (Senior Sister) 
 
Accounts stressed the need for the changes in practices and attitudes encouraged by the SPI 
to become “taken for granted”, and reproduced routinely in organisational settings without 
contestation or resistance, but many strategic stakeholders feared that the SPI would not 
enjoy the legitimacy it needed among front-line practitioners. The most common view 
(raised by 52 hospital stakeholders) was that “people” issues were hugely important, and 
that although some people in the organisation were enthusiastic, other sharp-end and often 
powerful stakeholders (especially doctors) were “cynical”, “wary”, “too busy” or “resistant”, 
although only seven participants felt that people in their organisation primarily felt 
negatively or sceptical towards the initiative. 
I think the reaction has been mixed. I think there's been a lot of people who have felt it's 
nothing to do with them and therefore haven't shown any interest. I think there's been a 
lot of people who certainly at the outset felt it was just yet another thing that the 
management had signed us up for. I think there were some people who thought, “Yeah 
actually this has got some useful things in it but some of it's not for us”, and I think there 
were one or two zealots who thought it was the greatest thing that they'd ever heard. 
(Consultant) 
 
Really just the staff are upset about having more work to do. I would say it would be the 
general feeling on the on the ground. (Senior Nurse)  
 
Specific barriers to implementation identified in strategic stakeholders' accounts included 
increased work and bureaucracy, lack of communication about the initiative, trying to take 
on too many changes at once, lack of preparation, unrealistic time scales and concerns about 
maintaining momentum over longer periods of time. The “complainability” of these issues 
was seen as being a threat to legitimacy, in part because of the costs they imposed. 
 382 
 
When you start to implement change and bring maybe an additional form that they 
have to fill in, they automatically, you get negative feedback … “We're filling in enough 
forms and we've enough to do as it is. We haven't time for this” (Pharmacist) 
 
These doubts about the organisational feasibility of implementing the initiative were joined 
by doubts about the scientific legitimacy of some aspects of the programme in many (n=32) 
hospital stakeholder accounts. Scientific doubts arose in relation to difficulties measuring 
change and reaching targets in that relate to changes in behaviour, lack of evidence for some 
of the interventions, changes that did not fit easily with current practice, problems with 
definitions leading to difficulty in measuring outcomes (particularly in relation to infections), 
the abstract nature of the initiative, and problems with translating and applying an 
programme developed in the USA to the UK context. These accounts often appeared to 
point to the existence of professional subcultures that did not share the same view of 
specific issues as the SPI.  
[There has been] a lack of knowledge or a lack of belief if you like in the evidence, and 
there have been a couple of points in the surgical site infection bundle where people 
have questioned the evidence that has been given forward for doing something, and in 
fact in one of those instances they, with regards to beta blockers there is such 
widespread disbelief in the evidence that the Safer Patient Initiative has watered that 
down now. (Medical Director)  
…we're not sure what an infection is you know and I feel strongly … maybe it's from a 
scientific background as opposed to a management background but if we're counting 
apples and oranges we need to know what an apple is. And not just a round fruit. 
(Clinical Director) 
 
Structural barriers related to the organisation/trust were raised by 50 participants and 
included the large size of the organisation, lack of systems already in place, lack of resources 
(money or staff) and the mobility of medical staff.  
 383 
 
I think you know staffing issues is a big thing, you plan to staff a ward, you get last 
minute sickness, you get bank and agency nurses, and that I think is the difference really 
if you're getting agency nurses you haven't always got that ownership … You know it's   
B.3.4 Quantitative analysis of interviews 
Seventy-three percent (44/60) of participants scored above 5 on the knowledge scale and 
83% (50/60) scored above 5 on the enthusiasm scale. The correlation between knowledge 
and enthusiasm varied depending on the rater (the ICCs between enthusiasm and 
knowledge for the three raters were (0.61, 0.69 and 0.91). The correlation between raters 
was medium to high (the ICC’s between the three pairs of raters for knowledge were 0.54, 
0.56; and for enthusiasm, 0.63; and 0.58, 0.70 and 0.71).  The overall correlation (Figure B.2) 
between knowledge and enthusiasm was 0.79 (p>0.0001).   
Figure B.2: Correlation between knowledge and enthusiasm for SPI among strategic 
hospital stakeholders (some dots represent more than one interviewee n=60) 
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B.4 Discussion 
Strategic stakeholders generally saw the aims of the SPI as legitimate and sound. They 
accepted that there was a need to control risk (the likelihood of harm occurring) and that 
patient safety was an important priority for hospitals. Only seven of the 60 (12%) hospital 
stakeholders were unable to describe the SPI accurately or in detail; the majority of 
accounts from hospital stakeholders appeared to demonstrate a shared understanding of 
the main elements of the initiative. Most, for example, gave a reasonable account of the 
PDSA cycle (see 3.6.3.1). There was considerable enthusiasm for the initiative, but there 
were also concerns about the ambitious reach of the programme, whether resources would 
be equal to the demands, and whether resistance might be encountered at the sharp end.  
The quantitative analysis corroborates the qualitative analysis such that those participants 
that exhibited greater knowledge where more enthusiastic about the SPI.  
A limitation of this sub-study was that the number of strategic stakeholders at each site was 
relatively small (on average 15 per hospital).  Also the assessment of the agreement 
between the accounts of external stakeholders and hospital stakeholders was limited by the 
small number of external stakeholders interviewed. It is also possible that those who agreed 
to be interviewed were to some extent self-selected enthusiasts.  
Nonetheless, this study does offer insights: First, it suggests that it is possible to get 
strategic-level individuals across geographically spread and organisationally diverse settings, 
and interviewed over a period of time, to understand and agree upon a shared model that 
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can be used in their organisations. Second, it suggests that people at a strategic level are 
able to recognise the competing interests within their organisations that forms the context 
of negotiation in which the programme of change is enacted. In particular, they are able to 
acknowledge the complexities of how to mobilise people, technologies, organisational 
structures, resources and “culture” around a new effort. 
In Suchman’s terms (1995), the initiative enjoyed both “pragmatic legitimacy”, where it was 
seen to be of benefit to participants’ organisations, and “moral legitimacy”, where it was the 
right thing to do.  However, participants also had specific doubts, particularly relating to 
feasibility of implementation and scientific legitimacy of some elements of the initiative.   
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Appendix C: Ethnographic study 
C.1 Introduction 
Participants at the “sharp end” of healthcare may not always share the same understanding 
of the intervention as those at the “blunt end”.  This sub-study explores the impact of the 
intervention on these participants and seeks to explain how they identified and classified 
patient safety risks through observations on medical wards. 
C.2 Methods 
An ethnographic study was conducted at ward level in each of the four SPI1 hospitals.  Two 
respiratory wards, 1 general medical ward, and 1 ward for the care of the elderly were 
studied.  These wards were selected so that they mirrored the data collection in the case-
note review of acute respiratory patients (Chapter 6) and so that triangulation between the 
sub-studies could be made.  Three rounds of data collection were undertaken (Figure C.1): 
• a week-long visit to each of the wards involving approximately 150 hours of 
observations and 47 interviews with different types of ward staff, focusing on 
general issues relating to patient safety and the SPI. These visits were conducted 
between April and September 2006, as SPI1 was being rolled out; 
•  a week-long second visit to each ward, involving a further approximately 150 
hours of observations and 41 interviews, this time with a particular (although not 
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exclusive) focus on making observations of the patients’ condition and 
responding to abnormalities, thus allowing insight into the early warning and 
rapid response systems used to detect and support deteriorating patients. These 
visits were conducted April-June 2007, during the “embedding and spread” 
phase of SPI1; 
• a third visit involving three focus groups at each hospital (one at study ward 
level, one involving people with patient safety/SPI responsibilities and one at 
strategic (hospital-wide) level). In these focus groups, preliminary findings from 
the first two visits were fed back and reflections were sought on the SPI and on 
the way forward for patient safety. These visits were carried out between May 
and July 2008, towards the end of the formal completion of the SPI programme 
in the SPI1 hospitals (September 2008).  
Figure C.1: A summary of the ethnographic study 
 
What?
Ethnography
to understand safety 
culture at the “blunt 
end”
Where?
4 SPI1
intervention 
hospitals
Who?
x2 week long visits to 3 
respiratory and 1 geriatric 
ward
x1 focus group at ward 
level,  patient safety 
managers & strategic level 
When?
SPI1 intervention: Jan ‘05 – Sept  ’06
Data collection (ward visit):  Apr – Sept ‘06
Data collection (ward visit):  Apr – Jun ‘07
Data collection (focus groups):  May – Jul ‘08
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Data analysis was based on the constant comparative method (Glaser and Thomson, 1967).  
For the interviews, initial “open codes” were revised, expanded and collapsed as the analysis 
progressed and then organised into categories in a coding scheme, through which data was 
processed. This was facilitated by the use of NVivo software. For focus groups and 
fieldnotes, simple coding procedures were used to categorise the data. Categories were 
inspected to build a theoretically-informed interpretation. In order to ensure anonymity, 
extracts from the data have not been labelled by hospital. 
C.2.1 Ethical considerations 
Please see B.2.1.   
C.3 Results 
The first two visits provided insights into the sharp end of practice on the wards, while the 
focus groups undertaken on the third visit also provided insights into the other layers of 
management and strategy in the hospitals. The ethnography was able to identify staff views 
on the SPI as they experienced, and what they thought would help in the ”spread” of safer 
practices for the future. 
Reflecting the findings of the strategic stakeholder interviews (see Chapter 4), the focus 
groups across the four hospitals agreed that the senior people in the hospitals were 
committed and enthusiastic about the SPI, made a significant strategic contribution, gave 
weight to the initiative and generally set a good example for staff.  
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if these guys aren’t behind it very quickly your clinical directors and you know other 
directors, you know (other) senior people start to fall by the wayside and so I think that’s 
absolutely paramount having the top guys leading the way so I think that has been one 
of the big successes. (Focus Group) 
The SPI was seen as having encouraged a change from patient safety being something taken 
up by individual (but sometimes unaccountable) voluntary enthusiasts, towards being a 
more mainstream priority. The involvement of the IHI in the SPI was seen as crucial in 
lending credibility and support to the implementation of the SPI, and was much valued as a 
source of expert knowledge and expertise.  
it’s fundamentally important for people who teach you have credibility, and I think IHI in 
the States know their stuff and they have their way of teaching things and it’s culturally 
a bit difficult to get into it but once you know once you’ve got, you are there, it’s just, 
you know, it’s really empowering. (Focus Group) 
Despite the enthusiasm and support at a strategic level, the management layer (often ward 
sister or consultant level) between the blunt end and the sharp end appeared less engaged 
in the SPI than the strategic level. 
I think it starts from the top but I don’t know if it actually gets right down and the same 
from the bottom up, I think we’ve got that middle layer that often it gets lost in 
sometimes. (Focus Group) 
The challenges of engaging middle management and frontline staff were not because they 
were not interested in or concerned about patient safety. In interviews, these staff gave 
detailed accounts of the kinds of risks they confronted on wards, and they expressed anxiety 
that some of these were not managed well. The risks they described were often those being 
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targeted by either the generic or the specific interventions of the SPI, such as, for example, 
communication and handovers. 
I think the biggest problem we have on this ward, and I think that’d be in anywhere 
where you get a big establishment with a lot of people - you’ve got the doctors, the 
phyios, the OTs - it’s communication. Like the doctors will quite often come and do their 
ward round and they’ll go around and they’ll say, “Oh Mr so and so you can go home 
today”, but they won’t tell [..] anyone else.(Interview with ward staff) 
Some of problems of engaging middle-management staff and ward are likely to be explained 
by the day-to-day nature of their work, which was often focused on managing highly 
complex clinical and organisational demands. Observations suggested that the wards were 
often very busy and stressed places in which to work, and staff interviews pointed to 
problems of managing with limited resources, including and especially inadequate staffing or 
problems of skill mix and shortages of equipment (Dixon-Woods et al., 2009). This meant 
that staff perceived that they were often too stretched to give priority to things other than 
the tasks that required to be done immediately. There were suggestions that the effort to 
improve patient safety needed to be focused on improving aspects of structure rather than 
on processes: 
I was telling somebody that if I had one more doctor and a couple of more trained 
nurses. What I want is trained nurses on the ward so I can manage the ward better 
and we can discharge many patients sooner and we can reduce the number of 
complaint letters and of things going off. (Interview with ward staff) 
It was clear also that there were problems of “initiative fatigue” and, for middle managers in 
particular, challenges in constantly balancing a raft of competing priorities.  
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there’s so many things now that the nurses in the wards have to do and every time you 
bring something in, I mean the same time we’re bringing in the Safer Patients Initiative 
I’ll be bringing in health and safety risk management training, I’ll be bringing in fire 
safety training, you know, our contingency arrangements, emergency 
evacuation…[..]and they all go through the senior nurse on the ward… 
so you’ve got things being dropped from a great height down onto the nurses so you can 
see how in some ways we’re creating part of the confusion and that we’re just … ‘cos we 
all think it’s important they know that and they're doing it but if it’s 20 or 25 different 
issues for a nurse then it’s a heck of a lot to take on board. (Focus Group) 
Where ward staff did know what was going on in relation to the SPI, they were generally 
positive. 
the safety briefings has improved the way we work from a point of view that we have 
you know a better system of monitoring our equipment, where is our equipment going, 
we get it fixed quicker because it’s been highlighted in the morning as part of a safety 
brief, we come out of handover and we’re all aware of particular wandering patients. 
[...] if there was some medication error, we’re using the safety briefings to maybe say, 
not naming names but you know a patient isn’t receiving this, can we please make sure 
they do because they were complaining overnight about it. So I think it’s improving the 
communication between the nurses from that point of view. (Interview with ward staff) 
However, the ethnographic work suggested that the impact of the SPI at the level of medical 
wards were mostly difficult to detect. Apart from improved monitoring of patients using the 
EWSS, the SPI was not routinely evident in the everyday practices of people caring for 
patients on the front line. For the most part, the sharp end staff tended either to know 
relatively little about SPI procedures, practices and principles, or they viewed them as 
handed down (top-down) rather that something that they had been involved in developing 
(bottom-up). Outside a small number of pockets of activity, there was little evidence that 
front-line staff perceived a sense of ownership over the initiative. There was also a 
perception, in interviews and the focus groups, that the SPI had allowed a small number of 
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people to become an elite group with enhanced career prospects who then moved on, while 
others were left feeling excluded. 
SPI was a select group of twenty people. I think we could only bring down twenty 
people and you're starting off in small areas and of course the by-product of that is 
that you’ve got a small group dealing with those small areas so there is, although we 
may not like it, there is a perception in some parts of the organisation that SPI is a an 
elite entity. (Focus Group) 
The gap between the strategic level view and what was happening at the sharp end was 
evident in a number of different ways. For example, Leadership WalkRounds were discussed 
enthusiastically in the leadership focus groups, and were seen as a highly effective way of 
understanding the issues that the sharp end finds problematic. They appeared useful and 
welcome in raising senior managers’ understanding and awareness of life at the sharp end. 
so you know if I wanted to find out what was going on a ward I could do a sort of 
incident reporting system but I also know that that won’t tell me what life is really like on 
that ward, so actually going on the ward and listening to staff talk specifically about 
harm to patients is something that I don’t believe that most executives get in their 
normal practice. We all get trapped in offices. (Focus Group) 
However WalkRounds were only seldom mentioned by ward staff in interviews (and they 
were not witnessed over the ~300 hours of observations – though this may simply have been 
an artefact of the data collection process). When discussed in one focus group, it was 
evident that staff at the sharp end felt that the process was disappointing and may even 
have undermined the SPI, because it appeared to demonstrate a failure to connect senior 
management with the wards in meaningful ways. 
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HAVE YOU HAD ANY LEADERSHIP WALKROUNDS ON YOUR WARD? 
A: Yeah we had erm … what’s his name? One of the guys came down with [name] not 
that long ago, about a month ago or something it was, he came down for a 
walkaround. 
WHAT WAS IT LIKE? 
A: Well he came around and spoke to a few people and just asked about any 
concerns. He said he was interested to know how the nursing staff felt and he wanted 
to know one thing that he could take back to the rest of the board about any issues 
that nursing staff had. Afterwards they sent a letter to say thanks but you never hear 
any … well we haven’t heard anything more than that so … 
HOW LONG TIME AGO WAS THAT? 
B: I think it was about [two months ago] 
WAS THERE AN ITEM THEY THEN TOOK BACK? 
A: Well we had said that we were concerned about working short-staffed so often 
and also about the lack of opportunities for staff to do on-going study 
B: Yeah about the lack of equipment … 
A: The lack of equipment and … well we said a few things and I think it was quite 
general across all the wards 'cos they went along the whole floor on different days 
and visited all the wards along the medical floor and I think it was quite common 
ground that everybody was sort of mentioning the same things. But we’ve never 
heard anything about change because of it, but we did have our little moan. 
Similarly, the stakeholder interview and focus groups participants agreed that there were 
great benefits of the PDSA approach: it developed expertise, enabled the hospitals to try out 
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new ways of working, allowed staff to experiment, gave space and “privacy” for correcting 
mistakes, and allowed local customisation.  
it gives you permission to try new things and if it doesn’t work it doesn’t work, you 
know, you haven’t sort of broken any rules because in hospitals we are very much 
bound by, is this the accepted way, is this the allowed thing but PDSA has given us 
permission to try different things even for a day, a shift, you know make changes . 
(Focus Group) 
Several PDSA “success stories” were reported in the focus groups. However, few frontline 
ward staff who were interviewed seemed aware of PDSA. Thus, somewhere between the 
blunt end and the sharp end, the model of participative engagement on which the SPI was 
based got rather lost.  
It appeared that there were several important influences on the extent to which SPI 
interventions became embedded on the wards. One was legitimacy. Sometimes staff simply 
did not see particular interventions as being scientifically legitimate: 
something that appears on the surface very simple like the definition of a surgical 
infection caused an absolute riot (Focus Group) 
Scientific legitimacy problems were, perhaps paradoxically, compounded by the use of PDSA 
cycles. Some clinical staff were reported to see the data collected during the cycles as 
unreliable and lacking in credibility, and therefore as not providing enough of a prompt for 
change – though it may also be the case that claims of problematic evidence were being 
used simply as a means of resisting change and reinforcing inertia. Legitimacy problems also 
arose when staff did not recognise that the problem being tackled was a ‘real’ one requiring 
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a particular response, or they did not feel that the resources that would be required to 
implement the intervention was a legitimate use of staff time in light of other priorities. 
There were also suggestions that that legitimacy varied among different staff groups; junior 
doctors were often seen (by nurses in particular) as especially difficult to engage. 
I think it’s very variable, I think there’s some senior clinicians that are very supportive 
and I think on the whole at that level they are supportive and they seem to be 
supportive and they show that support but we still don’t seem to be solving the 
problems with the junior doctors.’ (Focus Group) 
The second related to how “trackable” any improvements were. One of the reasons why the 
EWSS seemed to penetrate practice was that it left a visible trace (in the form of a record of 
observations of vital signs), and thus promoted a sense of accountability. It was also clearly 
linked to a long nursing tradition of conducting observations of patients’ vital signs, and was 
seen as addressing the legitimate and important problem of identifying and responding to 
patient deterioration. In contrast, ethnographic observations suggested that safety briefings 
were rarely used in a recognisable form on the wards, even though staff saw handovers as a 
risky area. Similarly, the SBAR communication technique seemed to have relatively low 
uptake. In the focus groups, the apparent “failure” of the safety briefings and SBAR was 
attributed partly to the fact that it was difficult to demonstrate the improved practice and 
hence there was little incentive to comply.  
I think one of the reasons why it [safety briefings] wasn’t complied to as part of SPI it 
wasn’t a measurement, it wasn’t something we were asked to report on. (Focus Group) 
One of the issues for me with SBAR is that we’ve been so focused on measurement [but] 
it’s one of those things that’s really difficult to measure. (Focus Group) 
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Observations identified several further barriers to adopting safety initiatives, including the 
instability of teams caused by rotating staff and frequent substitutions by agency staff. This 
meant that it was difficult to sustain a collective knowledge and faith in the SPI over time. 
For example, in a discussion of hand-washing, ward staff reported that: 
A: nursing-wise it’s quite consistent but in medical staff, the doctors … 
B: … we’re having still poor response, yeah, poor compliance. 
A: I think plus we’ve had a lot of bank and agency working haven’t they and they 
sometimes they don’t seem to be as hot on it do they as kind of the regular staff 
because we’re aware of it. (Focus Group) 
It is important to emphasise that the SPI did have positive impacts, which were clearly 
evidenced in some of the interviews and the focus groups. In particular it helped to increase 
managerial recognition and focus on patient safety, and promoted a systematic approach to 
tackling patient safety problems. One of its more lasting benefits was that over time, 
hospitals began to recognise challenges more clearly.  
I mean with the [recently commenced patient safety strategy/initiative] we’ve got 
our tasks set out for us but I suppose most of the participants we, we’ve got a bit of 
history on this, we have progressed quite substantially, okay there’s a duty on us to 
ever do better so in terms of those interventions… … we actually have the opportunity 
to innovate, we’ve got the methodology and we should be looking to spread, and so 
we are looking to spread that methodology, that’s the challenge for us to ever go 
forward. (Focus Group) 
A key achievement of the SPI was encouraging organisational learning about how to 
manage quality improvement efforts in the future.  
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I think we have to be careful and I think we have to recognise that yes, we’ve done 
some great work but only in small areas and now this is a big huge thing for us to 
spread this across the organisation and admit that some of the things that we did in 
SPI we didn’t maybe do as well as we could have done… (Focus Group) 
Hospitals reported that they had begun to devise and implement strategies for future 
implementation of patient safety programmes. One of the major lessons learned was the 
scale of resource and organizational support required to make patient safety efforts work. 
There was a perception that hospitals had underestimated this, and that they had been, in 
the early stages, too ambitious and too ready to assume that something that worked in a 
defined clinical area (such as ICUs) would easily transfer to other environments. 
I wonder if we tried to do too much. The Safer Patients Initiative had, I think, 
something like 29 simultaneously (…) I know the American experience was they could 
choose only six and now with the latest experience they can choose from twelve so we 
were trying something very new and I just wonder if we tried too much and weren’t 
able to devote enough focus on every element of it. 
I kind of feel that we’ve not made the same progress… well clearly we haven’t made 
the same progress on all 29 initiatives in all five work streams and I wonder if we 
spread ourselves too thinly at times. (Focus Group) 
For the future engaging senior clinicians and encouraging local ownership was widely seen as 
the key to success.  
it’s getting the leadership there you know, the clinical lead, to sign up to it and to 
really drive it because we don’t have that leadership you know. I think we’re at an 
advantage nearly now because we have learnt a lot from what we have done over the 
past three years that now when we do move to spread throughout the organisation 
we have all that learning behind us and we’re able to reflect on that and take it 
forward perhaps in a slightly different way and learn to engage people maybe more 
at the start which is something that we didn’t do three years ago. 
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[name] is now going to the meetings, the monthly meetings between medical director 
and the clinical director and also the clinical managers on a monthly basis so that 
we’re starting to get that information to them and starting to ask to get ownership 
from them about what change needs to happen ‘cos that middle layer wasn’t really 
working (Focus Group) 
Strategies for the future included using reputational incentives to encourage people to 
cooperate: 
I don’t think we’ve got to a position where the peer pressure’s breaking through and 
people are saying well “I really have to do that, so I think this, I think we’re getting 
close to that”. (Focus Group) 
Avoiding “paperwork” associated with patient safety work was also seen as important in 
securing the cooperation of front-line staff. One focus group discussed how important it is to 
develop more meaningful ways to measure and prompt compliance without overloading 
staff with audits and data collection. In their organisation, each clinical area can decide how 
they implement and measure safety briefings for themselves.  
you can have tick box and say yes a safety briefing has taken place, but how effective 
is that? One of the ways that we’ve advised the staff to think about is well if you 
asked a member of staff later on that day “what was the three things on the safety 
briefing?” they should be able to tell you. 
It’s making it doable, measurable but not more data, not more audits, it’s how you 
capture that. (Focus Group) 
Creating new structures to support patient safety work was also seen as important in some 
hospitals.  
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by having the small groups it was actually preventing us from spread. Each clinical 
group now has responsibility and each hospital has responsibility for patient safety 
within whichever structure they choose whether it’s clinical governance or health and 
safety they all have a small patient safety group within each clinical group because 
what we found is if you were in the general ward work stream you just focused on the 
general ward work but some of the critical care stuff actually applied to you and vice 
versa. 
one of the first things we did actually was not ban the things we learnt from SPI but 
stop calling things SPI committees and things… … we didn’t need to use it any more so 
we just literally changed it to Patient Safety Committee as opposed to an SPI 
committee but taking forward all the stuff that was learned of course, part of the 
culture change as well and involving everybody. 
we are going to stop having a Safer Patients Initiative steering group and we’re 
gonna have a Patient Safety Committee safety representative for each Directorate 
who will be responsible with the Clinical Director and General Manager for that 
Directorate for delivering on all the workstreams, i.e. they will monitor them within 
their Directorate and at the Safety Committee will just monitor certain high level 
(Focus Groups) 
Organisational changes, critically, also meant embedding the work within those less engaged 
“middle layers” of the hospitals. Thus, some hospitals gave departments/divisions more 
responsibility for implementing and monitoring patient safety. 
we will leave it to individual departments to monitor them and make correction action 
where necessary and we’ll just monitor the outcomes, so it’s gonna be a different way 
of.. well we are hoping it will embed it by making it everyone’s responsibility but at 
the same time and in order to introduce new work streams ‘cos we’re introducing 
training and a few other things as well as… … and they’ll be improvement team 
support for the directorates and the Safety Leads in the directorates, so it’s gonna be 
a different way of looking at it in … with the aim of trying to embed it more. (Focus 
Group) 
C.4 Discussion 
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The analysis shows that there is a disconnect between the strategic stakeholders and front-
line staff perception of the SPI.  Strategic stakeholder focus groups reinforced the findings of 
the interviews in Chapter 4 and showed enthusiasm and dedication to the SPI, whilst, staff 
at the “sharp-end” were unable to describe the SPI in any great detail.  A possible reason for 
this was the lack of engagement of middle management, who described a concern for 
patient safety but were balancing these concerns with other competing priorities.   
This gap was also noticeable in the description of the intervention – strategic stakeholders 
were able to articulate the SPI in detail and describe components such a WalkRounds and 
PDSA cycles.  However, the EWSS was the only aspect that was readily observed on the 
wards, perhaps as EWSS created a physical record, whilst, there is no such artefact for other 
components such as safety briefings and SBAR and thus no imperative to engage in these 
types of activity.   
Front-line staff also had little knowledge of the other parts of the intervention and perceived 
the SPI as being handed down to them rather than the participatory model espoused by the 
IHI.  In fact there was a perception of elitism and better career prospect for those that were 
actively involved in the SPI.  
Another barrier to compliance was a lack of perceived scientific legitimacy of the methods 
used in the SPI and the inability to sustain momentum because of continuous staff changes. 
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Nevertheless, there was a positive impact with the SPI sites, primarily a managerial 
recognition and focus on patient safety.  
Overall the ethnography within the evaluation suggests that staff at the sharp end had a 
vague idea of the intervention and few had direct experience of most of its components 
except in the area of recognising and responding to the deteriorating patient.   
However, a limitation of this study is that it focuses on medical wards and it is unknown if 
this experience of the SPI is shared by frontline staff working within surgical theatres and 
the ICU – areas which were subject to more targeted components of the intervention, i.e. 
the peri-operative care bundle and the critical care bundle respectively.   
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Appendix D:  Staff survey questions 
The following 13 questions were identified as being relevant to the SPI evaluation (*these 
scores were not included in the SPI1 evaluation).  Six of these thirteen scores are 
straightforward percentages: 
 
1. “Percentage staff having well structured appraisals” reflects the percentage of 
respondents who not only say that they had received an appraisal in the previous 12 
months, but that this appraisal helped them improve how to do their job, helped agree 
clear objectives for their work, and left them feeling that their work was valued by their 
organisation. These aspects of appraisal have been shown to be particularly important 
for organisational outcomes in many sectors, including healthcare (Guzzo et al., 1985; 
West et al., 2006) 
 
2. “Percentage staff working in well-structured teams” is the percentage of respondents 
who said they worked in teams, that their teams had clear objectives, that they had to 
work closely with team members to achieve these objectives, and that the team met 
regularly to discuss their effectiveness and how it could be improved. These are features 
of team working that have been shown to be critical for achieving high-quality team 
outcomes (Borril et al., 2000) 
 
3. “Percentage staff witnessing potentially harmful errors or near misses in previous 
month” was the percentage of respondents who said they had witnessed an error or a 
near miss in the previous month that could have harmed either patients or staff.  
 
4. “Percentage staff suffering work related injury” is the percentage of respondents who 
said they had suffered injury or illness as a result of moving or handling; needlestick or 
sharps injuries; slips, trips or falls; or exposure to dangerous substances in the previous 
12 months; 
 
5. “Percentage staff suffering work related stress” is the percentage of respondents who 
said they had suffered injury or illness as a result of work related stress in the previous 
12 months; and  
 
6. “Percentage staff experiencing physical violence from patients/relatives” was the 
percentage of respondents who said they had personally experienced physical violence 
at work from either patients, or relatives of patients, in the previous 12 months. 
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Six of the other seven scores were calculated as the mean of a number of separate 
questionnaire items, each scored from 1 to 5 representing answers form “strongly disagree” 
through to “strongly agree”, or from “very dissatisfied” to “very satisfied”: 
 
7. “Intention to leave” shows the extent to which employees are considering leaving their 
jobs. It is based on three questionnaire items.  
 
8. “Staff job satisfaction” is a measure of employees’ overall satisfaction with their jobs, 
and is based on seven items.  
 
9. “Quality of work life balance” measures the support provided by organisations for 
employees to maintain a good work-life balance, and is based on three items. 
 
10. “Support from supervisors” is a measure of the extent to which employees feel 
supported by their immediate managers at work, and is based on five items.  
 
11. “Organisational climate” is a measure of the overall climate, or positive feeling, within 
the organisation, including factors such as hospital in management, communication, 
staff involvement in decision making, and emphasis on quality. This is based on six 
items. Each of these scores has been shown to relate to performance outcomes, 
including quality of care, in health care organisations (Michie and West, 2004) 
 
12. “Fairness and Effectiveness of Incident Reporting Procedures” is a measure of the extent 
to which employees their hospital’s procedures for reporting and dealing with errors, 
near misses and incidents are effective and fair. This is based on seven items.* 
 
One other variable was also measured on a similar scale, but with some slight differences: 
 
13. “Availability of Hand Washing Materials” is a measure of the extent to which hand 
washing materials (hot water, soap and paper towels, or AHR) are available when 
needed by different groups. This was originally measured on a scale from 1 to 4 
representing answers from “never” through to “always”, and than adjusted to fit a 1 to 
5 scale for consistency with the other scale scores. * 
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Appendix E:  Prescribing errors - stage of drug process and their definition 
- Need for a drug: includes the following:  
 
1) Omission of drug 
Any situation in which a drug is not prescribed for a clinical condition for which a drug is 
indicated; this includes the erroneous omission of drugs from an inpatient drug chart or 
discharge prescription. Also included is the premature discontinuation of a prescribed 
medication 
 
2) Drug no longer needed 
Continuation of a prescribed drug for a longer duration than necessary.  
 
3) No indication for drug prescribed 
Prescription of a drug without a corresponding indication. 
 
4) Duplication of therapy 
Prescription of two or more drugs with the same therapeutic action when only one of the 
drugs is necessary, or the prescription of the same drug more than once.  
 
- Selection of drug: includes the following: 
 
1) Prescription of drug to which patient has significant allergy 
This would include the prescription of penicillins in a patient with a confirmed penicillin 
allergy and the prescription of NSAIDs in an asthmatic patient who is hypersensitive to drugs 
of this class. 
 
2) Prescription of drug that is contra-indicated due to drug interaction 
This includes the prescription of buprenorphine in a patient receiving other opiates, and the 
prescription of drugs which interact with anti-retrovirals.  
 
3) Prescription of drug to which patient has clinical contra-indication 
Prescription of drugs that are contra-indicated due to pre-existing medical conditions such as 
diabetes, severe renal impairment or liver disease. 
 
4) Prescription of drug that was not intended 
Any situation in which the drug prescribed was not that desired. This includes errors in 
medication history taking and transcription errors when rewriting drug charts or discharge 
prescriptions, as well as inappropriate clinical decisions. 
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- Selection of dose: includes the following: 
 
1) Failure to specify maximum dose 
Failure to specify the maximum dose for a drug prescribed to be given as required. 
 
2) Failure to take into account drug interaction 
The prescription of a drug in a dose that is not appropriate because of a concurrent drug 
interaction. 
 
3) Dose/rate mismatch 
Prescription of a drug to be infused on a mg/kg/hr basis, where the ml/hr rate calculated 
does not correspond to the dose required. 
 
4) Total daily dose divided incorrectly 
Any situation in which the total daily dose is correct, but is divided into an incorrect number 
of daily doses. For example, cyclizine prescribed 150mg once daily instead of 50mg three 
times a day. 
 
5) Overdose 
Any situation in which the patient is prescribed too high a dose of a drug, that is not covered 
by the situations described above. 
 
6) Underdose 
Any situation in which the patient is prescribed too low a dose of a drug, that is not covered 
by the situations described above. 
 
7) Failure to specify the strength of formulation 
The prescription of a drug where there is more than one strength for one formulation and 
not specifying the strength intended for the prescription 
 
- Selection of formulation: 
Prescription of the wrong formulation for the drug and dose regimen prescribed.  
 
- Provide information for supply: includes the following: 
 
1) Product or formulation not specified 
Any situation in which the product or formulation is not specified in enough detail for a 
supply to be made. This includes failure to adequately specify the product formulation 
intended and the prescription of illegible or otherwise ambiguous medication orders.  
 
2) Strength or dose not specified 
Any situation in which the strength or dose of a preparation is not specified in sufficient 
detail for the appropriate product to be supplied. 
 
3) Route not specified 
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Failure to state the route of administration for a drug that can be given by more than one 
route. 
 
4) Prescription not signed 
An inpatient or discharge prescription that has not been signed by the prescriber. 
 
5) Controlled drugs prescription requirements 
Failure to write a discharge prescription according to the controlled drugs 
requirements.
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Appendix F:  Difference at baseline for quality ratings, errors and adverse events 
Table F.1: Ratings and rates of adverse effects and errors: differences between SPI2 hospitals and control hospitals at baseline; and 
changes between Epoch 3 and baseline in the control hospitals (99% CIs are in parenthesis) 
 Comparisons at baseline 
* (1) Changes in Controls * (2) 
 Intervention – Control Epoch 3 – Baseline 
   
Quality Ratings   
Admission Rating † 0.12 (-0.27, 0.50) 0.11 (-0.32,0.26) 
Management Rating † 0.14 (-0.33, 0.61) 0.28 (-0.29, 0.84) 
Pre-discharge Rating † 0.00 (-0.54,0.54) 0.11 (-0.38,0.60) 
Overall Care Rating ‡ 0.10 (-0.30, 0.48) 0.29 (-0.12, 0.69) 
Errors / Adverse Events   
Number Errors Ф -5.78 (-23.84, 12.28) -14.35 (-32.42, 3.71) 
Number Adverse Events Ф -1.42 (-5.81, 2.97) -1.70 (-7.37, 3.96) 
Errors can be of multiple categories 
* Effects are estimated from a mixed effects model (see methods for details) and represent differences at baseline (1) and the effect of time (2). Baseline refers to 
the average scores over Epoch 1 and Epoch 2 
† Score scale: 1 (below best practice) to 6 (excellent care).  
‡ Score scale: 1 (unsatisfactory) to 10 (very best care) 
Ф
 Number of errors and number of adverse events are per 100 patients (patients could experience more than one error and more than one adverse event) 
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Table F.2: Rates per 100 patients of errors identified by broad category of error: differences between SPI2 hospitals and control hospitals 
at baseline; and changes between Epoch 3 and baseline in the control hospitals (99% CIs are in parenthesis) 
 Comparisons at baseline 
*(1) Changes in Controls * (2)  
 Intervention – Control Epoch 3 – Baseline 
   
Diagnosis/ Assessment/ Admission Error -3.28 (-27.15,20.60) -13.08 (-36.31, 10.14) 
Hospital acquired infection -0.00 (-0.93,0.93) 0.88 (-0.28,2.04) 
Technical/ management -3.58 (-10.50, 3.34) -1.17 (-9.66,7.31) 
Medication /Maintenance/ Follow-up -1.08 (-11.24, 9.07) -8.54 (-21.43, 4.35) 
Clinical reasoning -4.90 (-18.56, 8.76) -10.93 (-24.84, 2.97) 
Discharge information 0.62 (-9.43, 10.67) -5.63 (-16.14, 4.87) 
Errors can be of multiple categories 
* Effects are estimated from a mixed effects model (see methods for details) and represent differences at baseline (1) and the effect of time (2). Baseline refers to the average scores 
over Epoch 1 and Epoch 2.  
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Appendix G:  Details of fitted models 
Table G.1: Fitted models for rate of soap and AHR (litres) consumption per 1,000 bed days 
 Soap AHR 
 Coeff (se) p-value Coeff (se) p-value 
Constant 41.76(13.3) 0.000 3.80 (10.5) 0.708 
Intervention 0.73 (13.9) 0.941 10.90 (12.2) 0.371 
Time 0.73 (1.82)   0.623 3.91 (1.28) 0.002 
Time^2 -0.03 (0.08)   0.657 -0.12 (0.06) 0.034 
Time^3 0.00 (0.00) 0.501 0.00 (0.00) 0.065 
Intervention*Time 0.08 (0.44)   0.760 -0.05 (0.38) 0.889 
 
Table G.2: Fitted models for observed to expected mortality ratio (exponential scale) and 
mean length of stay for patients admitted to ICU unit 
 O/E mortality Mean LOS 
 Coeff (se) p-value Coeff (se) p-value 
Constant 1.28 (0.12) 0.000 180.4 (19.7) 0.000 
Intervention -0.14 (0.08) 0.068 -39.4 (17.2) 0.022 
Before -0.07 (0.06) 0.258 -12.9 (8.49) 0.128 
Intervention*Before 0.09 (0.08) 0.250 5.9 (11.11) 0.598 
APACHE II Score 0.01 (0.01) 0.138 0.34 (1.18) 0.774 
Physiology Score -0.01 (0.01) 0.015 -1.34 (0.87) 0.123 
 
Table G.3: Fitted models for APACHE II and ICNARC physiology scores for patients admitted 
to ICU unit from a ward within the hospital 
 APACHE II score ICNARC score 
 Coeff (se) p-value Coeff (se) p-value 
Constant 18.47 (0.72) 0.000 20.95 (1.00) 0.000 
Intervention 1.20 (0.98) 0.225 2.32 (1.36) 0.087 
Before 1.85 (0.81) 0.022 1.77 (1.19) 0.136 
Intervention*Before -0.83 (1.09) 0.449 -2.26 (1.60) 0.158 
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Table G.4: Fitted models for rate of C. diff (per 1,000 bed days) and MRSA infections (per 
100,000 bed days)  
 C. diff MRSA 
 Coeff (se) p-value Coeff (se) p-value 
Constant 0.94 (0.22) 0.000 15.36 (2.51) 0.000 
Intervention 0.05 (0.28) 0.853 2.37 (0.14) 0.420 
Time -0.13 (0.07) 0.051 0.26 (0.50) 0.601 
Time^2 -0.01 (0.01) 0.264 0.01 (0.03) 0.789 
Time^3 0.00 (0.00) 0.784 -0.00 (0.01) 0.208 
Intervention*Time -0.01 (0.02) 0.652 -0.05 (0.14) 0.693 
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Appendix H:  Patient survey questions 
Five scores were identified as being relevant to SPI. 
 
Each of these was scored between 0 and 100. The three satisfaction scores were:  
 
1. “Overall, how would you rate the care you received?” (five possible responses:  
Excellent = 100, Very good = 75, Good = 50, Fair = 25 and Poor = 0);  
2. “How would you rate how well the doctors and nurses worked together?”  
(same response options);  
3. “Overall, did you feel you were treated with respect and dignity while you were in the 
hospital?” (Yes, always = 100; Yes, sometimes = 50; and No = 0).  
 
The two scores related to cleanliness were: 
 
4. “In your opinion, how clean was the hospital room or ward that you were in?”  
(possible responses: Very clean = 100, Fairly clean = 67, Not very clean = 33, and  
Not at all clean = 0); 
5. “How clean were the toilets and bathrooms that you used in hospital?”  
(same response options, plus “I did not use a toilet or bathroom”, which was excluded 
from the analysis). 
 
 
 
 
 
